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ABSTRACT 
Recent work has highlighted the central role of tissue factor (TF) in the physiological activation of 
haemostasis. This study was designed to investigate the use of physiological levels of TF as the triggering 
factor in the laboratory assessment of haemostasis. Endpoints based upon fibrin polymerisation and 
thrombin generation were selected as these have been shown to reflect the combined effect of the 
components of the haemostatic process. 
Sample quality was found to be of the utmost importance when picomolar concentrations of TF were used 
to trigger an assay. Sample mediated contact activation was found to be a major problem. The use of corn 
trypsin inhibitor (CTI) at a final concentration of 18.3ýtg/ml of whole blood was found to be optimum for 
the elimination of the effect of factor XII activation which occurred during sample collection and 
subsequent manipulation. In the absence of CTI significant thrombin generation was evident 
(1425nM. min, SID 582) resulting from intrinsic sample activation. 
TF concentration was optimised for the detection of both hypercoagulable and hypocoagulable samples 
using the calibrated automated thrombin generation method (CAT), rotational thromboelastometry 
(ROTEM) and a clot kinetic assay (CKA) as global tests of haemostasis. The incorporation of 
thrombomodulin (TM) into the reagent was found to improve the assay sensitivity to hypercoagulable 
samples. Final concentrations of TF / TM were found to differ between the CAT assay of thrombin 
generation and the ROTEM and CKA assays of fibrin polymerisation. 
The optimum reagent for the CAT assay was found to be 15pM TF in combination with 7nM TM. 
Although this combination was able to discriminate hypocoagulable, hypercoagulable and normal 
individuals, the high assay coefficient of variance of around 50% was unacceptable when the 
hypocoagulable samples were assessed. This variance could be halved by the use of 4pM TF in the 
absence of TM for this patient group. The ROTEM and CKA were optimised at much lower reagent 
concentrations (2pm TF / 0.5nM TM and IpM TF / 0.5pM Tm respectively). However, neither of these 
assays of fibrin polymerisation was able to fully discriminate between mild haemophiliacs and normal 
individuals. 
These optimised reagents were used to assess 54 patients previously found to have suffered a venous 
thromboembolic event (VTE). It was found that each assay identified >20% of the VTE patients with 
values above the upper limit of normality. The ability of the assays to detect an identifiable thrombophilic 
defect, within the VTE patient samples, varied from 0-100% depending upon the defect / assay 
combination. The assays were clearly identifying different patient populations. The question as to which, 
if any, are most at risk remains to be answered and a follow-up prospective study has been initiated in 
conjunction with Haemostasis Unit at the University of Leiden to attempt to answer this question. 
Both the CAT and CKA were also used to assess haemostasis in 13 severe haemophiliacs undergoing 
routine assessment of post infusion recovery or full product half life studies. The CKA was found to be 
uninformative in these patients. However, the CAT using both 15pM TF / 7nM TM and 4pM TF reagents 
could be used to monitor factor concentrate infusion. The longer half-life calculated using the CAT rather 
than conventional single factor assays suggested that haemophiliacs retain an enhanced haemostatic 
function beyond the time calculated from traditional half-life calculations. A follow-up study has been 
initiated to ftuther investigate this finding. 
This study supports the view that assays triggered using low TF concentrations may produce more 
clinically relevant findings that the current "routine" screening tests. 
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1.0 INTRODUCTION 
1.1 Activation of the coagulation Dathway. 
The first steps to the current understanding of the coagulation system were taken in the 
early 1960s when the cascade (MacFarlane, 1964) or waterfall (Davie and Ratnoff, 
1964) theories of biochemical amplification were proposed. For the first time the idea 
that the blood contained a series of inactive proteins (zymogens) which were activated 
sequentially was proposed (Figure 1.1). 
Surface Contact 
xil o. Xlla 
X1 o Xla 
Va 
ix 
Vill Villa 
x P, Xa 
v No Va 
Ila (Thrombin) 
1> la (Fibhnogen) 
Figure 1.1 The cascade theory of blood clotting. Reproduced from an article by RG 
Macfarlane (1964). 
Additionally two routes for the activation of factor X (FX) were proposed, intrinsic 
activation originating from factor XII (FXII) activation, and extrinsic from activation of 
factor VII (FVII). The main developments since these theories were published have 
been in detennining the exact sequence of events and the interdependent nature of the 
I 
activation process. The fact that haemophiliacs have a severe bleeding tendency was not 
explained by the cascade model. The ability of factor Vlla (FVlla) to activate factor IX 
(FIX) had been recognised (Josso and Prou-Wartelle, 1965) but the implications of this 
were not widely appreciated until much later. By the early 1990s the idea of an intrinsic 
and extrinsic route of activation were starting to be questioned (Davie et al., 1991) 
(Figure 1.2). The concept that tissue factor can activate FIX in addition to VII when in 
low concentration (the Josso Loop) was illustrated in their schematic diagram (Figure 
1.2). 
The extrinsic pathway was felt to be the main activation route with progression to 
thrombin generation via direct FX activation by a tissue factor/FVIla complex. This 
activation was believed to be short lived due to inactivation of the tissue factor/FVlla 
complex by a specific inhibitor (Broze et al., 1988). The main route of activation then 
switching to activation of FIX by tissue factor/FVlla. This was offered as the 
explanation for bleeding in the haemPhiliac population. However, the bleeding diathesis 
associated with factor XI deficiency (Asakai et al., 199 1; Bolton-Maggs et al., 198 8) is 
not explained by extrinsic activation as the primary route of activation for haemostasis 
with a switch between factor Xa (FXa) activation and factor IXa (FIXa) activation 
occurring through inhibition. The first clue to this puzzle was the discovery that 
thrombin could activate FXI (Naito and Fujikawa, 1991) and the realisation that this 
offered an alternative activation mechanism to factor Xlla (FXlla) (Gailani and 
BrozeJr., 1991). These early discoveries have shaped our current understanding of the 
haernostatic mechanism. 
2 
Intrinsic Pathway 
Thrombion 
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Figure 1.2 Coagulation cascade and fibrin formation by the intrinsic and extrinsic 
pathways. Reproduced from an article by EW Davie et al (199 1). 
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The current theory is that of tissue factor initiated activation in vivo. The intrinsic 
activation pathway having a role in vitro and during contact with foreign surfaces such 
as surgical implants (Lamba et al., 2000). 
FVII has some unique properties when compared to the other coagulation proteins. The 
first is that FVlla is resistant to inhibition in the circulation with antithrombin being the 
only identified inhibitor of free FVlla (Kondo and Kisiel, 1987). This is bome out by 
the observation that injected FVlla has a half-life of hours compared to seconds for the 
other activated coagulation proteins (Seligsohn et al., 1979). This observation was a 
concern for early vitamin K dependent clotting factor concentrates as it was felt this 
could pose a thrombotic risk (Seligsohn et al., 1979). Although the presence of FVIIa in 
the nonnal circulation had been postulated, it was not until 1993 that this was 
conclusively demonstrated when it was established that around 3.6ng/ml (75pM) of 
FVIIa was present in normal plasma (Morrissey et al., 1993). This represents around 
1% of the circulating FVII. Therefore the first step in the initiation of coagulation is the 
contact between tissue factor (TF) and circulating FVlla. The origin of the FVlla is not 
known, although markedly reduced levels seen in severe haemophilia B patients 
suggests a major role for FIX (Wildgoose et al., 1992). 
TF is normally absent from all cells in contact with plasma. As it is an integral 
membrane protein TF is largely restricted to the surface of cells that can synthesise it. 
The cellular expression of TF varies. TF expression has been shown in large quantities 
in brain, lung, placenta, autonomic ganglia and peripheral nerves (Fleck et al., 1990). 
Epithelium of skin, mucosa and glomeruli also demonstrated TF expression (Fleck et 
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al., 1990). Skeletal muscle and smooth muscle did not show TF expression although 
cardiac muscle and the muscularis mucosa did show TF expression (Fleck et al., 1990). 
These higher levels of TF expression are seen in areas where bleeding would be most 
catastrophic. Thus the hypothesis that this is a major trigger mechanism for haemostasis 
is supported. 
A truncated soluble TF molecule has been found in circulating plasma of normal 
individuals but its role is not understood (Giesen et al., 1999). The presence of this 
soluble TF is marked in some pathological states (Marmur et al., 1996; Song and Kim, 
2004; Sturk-Maquelin et al., 2003). In pathological states the blood-bome TF is carried 
in cell-derived microparticles (Aras et al., 2004; Biro et al., 2003). 
TF will bind FVlla and FVII equally and although only the TF/FVlla complex is 
biologically active it has been shown to autoactivate TF bound FVII (Nakagaki et al., 
1991). Other proteases, FIXa and FXlla (Seligsohn et al., 1979), and FXa and thrombin 
(Radcloffe and Nernerson, 1975), have been shown to be capable of back-activating TF 
bound FVII. The natural substrates for the TF/FVlla complex are the zymogens FVII, 
FX and FIX (Huang et al., 1996). Therefore coagulation will be initiated via FX or FIX 
activation by the TF/FVIIa complex. 
The route of activation is governed by two mechanisms. Firstly the tissue factor 
concentration will dictate the preferred route of activation (Josso and Prou-Wartelle, 
1965; Keularts et al., 2001). At high levels of TF the route to thrombin generation will 
proceed via the extrinsic pathway directly from TFNIIa to FXa. As the TF 
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concentration falls the preferred route is via TFNIIa to FIXa (Marlar et al., 1982; 
Osterud and Rapaport, 1977). This helps to explain the sites of bleeding associated with 
Haemophlia. Haernophiliacs characteristically bleed into load bearing joints and muscle 
tissue. These are areas of very low tissue factor activity therefore favouring the 
truncated intrinsic pathway route (Fleck et al., 1990). At very low levels of tissue factor 
(I -2pmol/1) factor XI has a significant role in thrombin generation through feedback 
activation. However at moderate levels (5-IOpmol/1) factor XI plays little part in 
thrombin generation (Cawthern et al., 1998). The second mechanism, which regulates 
the route to thrombin generation is the inhibition of the TFNIla complex by tissue 
factor pathway inhibitor (TFPI). 
TFPI uniquely has three tandem Kunitz-type proteinase inhibitory domains (Wun et al., 
1988) indicating multiple inhibitory targets. The first Kunitz-type site reacts slowly with 
the active site of FVIIa but only when bound to TF. The second Kunitz-type site reacts 
with the reactive site of FXa. The binding of this second site to FXa results in high 
affinity binding of the first site for the FVlIa within the TF/FVlIa complex (Broze, 
1995). The result is a fully inhibited tetramolecular complex (TF/FVlla/TFPI/FXa). 
This mechanism effectively shuts down the extrinsic activation pathway TF/FVlla to 
FXa allowing activation to proceed preferentially via the TF/FVlla to FIXa route. Thus 
at low tissue factor concentrations, FXa activation occurs through the truncated intrinsic 
pathway via activation of FIXa. As the TF concentration rises TFPl is overwhelmed and 
direct activation of FXa via the extrinsic pathway can proceed. The target for the third 
Kunitz-type site of TFPI is unknown. 
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1.2 Role of Thrombin- feed back activation 
Following production of FXa coagulation proceeds via the formation of the 
prothrombinase complex through to thrombin generation. Thrombin is the major 
reactive product of the coagulation system. Its major function is the conversion of 
fibrinogen to a stable fibrin mesh (Section 1.3). However, before this point can be 
reached thrombin serves an equally important role. That role is in the back-activation of 
components of the coagulation system (Mann et al., 2003). Initially, following 
TF/FVlIa complex formation sub-picomolar amounts of FXa and FIXa are assembled 
on a phospholipid membrane. These activate a small amount of prothrombin to 
thrombin. This is termed the initiation phase of coagulation and represents the 
generation of the first I Onmol/I of thrombin. The end of the initiation phase 
approximates to the clotting time of blood. The thrombin generated then activates trace 
amounts the cofactors factor V (FV) and factor VIII (FVIII) (Lawson et al., 1994). The 
trace amounts of thrombin also activate platelets providing the anionic phospholipid 
surface necessary for coagulation factor complex formation (Davey and Luscher, 1967) 
and making available platelet bound coagulation factors such as factor V (Tracy et al., 
1984). The formation of activated factor VIII (FVllIa) and the availabilty of negatively 
charged phopholipids allow the formation of the intrinsic tenase complex 
(FIXa: FVllla: FXa) which has been estimated at 50 times more effective than TFNIla at 
generating FXa (Mann et al., 2003). Subsequent formation of the prothrombinase 
complex (FXa: FVa: prothrombin), as a result of FV activation to FVa, allows for rapid 
thrombin generation. This is termed the propagation phase of coagulation and results in 
a 10 4_106 fold increase in thrombin generation (Mann et al., 
2003). Thrombin 
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generation then proceeds via the intrinsic tenase complex as thrombin back-activates 
FXI generating increased amounts of FIXa whilst TFPl progressively inhibits the 
TF/FVlla/FXa complex. 
1.3 Conversion of fibrinogen to fibrin 
The fibrinogen molecule is a dimeric molecule consisting of three pairs of disulphide- 
bonded polypeptide chains, designated A(x, Bp and 7. Thrombin is a serine protease 
with limited specificity. It readily cleaves the Arg-Gly bonds at positions 16-17 of the 
A(x and 14-15 of the Bp chains releasing fibrinopeptides A and B (FPA, FPB). These 
fibrinopeptides account for only 2% of the original mass of fibrinogen (Kaminski and 
McDonagh, 1983). Thrombin is bound to fibrinogen by a series of hydrophobic 
residues. This binding positions the thrombin active site to cleave the Argl6-Glyl7 
bond of the A(x chain releasing FPA. A conformational change in the molecule allows 
simultaneous cleavage of the Argl4-Glyl5 bond of the Bp chain releasing FPB. The 
sequence of fibrinopeptide cleavage is however, disputed in the literature. There are two 
possibilities, competitive cleavage or sequential cleavage. The affinity of the A(x and 
Bp chains for thrombin in the early stages of the reaction are the same. However, FPA 
is released at a faster rate than FPB because the rate constant for the hydrolysis of the 
specific Arg-Gly bond in the A(x chain is greater than that for the BO chain (Martinelli 
and Scheraga, 1980). This variance in the rate of release of the fibrinopeptides gives the 
appearance of a sequential cleavage as FPA appears ahead of FPB. Once the 
fibrinopeptides have been cleaved from the fibrinogen molecule the molecule is referred 
to as a fibrin monomer. 
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Removal of FPA exposes the "A" binding sites within the central E domain of the fibrin 
monomer which bind to complementary "a" sites on the y chain of the D domain of 
another fibrin monomer (Olexa and Budzynski, 1980). Removal of FPB in the absence 
of FPA release has been shown to allow a similar association at low temperatures but 
dissociation occurred at 37'C. The aggregation of fibrin monomers through FPB release 
was shown to hinder FPA release (Shainoff and Dardik, 1979). This situation is only 
seen when snake venoms are used to cleave the Arg-Gly bonds but does provide an 
insight into the mechanisms present during the thrombin-mediated cleavage of the 
fibrinopeptides. The association of the "A" binding sites and the "a" sites results in 
fibrin dimer fonnation followed by further polymerisation to form 2-stranded 
protofibrils (Blomback et al., 1978). The formation of the protofibrils occurs through 
the same non-covalent bonding involved in dimer formation. 
These protofibrils are intermediates in the fibrin formation process. The next stage is 
lateral polymerisation of the protofibrils into fibrin fibers. This is believed to involve 
the association of the "B" binding sites exposed by the cleavage of FPB with the "b" 
binding sites (Weisel, 1986). Light scattering measurements and electon microscopic 
observations estimate the protofibrils reach lengths of 600-800nm, or approximately 30 
fibrin monomer units, prior to lateral association. The requirement for such a long 
protofibril prior to lateral association suggests weak binding and the need for multiple 
sites. The light scattering experiments demonstrated that within 60 seconds the light 
scattering intensity of the protofibrils had increased 10 fold as fibre forniation occurred. 
Also, the increase in fibre thickness and subsequent cross-linking occurs over a 
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relatively wide time span (Hantgan et al., 1980). This phenomenon is utilised in this 
study as an end point for the ROTEM and clot kinetic assays (Sections 3.3 and 3.6). 
The fibrin fibres consist of 14-22 protofibrils. These are arranged as a twisted structure. 
It is the energy required to maintain this twisted form that limits their maximum 
diameter to less than 100nm (Weisel et al., 1987). The strands are thicker when both 
fibrinopeptides are removed as in thrombin cleavage rather than FPA alone as seen in 
cleavage by reptilase. The same associations seen in lateral association of the 
protofibrils now allows protofibrils, fibrin fibres and thicker fibrin strands to associate 
into a sufficiently stable network to act as a haemostatic plug. The process from 
fibrinogen to stable fibrin mesh is shown in Figure 1.3. It is worth noting that 
incomplete or dysfunctional fibrin polymerisation occurs in some conditions. When 
thrombin levels are low and FPA cleavage incomplete, fibrinogen to fibrin association 
can occur particularly at high fibrinogen concentrations. These stable soluble complexes 
can impair stable fibrin formation (Wilf and Minton, 1986). This process may have 
relevance in assays where thrombin generation is low. 
The end-stage of the fibrin haemostatic plug formation involves stabilisation via factor 
XIII (FXIII) mediated cross-linking. FXIII is activated by thrombin and initially forms 
cross-links between y chains of associated fibrin molecules. A slower process of cross- 
links between glutamyl and lysine residues on the (x chains then ensures a highly cross- 
linked stable fibrin mesh (Chen and Doolittle, 1969). 
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Thrombin can bind to fibrin and this can be regarded as a regulatory mechanism as it 
limits the amount of free thrombin available at the site of clot formation following fibrin 
formation. This may explain the predisposition of some patients with 
dysfibrinogenaemia to thrombosis, as failure of this control mechanism results in 
excessive thrombus formation. The bound thrombin remains catalytically active and is 
protected from inactivation by antithrombin. This fibrin bound thrombin may be 
associated with a prothrombotic state seen in some cases where a persistent FPA 
elevation is seen (Francis et al., 1983). The clot bound thrombin may also be significant 
when interpreting assays of thrombin generation (Section 1.8). 
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Figure 1.3 A model for fibrin assembly involving two sets of eomplementary 
binding 
sites: one for protofibril formation and another 
for lateral aggregation of protofibrils. 
Adapted from JW Weisel (1986). 
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1.4 Regulation of the coagulation system. 
The major role of antithrombin (AT) as an inhibitor of thrombin was shown by Butenas 
et al (1999). In their experiments they demonstrated that altering the concentration of 
AT within "normal limits" had a marked effect on the total thrombin produced. Altering 
the AT concentration between 50% and 150% of normal with the other plasma proteins 
maintained at 100% levels resulted in a 50% increase or decrease respectively in 
maximum thrombin concentration and total thrombin generated. AT regulates the 
coagulation system by the inhibition of thrombin and the subsequent down-regulation of 
the back-activation processes. 
Another major regulatory mechanism has emerged in the past 20 years. This is the 
protein C (PC) pathway. This pathway is initiated by the binding of thrombin to 
thrombomodulin (TM) on the vascular endothelium. TM is a transmembrane molecule 
and does not possess intrinsic enzymatic activity. Endothelial membrane bound TM 
forms a high-affinity complex with thrombin and inhibits thrombin interaction with 
fibrinogen and protease-activated receptor (PAR)-1 via thrombin exosite I (Weiler and 
Isermann, 2003). Additionally the TM-thrombin complex is a potent activator of PC 
increasing thrombin dependent PC activation two-fold. The abundance of TM in the 
microvasculature means that the vast majority of thrombin generated under ambient 
conditions is sequestered by TM. PC can be activated by TM-thrombin complexes in 
solution. However, membrane surfaces accelerate the activation considerably. PC is 
probably presented to the TM-thrombin complex via calcium dependent binding to 
negatively charged surfaces or via a complex with endothelial cell PC receptor (EPCR) 
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(Weiler and Isermann, 2003). Inhibition of the procoagulant function of thrombin and 
activated protein C formation (APQ are an essential mechanism for the regulation of 
thrombin generation via proteolysis of FVa and FVllla (Weiler and Isermann, 2003). 
Inactivation of FVa follows cleavage of bonds Arg-506, Arg-306 and Arg-679. The 
function of PC is enhanced by the action of a co-factor protein S (PS). PS is thought to 
enhance the function of PC by changing the orientation of the active site of APC 
bringing it closer to the ARG-306 cleavage site of FV (Esmon, 2000). Interest in the PC 
system has arisen from the finding that mutations within these cleavage sites, FV 
Leiden (Bertina et al., 1994), FV Cambridge (Williamson et al., 1998) and FV Hong 
Kong (Chan et al., 1998) lead to a clinical condition referred to as APC resistance. APC 
resistance has been recognised as a risk factor for thrombosis with or without an 
associated mutation (deVisser et al., 1999). 
The TM-thrombin complex also activates latent plasma carboxypeptidase enzymes such 
as thrombin activatable fibrinolytic inhibitor (TAFI). Activated TAFI (TAFla) removes 
carboxy-terminal arginine and lysine residues from fibrin rendering it more resistant to 
lysis. Therefore thrombin can act not only as a procoagulant but also as an anticoagulant 
and fibrinolytic enzyme. 
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1.5 The need for a screening test for thrombotic risk. 
The current approach to thrombophilia screening is to assay the individual factors that 
have so far been described. The inclusion or exclusion of tests from the thrombophilia 
screen offered at different laboratories depends upon the equipment, workload, cost, 
expertise and relative risk associated with that test. Despite national guidelines (BCSH, 
2001) there is considerable variation in the range of tests offered at different centres and 
the quality of the results produced. High coefficients of variation (CV's) and a broad 
range of results were seen in a recent evaluation of results from the program for 
thrombophilia sereening of the ECAT foundation (Meijer et al., 2003). The main reason 
was determined as the long-term within-laboratory variability and the need for better 
standardisation was highlighted. Another contribution to variablity is the different 
sensitivities of kits supplied from different manufacturers. A recent publication from the 
UK NEQAS group highlighted the need for locally determined reference ranges with 
well-standardised reference plasma in respect to the assay of PS (Jennings et al., 2003). 
The utility of the current approach has been questioned by a number of recent authors. 
Evaluation of a prospective cohort study at Addenbrookes Hospital demonstrated that, 
in unselected patients who had a first episode of a venous thromboembolic event (VTE), 
testing for heritable thrombophilia did not allow prediction of recurrent VTE in the first 
2 years after stopping anticoagulant therapy (Baglin et al., 
2003). Other reports have 
also cast doubt on the clinical relevance of thrombophilia screening with the current 
panel of tests (Greaves and Baglin, 2000). The interest 
in this area was highlighted by a 
pair of articles in the opening issue of the Journal of Thrombosis and 
Haemostasis 
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discussing the pros and cons of thrombophilia screening (Machin, 2003; Martinelli, 
2003). Even in the pros argument the conclusion was that thrombophilia screening was 
appropriate in a few selected instances but in other situations was not useful and 
represented a waste of resources (Martinelli, 2003). There is a growing opinion that 
more focus should be given to prophylaxis and appropriate treatment than on costly and 
at times invasive testing for thrombophilia (Deitcher and Gomes, 2003). The problem 
with the current approach was that the test panels used were incomplete. It was accepted 
that at best only 40% of patients investigated for thrombophilia would be given a 
laboratory diagnosis that may account for the condition. The treatment for individuals 
who receive a "label" for their thrombophilia was no different to those with a strong 
history and no detectable defect. This was the main argument against the current 
approach to thrombophilia screening. 
The chance that an individual will suffer a VTE is governed by many hereditary, 
acquired and enviromnental factors. The diagnosis of a deficiency in an anticoagulant 
process (e. g. PC deficiency) does not mean that an individual will have a VTE. The 
deficiency represents a risk factor which, if combined with other risk factors, may lead 
to a VTE. Similarly the risk depends upon the level of the specific proteins involved in 
haernostasis. It has been shown that deficiencies on one side of the haemostatic balance 
can compensate others on the other side of the balance. Examples of this can be found 
in the haemophilia literature where individuals have had much milder clinical pictures 
as a result of prothrombotic defects (Ettingshausen et al., 2001; Vianello et al., 2001). 
Therefore the requirement for a global assay of multifactorial thrombophilia is clearly 
identified but is as yet unavailable (Mannucci, 2002). 
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1.6 Screenine available for throm 
The methods available for the assessment of haemostasis are primarily the prothrombin 
time (PT) (Quick, 1935) and activated partial thromboplastin time (aPTT) (Langdell et 
al., 1953). The tests are crude having been developed for fast throughput and rapid clot 
generation. An example, in the prothrombin time, is the use of a TF based reagent 
(thromboplastin) which consists of a mix of lipids and TF. The TF concentrations used 
are often several thousand times greater than those encountered in vivo at the site of 
vascular injury. While these tests have proved useful in identifying bleeding risk, they 
have limited utility when applied to the evaluation of thrombotic risk. Screening tests 
for thrombosis have been proposed. A number have developed from assays originally 
formulated to assess APC sensitivity. The most widely accepted of these assays was the 
ProCqD Global assay (Kraus et al., 1995). However, this screening test is very sensitive 
to changes in APC sensitivity but performs less well for other proteins in the PC 
pathway, particularly PS deficiency and is insensitive to deficiencies of AT. The assay 
suffers from poor specificity with up to 38% of patients with no detectable abnormality 
giving an abnormal result (Toulon et al., 2001). Assessment has been in terms of its 
1-11.1 ability to detect recognised defects rather than an assessment of thrombotic risk. A 
modification of the thrombin generation assay (Hemker et al., 1986) was described by 
D- 
Rosing et al (1997) which looked at the amounts of thrombin-a2macroglobulin complex 
formed in the presence and absence of exogenous APC (Rosing et al., 1997). Samples 
from the Leiden thrombophilia case-control study (474 patients with a first episode of 
deep vein thrombosis and 474 age- and sex-matched control subjects) were analysed. It 
was concluded that a high APC sensitivity ratio (APCsr) predicted venous thrombotic 
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risk, in populations with and without FV Leiden. In addition, it was shown that acquired 
APC resistance resulting from oral contraceptive (OC) use predicted an increased risk 
for venous thrombosis independent of FV Leiden. Although the study was performed 
using a TF trigger the nanomolar concentrations used were 1000 times those seen at a 
wound site. However, high local concentrations can be found at high risk sites such as 
the brain (Fleck et al., 1990). 
Other assays such as the overall haemostatic potential (OHP) (He et al., 1999) or its 
most recent modification the coagulation inhibitor potential assay (CIP) (Andresen et 
al., 2004) have been proposed. These involve the measurement of fibrin polymerisation 
over time in the presence of exogenous thrombin and tissue plasminogen activator 
(tPA). The CIP modification of this assay incorporates the addition of a Protac 
activation step to improve sensitivity to the PC system and pentasaccharide to improve 
AT sensitivity. The assay performed well in the study of Andresen et al (2004) but was 
only tested against a panel of 24 patients (Andresen et al., 2004). The preparation of this 
complex set of reagents may lead to difficulties in applying the assay in a routine 
clinical laboratory. 
New technologies such as the Haemodyne(& hemostasis analyser (Carr et al., 2003), the 
Sonoclot coagulation analyser (Liszka-Hackzell and Ekback, 2002) and the ReoRoxg 
(Ramstrom et al., 2002) rely on measurements of the viscoelastic properties of blood 
during clotting. It remains to be seen if they can offer any advantage over the well 
established thrombelastography (TEG) (Section 3.6). 
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Two assays have been described that measure the generation of thrombin over time. 
These are either through the formation of thrombin-antithrombin (TAT) complex (Rand 
et al., 1996) or detection of active thrombin (Hemker et al., 2003). The latter assay is 
more readily applied in the routine clinical laboratory and was assessed further in this 
study (Section 3.5). The assay described by Rand et al (1996) remains very much a 
research tool due its high demands on technical expertise (Rand et al., 1996). A similar 
position to the early manifestations of the assay described by Hemker et al (1986). 
1.7 Thrombelastographv 
Thrombelastography was first described by Hartert in 1948. The viscoelastical changes 
that occur during coagulation were recorded, providing a graphical representation of the 
fibrin polymerisation process. The end-point of the thrombelastograplig (TEG) is based 
upon detection of fibrin polymerisation (Section 1.3). The rate of fibrin polymerisation 
as well as the overall clot strength is assessed and all aspects of the process are 
monitored as shown by the ability of rotation thrombelastometry (ROTEM) to detect 
polymorphic changes in FXIII (Schroeder et al., 2001). Thus, the TEG or ROTEM 
enable a complete evaluation of the process of clot initiation and the structural 
characteristics of the formed clot and its stability (Mallett and Cox, 1992). The 
technology is applicable to both whole blood and plasma. 
Thrombelastography and ROTEM give a graphic representation of clot fonnation and 
lysis. Blood is placed in a heated (37'C) cup. Within the cup is suspended a pin 
connected to a detector system. This is a torsion wire in the case of the TEG9 5000 
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instument (Medicell Ltd) (Figure 1.4) or an optical detector in the ROTEM instrument 
(Pentapharyn Ltd). The cup and pin are oscillated relative to each other through 40 45' 
(Figure 1.4). In the TEGR 5000 the cup is rotated and in the ROTEM the pin is rotated. 
As fibrin fonns between the cup and pin the transmitted rotation from the cup (TEGS 
5000) or impedance of the rotation of the pin (ROTEM) is detected at the pin and a 
trace generated. 
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Figure 1.4 Diagrammatic representation showing a cross section of a cup and pin to 
illustrate the principle of thromboelastography. Reproduced from AwwAaemoscope. co . 
Four parameters are routinely measured as shown in figure 1.5 The r-time is taken as the 
time taken from addition of blood to the cup to the point when a 2mm variance from the 
across the trace is detected. The K time is the time taken for the trace to progress from 
the 2mm. variance to a 20mm variance. The angle is the maximum tangent of 
developing trace. Maximum amplitude (MA) is the greatest maximum width of the 
trace. Any subsequent decrease in amplitude following the point of MA represents lysis 
of the clot (i. e. A60 shows degree of lysis at 60 minutes post MA). The r-time, K time 
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and angle assess the interaction of the coagulation factors and platelets from activation 
through to fibrin polymerisation. The MA shows the ultimate strength of the clot. 
GýIalion FibrinotyWo ý 
-Tatne - 
Figure 1.5 A schematic of a thrombelastograph. Reproduced from (Salooja and Perry, 
2001) 
Abbreviations: MA = maximum amplitude, A60 Amplitude at 60 minutes post MA. 
The main uses of the TEG have been to monitor blood component therapy during 
surgery. Its use was first documented in the field of liver transplantation (Kang et al, 
1985) where the risk of bleeding is not clearly defined by routine tests of haemostasis 
(Kelly and Tuddenham, 1986). A further complication of hepatic surgery is the risk of 
thrombosis (Harper et al., 1988; Stahl et al., 1990) which could equally be monitored 
using the TEG. The use of the TEG was later described in cardiac surgery (Kang et al., 
1989; Spiess et al., 1987). Hepatic and cardiac surgery are both associated with the 
potential for massive blood loss. The haemostatic system can easily be overwhelmed as 
a result of multiple insults. 
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The haemostatic system can be compromised as a result of activation, depletion or 
inhibition. Activation most often occurs as a consequence of surgery through the release 
of TF, at the wound site, triggering thrombin generation through TF/FVlla formation. 
Activation also occurs through blood contact with foreign surfaces such as those used in 
bypass circulatory equipment. In the case of extracorporeal circuits platelet activation is 
common and fibrinolysis is often triggered. Platelet activation occurs as a result of 
mechanical trauma caused by oxygenators, roller pumps and suction devices. Platelets 
can also be activated as a consequence of the activation of other systems. Contact 
activation and the initiation of the intrinsic pathway of haemostasis occurs through 
autoactivation of FXII as it binds to artificial negatively charged surfaces (Silverberg et 
al.,, 1980). Activated factor X11a (FX11a) can activate FVII (Kisiel et al., 1977). In the 
presence of exposed TF this results in further activation of haemostasis. The 
complement system is also activated during contact with a foreign surface and 
activation peptides such as sC5-9 have been shown to activate platelets (Hong et al., 
1999). The latter mechanism is important as non-anionic surfaces such as PVC or 
polypropylene are used wherever possible to minimise autoactivation of the contact 
system. Contact activation of blood cannot be avoided during extracorporeal circulation 
and the resultant intrinsic activation of fibrinolysis is a major complication of this 
process (Woodman and Harker, 1990). Recently the effect of increased fibrinolysis has 
been minimised by the routine use of the antiplasmin like fibrinolytic inhibitor, 
aprotinin (Porte et al., 2000). Massive activation of haemostasis occurs on reperfusion 
of the grafted organ as blood flows over a damaged endothelial surface. 
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Depletion of components of the haemostatic system is also an important consideration 
in both hepatic and cardiac surgery. In the case of hepatic surgery particularly 
orthotopic liver transplantation (OLT) the patients are compromised preoperatively as 
the failing organ is the major site of synthesis of coagulation factors. In addition 
inadequate vitamin K absorption may occur as a result of failure of bile salt secretion 
into the intestine. This will result in impaired function of the vitamin K dependent 
haernostatic proteins prothrombin, FVII, FIX, FX, PC and PS. Platelet numbers may be 
low due to inadequate marrow production, sequestration associated with hypersplenism 
or consumption by low grades of disseminated intravascular coagulation (DIC). 
Dilutional coagulopathy is a problem as the lost blood volume is replaced by artificial 
volume expanders. 
The presence of inhibitors, in particular heparin, ftuther complicates the haemostatic 
picture in cardiac and hepatic surgery. Fleparin is used to prevent blood clotting on 
contact with the surface of the extracorporeal circuit. This is neutralised by the infusion 
of protarnine sulphate but the efficiency of this neutralisation is often poor. Exogenous 
heparin from the donor organ may also cause a problem as it is standard practice to 
administer 300 IU/Kg heparin to all donors prior to organ harvesting. The effect of 
heparin can readily be assessed using a modified TEG (Harding et al., 1997). 
Trauma patients can have the same pattern of multiple insults as described above. These 
result from tissue damage, vasoconstriction, ischaemia and acidosis. The 
TEG has been 
shown to predict early transfusion requirements in trauma patients 
(Kaufmann et al., 
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1997). The same study identified a hypercoagulable group of patients and raised the 
question of which treatment these individuals should receive. 
The advantage that the TEG offers is its bedside capability to deliver a snapshot of the 
cumulative effect of several components of coagulation at a given time-point (Salooja 
and Perry, 2001). Within 30 minutes a result is produced which represents the sum of 
platelet function, coagulation proteases and inhibitors, and the fibrinolytic system. Its 
role in this bedside intra-operative setting is not in question. 
It is only recently that the TEG has been used within haemostasis laboratories. The poor 
acceptance of the technology stems largely from the lack of agreement with standard 
laboratory variables (Zuckerinan et al., 1981). In their study Zuckerman et al (1981) 
assessed the TEG variables (r, k, NIA and cc angle) against the standard tests used to 
assess haemostasis (haematocrit, platelet count, PT, aPTT, fibrinogen and fibrin 
degradation products) (Zuckerman et al., 198 1). Their results demonstrated that, 
although there was a strong relationship between the thrombelastographic variables and 
the common laboratory tests, specific correlation between variables was poor and often 
failed to reach statistical significance. 
The use of the TEG in the laboratory setting represents a significant change of use for 
the instrument. It was originally designed as a bedside monitor using native whole 
blood. To perform tests within the laboratory it is not practical to use native blood and 
citrated samples are used for analysis. A recent study looked at the comparability 
between native blood and citrated blood analysis (Zambruni et al., 2004). They found 
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that TEG parameters following citrate storage were not comparable with native whole 
blood and felt that this was probably due to incomplete inhibition of the activation of 
the coagulation cascade. In agreement with previously published findings (Sorensen et 
al, 2003, Vig et al., 2002) TEG parameters following citrate storage remained stable 
between 30 minutes and 2 hours from initial sampling. They also confirmed the 
observation of Vig et al (2002) that repeated sampling over a4 hour period produced a 
significant overall trend towards hypercoagulability (Vig et al., 2002). 
At the bedside the TEG has gained acceptance because it gives a "global" assessment of 
the haemostatic capability of the blood at a given time. The elements of the TEG trace 
have been dissected to assess the need for blood component therapy. The r-time was 
used as a guide for fresh frozen plasma, the NIA to judge the need for platelet infusion, 
differences between the TEG in the presence and absence of heparinase used to assess 
protarnine dosage and the degree of lysis used to indicate the need for antifibrinolytic 
therapy. 
In the laboratory the "global" aspects of the TEG are used to identify or monitor 
specific defects. Screening for hypercoagulability using the TEG has been suggested 
(O'Donnell et al., 2004; Salooja and Perry, 2001). Others have suggested a relationship 
between hypercoagulable TEG and prothrombotic screening tests (Handa et al. 1997). 
However, overall the data is preliminary and inconclusive. The TEG can clearly 
distinguish a group of patients as hypercoagulable within a cohort of patients who have 
experienced a VTE. However, this hypercoagulable group is not necessarily the same as 
the group identified by routine thrombophilia screening (O'Donnell et al., 
2004). They 
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demonstrated that 34% of patients had a positive thrombophilia screen whereas 45% 
had a positive TEG trace. This study did show that some patients fell into the 
hypercoagulable group by both screening methods (33% of those with an abnormality) 
and questions whether these individuals are at greater risk of further thrombotic events. 
Furthennore O'Donnell et al (2004) suggest that those individuals with a positive 
history of VTE, hypercoagulable TEG and normal routine thrombotic screening may be 
good candidates for linkage analysis to identify novel constitutional or acquired 
thrombophilic traits (O'Donnell et al., 2004). The current thrombophilia screening tests 
do not predict for future risk of thrombosis (Baglin et al., 2003). The significance of an 
abnormal TEG in these patients with regard to thrombotic risk is unknown. The only 
prospective study investigating the relationship between TEG parameters and risk of 
VTE was carried out by Traverso et al (1993) (Traverso et al., 1993). They found that 
the NIA of the TEG was predictive of DVT development with a sensitivity of 72% and a 
specificity of 69%. It is not therefore possible to know without further studies whether 
an abnormal TEG, alone or in association with another prothrombotic defect, may 
predict increased risk. Following on from the findings of this study a prospective study 
has been initiated between Addenbrooke's Hospital haernostasis unit and the unit at the 
University of Leiden to hopefully answer this question. 
In the laboratory there are good screening tests for hypocoagulable defects which 
accurately predict bleeding risk. The TEG has a bedside role in the prediction of 
postoperative bleeding. Using the ROTEM the angle was found to have a high negative 
predictive value of 82%. This high negative predictive value allows early identification 
and targeted treatment of surgical bleeding by distinguishing it 
from significant 
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coagulopathy (Carnmerer et al., 2003). In the haernophilia population and non- 
responsive coagulopathic bleeding the monitoring of some fonns of replacement 
therapy is difficult using conventional laboratory tests. The TEG/ROTEM has been 
used to monitor replacement therapy in the haemophilia population. In particular, the 
monitoring of recombinant FVlla given to patients with antibodies directed against 
FVIII (Sorensen et al., 2003, Yoshioka et al., 1996). The assay of Sorensen et al used a 
low TF triggered system (0.35pM). The results obtained using TEG have been shown 
to reflect the clinical picture in terms of bleeding in patients receiving FVIII inhibitor 
bypassing agents. This was nicely illustrated in a recent case report by Hayashi et al 
(2004) (Hayashi et al., 2004) where both recombinant FVIIa and the prothrombin 
complex concentrate FEIBAS were used to arrest bleeding in patients with haemophilia 
A and a high titre inhibitor. The TEG has been shown to usefully predict the need for 
platelet infusion with the MA and K values being most affected (Bowbrick et al., 
2003a). The reverse situation was also identified by changes in MA. Hypercoagulabilty 
due to platelet activation has been demonstrated for up to 7 days postoperatively. This 
hypereoagulability has not been demonstrated by standard wagulation monitoring 
(Mahla et al., 2001). However, although able to identify grossly impaired platelet 
function, or number, it does not provide a comprehensive or sensitive reflection of 
impaired platelet function. Therefore in the laboratory investigation of platelet 
dysftmction, the TEG should be supplemented by other methods of platelet function 
assessment wherever possible (Bowbrick et al., 2003b). 
The TEG has also been used to monitor other pharmacological agents; thrombolytic 
therapy (Summaria et al., 1986), heparin (Klein et al., 2000; Nielsen, 2002) and anti- 
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platelet drugs (Fries et al., 2003) with the exception of aspirin where the TEG has 
proved uninformative (Mallett and Platt, 1991; Orlikowski et al., 1992). Fries et al 
(2003) were able to show that the ROTEM in combination with the PFA-100 suggested 
hypercoagulablity while routine coagulation screening showed hypocoagulability (Fries 
et al., 2003). Thrombus formation was detected surrounding a canula of the ventricular 
assist device that had been implanted. Antithrombotic therapy with clopidogrel (Plavix) 
was commenced and the device and patient survived and later underwent successful 
transplantation without major blood loss. This was a single case report. 
1.8 Endogenous thrombin potential. 
The idea of a thrombin generation test was first proposed by two groups namely 
MacFarlane and Biggs (MacFarlane and Biggs, 1953) and Pitney and Dacie (Pitney and 
Dacie, 1953) in the same 1953 issue of the Journal of Clinical Pathology. The method of 
MacFarlane and Biggs (1953) described a whole blood method whereas Pitney and 
Dacie 1953) described a plasma method. Native whole blood or recalcified plasma was 
added to a glass tube at 37'C and sub-samples transfeffed at I minute intervals to a 
fibrinogen solution. The time to clot of the fibrinogen solution was then translated 
into 
thrombin units by extrapolation from a previously constructed calibration curve of 
thrombin against clot time. The methods were shown to be sensitive to haemophilia and 
variations in platelet count. The addition of exogenous tissue 
factor was shown to 
shorten the time for thrombin generation but not affect the amount generated. 
Thus, it 
was concluded that intrinsic thromboplastin was of the same order of magnitude of 
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activity as the added brain thromboplastin (MacFarlane and Biggs, 1953). The thrombin 
curves generated by these assays are shown in Figure 1.6 
Although an adaptation of this method was used for the two-stage assay for prothrombin 
(Biggs and Macfarlane, 1967), the idea was largely forgotten for 30 years until a similar 
subsampling method to monitor thrombin generation in plasma was described (Hemker 
et al., 1986). The area under the thrombin generation curve was termed the endogenous 
thrombin potential (ETP). Here a method was described that allowed the calculation of 
the velocity of prothrombin conversion independent of thrombin inactivation processes. 
The method utilised the measurement of thrombin specific amidolytic activity over 
time. A burst of thrombin production and an eventual cessation of thrombin generation 
follow a short lag-time. If the clotting of fibrinogen was used as an end-point, as 
previously applied (MacFarlane and Biggs, 1953; Pitney and Dacie, 1953) the estimate 
of thrombin would eventually return to zero (Figures 1.6a and 1.6b). 
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Figures 1.6a and 1.6b The results of thrombin generation curves achieved by 
subsampling into a standard fibrinogen solution and converting the subsequent clot time 
into thrombin units. Taken from (MacFarlane and Biggs, 1953). 
Figure 1.6a shows the effect of TF addition in the form of human brain tissue (A) 
compared to the normal curve derived from 12 subjects. Figure 1.6b shows the curves 
generated from 4 haernophiliacs compared to the normal curve. 
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However, when using an amidolytic endpoint, zero is never achieved as the (x2- 
macroglobulin ((x2M) - thrombin complex has residual activity towards the substrate 
(Rijkers et al., 1998). A mathematical analysis of the curve generated allowed for the 
residual effects of thrombin bound to inhibitors such as oc2M to be calculated and 
subtracted from the overall amidolytic reading. This mathematical program was termed 
'-4'thrombinoscope" (Hemker et al., 1986). The method described consisted of measuring 
the course of amidolytic activity after triggering thrombin formation in a sample of 
defibrinated plasma and then eliminating the effect of the breakdown processes by 
compensating for their velocities. These are calculated from the concentration of 
thrombin and the breakdown constants. The problem with this approach is that the 
acceptability of the results obtained is entirely dependent upon the acceptability of the 
model and the mathematical process. 
The model assumes two breakdown processes for active thrombin. 
Prothrombinase 
Prothrombin 0. Thrombin 
KI 
00 oc2M-thrombin 
K2 
IF 
Inactive thrombin 
The first breakdown of thrombin is caused by antithrombin and other antiproteases and 
leads to inactive thrombin. The other is OM-dependent and leads to a product with a 
residual amidolytic activity. The model assumes pseudo first order kinetics for these 
reactions in relation to thrombin. This assumption is borne out by a logarithmic 
decay of 
thrombin to a steady end-level. To further validate the model Hemker et al (1986) 
demonstrated that the breakdown constant of thrombin did not change over the time 
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course of the experiment and the level of activity remaining in the plasma after 
activation is explained by the level of oc2M-thrombin present (Hemker et al., 1986). 
This latter finding was later used in a modification of the assay (Rosing et al., 1997). A 
further observation was that in the absence of a2M the final activity approached zero as 
seen in the earlier fibrinogen subsampling methods. A final validation of the model was 
the demonstration that the total amount of prothrombin as well as levels of cc2M- 
thrombin eventually obtained are independent of the dilution of thromboplastin used. 
Thus, demonstrating that the partition of thrombin between the TAT complex and the 
oc2M-thrombin complex was independent of the course of thrombin generation. 
The method described was the first attempt to measure a global effect of the coagulation 
process upon the generation of the final enzyme, thrombin. Until this time the 
investigation of haemostatic impairment was directed at assessment of individual 
coagulation proteins. Screening for factor deficiencies in bleeding patients could be 
adequately perfonned using the PT and aPTT. It was suggested that the ETP could be 
used as a better tool in the understanding of physiological interactions, and relative 
importance, of components of the haemostatic process. However, the sensitivity of the 
test would still be dependent upon the trigger selected. 
One of the early applications of the ETP was in the investigation of the action of 
heparin (Beguin et al., 1988). In this study both intrinsic and extrinsic activation were 
employed. The subsequent effect of heparin was limited to the ETP following intrinsic 
activation and felt to be the result of diminished thrombin generation resulting in poor 
feedback activation of intrinsic coagulation. 
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A follow-up study looked at the effect of heparin when platelet rich plasma and low 
levels of tissue factor were used (Beguin et al., 1989). The addition of tissue factor was 
seen to reduce the lagtime to the thrombin burst. However, it was noted that the platelet 
rich plasma clotted following recalification due to contact activation. Differences 
between the action of heparin in the presence or absence of platelets were noted and it 
was concluded that the platelets had a quenching effect possibly due to the release of 
platelet factor 4, a protein that neutralises heparin. The methods involved in the 
estimation of ETP in platelet poor plasma (PPP) and platelet rich plasma (PRP) were 
different. The measurement of the amidolytic reaction could only be achieved following 
subsampling from a reaction mixture into the chromogenic substrate. To enable this 
subsampling to take place fibrin needed to be eliminated from the reaction mixture to 
allow accurate pipetting. This was achieved by defibrination of the plasma, using a 
snake venom, reptilase, in the case of PPP and by manual removal of the clotted 
fibrinogen using a glass rod in the case of PRP. This difference in reaction conditions 
made evaluation of the platelet contribution difficult. 
To remove the need for subsampling a thrombin specific amidolytic substrate with a 
decreased thrombin sensitivity was sought. This would enable the measurement of the 
thrombin generation to be performed from the primary reaction mixture without 
exhaustion of the substrate. The substrate methylmalonyl-methylalanyl-arginyl- 
paraNitroaniline (SQ68) was found to be such a substrate (Hernker et al., 
1993). It was 
found that the concentration of the substrate used was critical to the reaction conditions. 
If too high a concentration was used prothrombin conversion became inhibited 
by the 
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substrate. If the concentration was too low then substrate depletion became a factor. It 
was found that at a concentration of 500[tM then neither was a significant factor. The 
use of continuous measurement rather than subsampling meant that the technique could 
be more readily automated. It was noted that the (x2M-thrombin level was a direct 
indicator of the thrombin potential allowing for individual (x2M fluctuations (Hemker et 
al., 1993). This more crude estimation of thrombin potential could be performed 
without the need for a mathematical calculation of area under the thrombin/time curve 
and subsequent correction for a2M interference. This measurement was later used in 
assays of APC resistance (Curvers et al., 1999; Curvers et al., 2002; Oger et al., 2003; 
Rosing et al., 1997; Tans et al., 2000). 
Previously, the need for subsampling had seriously limited the practicality of the 
methodology for routine application. However, the use of an amidolytic substrate still 
required the removal of fibrinogen from the sample to eliminate the turbidity associated 
with clot fonnation. Therefore the technique could not readily be applied to PRP. It was 
7 years later that a method was developed that would allow for continuous measurement 
of thrombin generation in the presence of platelets (Hemker et al., 2000). A number of 
fluorogenic substrates were evaluated for use in the continuous monitoring of thrombin 
generation in plasma (Ramjee, 2000). The substrate Z-Gly-Gly-Arg-AMC (a 
fluorochrome using 7-amido-4-methylcoumarin as a flouophor) was identified as most 
suited to the task. The use of a fluorescent substrate (Z-Gly-Gly-Arg-AMC) meant that 
the signal was not impaired by the turbidity of the sample. This removed the need for 
the defibrination step and thus allowed the use of PRP in the reaction mixture. This 
finally allowed the assay to be more widely applied in laboratories as automation was 
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now readily available and the technique considerably less time consuming. However, 
differences in the thrombin generation were seen. The main effect seen was that the 
correction for the thrombin-like activity, associated with the oc2M-thrombin complex, 
was much smaller in the presence of fibrinogen. This could readily be seen when the 
first derivative of the fluorescence curve (the thrombogram) was examined. The tail of 
the trace returning closer to zero than seen in the defibrinated plasma assays. In addition 
the amount of (x2M-thrombin complex measured in the presence of fibrinogen was only 
40% of that seen in defibrinated plasma thrombin generation (Kumar et al., 1994). 
Another major difference between continuous monitoring using the fluorogenic 
substrate rather than a chromogenic substrate was the presence of a fibrin clot in the 
monitored reaction. As mentioned briefly above (Section 1.3) thrombin will bind to 
fibrin and be incorporated into the developing clot. This scavenging of thrombin around 
the site of clot formation may act as regulatory mechanism to limit the levels of free 
thrombin. It has been shown that clot bound thrombin will shorten the clotting time of 
plasma and that thrombin bound in this way is resistant to activation by antithrombin 
(Bendayan et al., 1994). Heparin cofactor 11 may have a role in the regulation of this 
clot bound thrombin (Bendayan et al., 1994). As described above the initial sequence of 
coagulation factor activation results in trace amounts of thrombin being generated 
(Seetion 1.2). This thrombin then baek aetivates the eofaetors FV and FVIII (Lawson et 
al., 1994) and activates platelets (Davey and Luscher, 1967) providing the building 
material for formation of the Tenase and prothrombinase complexes. However, it has 
been demonstrated that rather than enhancing thrombin generation the presence of the 
fibrin clot gave a 30% reduction in thrombin generation when measured as the area 
under of thrombin generation curve (Kumar et al., 1994). This reduction occurred as 
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result of absorption of thrombin by the developing clot. This was deemed the most 
likely explanation as prothrombin consumption was unchanged and the level of 
thrombin bound to the inhibitor complexes TAT and a2M-thrombin was reduced. This 
effect was seen only when amidolytic substrates were used. When a fluorescent 
substrate was used a higher level of thrombin generation was seen suggesting that the 
fluorochrome measured both free thrombin and clot bound thrombin (Hemker et al., 
2003). 
The most recent development in the thrombin generation assay is the calibrated 
automated thrombin generation measurement (CAT) (Hemker et al., 2003). The 
continuous monitoring of thrombin generation using the fluorogenic substrate Z-Gly- 
Gly-Arg-AMC is still used. However a thrombin calibrator is now used to compensate 
for the effects of using a fluorescent substrate. The problems associated with the use of 
a fluorogenic substrate are non-linearity of fluoresence with the concentration of 
fluorescent molecules and substrate consumption. The substrate binds thrombin and 
thus acts as a competitive inhibitor of physiological feedback reactions. These changes 
associated with the presence of a flourogenic substrate cannot be corrected by 
comparison to standard plasma as the effect is sample specific. Therefore this inner 
filter effect is corrected by the use of a thrombin calibrator. The calibrated assay is run 
with the addition of a standard a2M-thrombin preparation (calibrator) to a separate well 
containing test plasma and fluorochome. As the rate of reaction between the calibrator 
and the fluorochrome is known, deviation from this can be corrected mathematically. 
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The measurement of thrombin generation in a whole blood system would then appear to 
be the next goal. It has been demonstrated that erythrocytes have an influence on 
thrombin generation (Peyrou et al., 1999) and a modification of the ETP assay has been 
applied to whole blood (Kessels et al., 1994). The assay described involves the removal 
of the cellular component by centrifugation following activation. This assay is very 
difficult to standardise and is only applicable to a research setting to investigate possible 
haemostatic interactions. The assay performed by Peyrou et al (1999) involved the use 
of non-citrated whole blood, therefore adding to the standardisation problems (Peyrou et 
al., 1999). 
As the assay of ETP was evolving centres applied the technology to investigate various 
aspects of the haemostatic mechanism. Much of the early work was performed in 
relation to the effects of heparin and its subsequent neutralisation (Beguin et al., 1989; 
Beguin et al., 1988; Rotteveel et al., 1996) but soon other applications were published. 
In 1994 a group from Paris looked at the effect of the addition of thrombomodulin to an 
ETP assay triggered by tissue factor (Duchemin et al., 1994). The assay was shown to 
be sensitive to the effects of varying plasma PC or PS levels in mixes of deficient 
plasmas and non-nal plasma. The assay was sensitive to decreased levels as a result of 
oral anticoagulants and was decreased in women using OCs. It was postulated that the 
assay could be applied to PC and PS screening. 
The potential applications for the ETP were reviewed in 1995 (Hemker and 
Beguin, 
1995). A clot forms when 10-20nM of thrombin is generated leaving 95% of the 
thrombin still to be generated. The extent and nature of this additional thrombin 
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generation can reflect both hyper- and hypo coagulant states. The ETP has the potential 
to reflect the total thrombin potential of a sample and as such should be able to reflect 
the haemostatic potential at a given point in time. This review (Hemker and Beguin, 
1995) suggested that the ETP could be adapted to detect both the hypercoagulable state 
as well as the hypocoagulable state, a prospect which at that time was not present in any 
other assay. A later study demonstrated that patients with deep vein thrombosis or 
coronary artery disease had higher ETP values than the normal population (Wielders et 
al., 1997). Thus, supporting the hypothesis suggested in the review of 1995 (Hemker 
and Beguin, 1995). Further evidence of the ability of the assay to reflect the haemostatic 
balance was provided from studies during pregnancy and following exercise (Eichinger 
et al., 1999; Hilberg et al., 2003). Here markers of coagulation activation such as TAT 
complex, D-dimer (DD) and prothrombin fragment FI+2 were elevated demonstrating 
an increased turnover of haemostasis. However, normal findings in the ETP 
demonstrated that the ability to generate normal levels of thrombin was unaffected. The 
ETP therefore better reflected the clinical significance of alterations in the haemostatic 
system. The ETP has recently been shown to be reduced in cases of inherited 
coagulation disorders associated with factors levels sufficiently low so as to produce a 
clinical bleeding tendency (Dieri et al, 2002). 
Most recently the ETP has been suggested as a tool to monitor drug therapies. An 
I"k abnormal ETP has been noted following administration of antiplatelet agents 
directed at 
reducing thrombin induced platelet aggregation (Wegert et al., 2002). The effects were 
seen when specific agonists were used to trigger platelet aggregation, this 
being the 
trigger mechanism for the subsequent thrombin generation. The effect was not seen 
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when tissue factor was used as the haemostatic trigger. With the availability of tests 
aimed specifically at monitoring platelet function it was not clear whether the ETP 
would have any advantages in this context. Another application where the ETP could 
prove useful is in the monitoring of oral direct thrombin inhibitors such as 
Ximelagatran. This new therapy cannot be monitored with conventional screening tests 
such as the prothrombin time, activated partial thromboplastin time or thrombin time. 
These assays are designed to give rapid initiation of clot fonnation and are relatively 
insensitive to the subtle changes that these therapies produce. Although one advantage 
of the new therapy was its dosage predictability it would be reasonable to assume that 
once they move into therapeutic use a means of detecting their effects would be 
required. An assessment would be required in cases of poor compliance or suspected 
overdose. Ximelagatran has been shown, both in vitro and ex vivo, to prolong the time 
to thrombin peak and reduce the ETP (Bostrom et al., 2003). From the results of this 
study it would appear that the ETP could be a useful tool in assessing the effects of this 
forra of anticoagulant therapy. 
An example of the output seen from an ETP assay is shown in Figure 1.7. The main 
variables are indicated; the time to initial thrombin burst (Lagtime), the size of that 
thrombin burst (Peak), the time to maximum thrombin generation (Time to peak) and 
the total thrombin generated as given by the area under the thrombin generation curve 
(ETP). 
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Figure 1.7 Example of thrombin generation curve showing lagtime, time to peak, peak 
thrombin generation and ETP (area under thrombin generation curve). Duplicate assays 
are shown in blue (one is shown in bold). The green trace shows the average of the 
duplicate traces. 
1.9 Clot Kinetics 
Following the initiation phase of coagulation when approximately 10nmol/l of thrombin 
has been generated the propagation phase of coagulation follows accompanied by rapid 
thrombin generation and fibrin polymerisation. The conversion of soluble fibrinogen to 
an insoluble,, stable, fibrin mesh is described in Section 1.3. The TEG has been used for 
many years to assess haemostasis at the bedside and monitors both the speed of fibrin 
formation and the overall strength of the fibrin mesh formed (Section 1.7). However, as 
much of the early work to assess fibrin polymerisation was carried out using light 
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scatter experiments (Hantgan et al., 1980), an optical end-point detection system would 
appear to offer an equally sensitive system for monitoring fibrin polymerisation. 
The multichannel discrete analyser (MDA) allows the optical changes during fibrin 
polymerisation to be monitored. The MDA series analyser is an automated haemostasis 
analyser capable of performing clotting, chromogenic and immunoassays in random 
access. The detection system is a rapid scanning spectrophotometer with a single 
tungsten-halogen light source and a single holographic diffraction grating. This allows 
simultaneous reading of 35 wavelength bands from 395nm to 710nm. Optical data is 
collected at 0.2 second intervals over a4 minute monitoring period generating 1200 
data points. This data is used to generate an optical profile of the clot formation. This 
sophisticated optical capability allows an accurate picture of fibrin polymerisation to be 
formed. Using mathematical transformation of the data (primarily first and second 
derivatives) the kinetics of the clot fonnation can be analysed (Braun et al., 1997). The 
light transmitted through the developing clot is plotted against time and the 
characteristic pattern produced has been termed the transmittance waveform (TW). It 
has been shown that the TW generated from the standard aPTT test can differentiate 
severe factor deficiencies and identify the presence of anticoagulants such as 
heparin 
(Figure 1.8). 
40 
1-4NM 
Eý: 
4000 
MOO 
Tfine 
Figure 1.8. Examples of TWs adapted from (Braun et al., 1997). 
A shows normal clot formation,, B shows delayed clot formation but norinal kinetics (as 
seen in heparin therapy), C and D are examples of impaired clot kinetics (as seen in 
factor deficiencies). 
The shape of the TW can be defined mathematically. Taking the second derivative of 
the TW (d 
2 T/dt2), the minimum value (min_2) represents the start of the propagation 
phase of coagulation. This point equates to the initial thrombin burst and the initial, 
rapid formation of fibrin. The time at which this point is defined as the clot time given 
by this instrumentation. The value of min_2 gives us a measure of the maximum 
acceleration in fibrin polymerisation. The maximum value of the second derivative 
(max-2) measures the maximum deceleration in fibrin polymerisation and marks the 
end of clot formation. In normal plasma samples no change in the light transmittance is 
seen prior to min_2 or following max-2. The minimum value of the first derivative 
(dT/dt) (min_l) of the TW gives a measure of the maximum rate of fibrin 
polymerisation. The rate of fibrin formation and subsequently the min_l value is 
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affected by severe factor deficiency. This is clearly demonstrated in Figure 1.8. Figure 
1.9 shows diagrammatically how these values relate to the TW. 
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Figure 1.9 Diagrammatic representation of TW. Reproduced with the kind permission 
of bioMerieux. Min-I (the value for the minimum of the first derivative) gives a 
measure of the maximum velocity of clot formation. Min -2 
(the value for the minimum 
of the second derivative) gives a measure of the maximum acceleration in the rate of 
clot formation. 
Interest in the TW has been predominantly in the detection of disseminated 
intravascular coagulation (DIC). DIC is a secondary response to a pre-existing primary 
pathology whereby the haemostatic response becomes perturbed and disseminated as 
opposed to the focused events in normal haemostasis. Downey et al (1997) were the 
first to note that within the intensive care population there were a group of patients who 
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demonstrated a drop in light transmittance prior to min_2 (Downey et al., 1997). This 
was termed a biphasic TW (bTW). This appeared to correlate with the onset of DIC. A 
follow-up prospective study looked at 1470 consecutive samples from 747 intensive 
care patients. They found that the bTW generally appeared before any abnormality in 
standard laboratory tests and showed a clinical correlation. The presence of a bTW was 
reported to have a 97.6% sensitivity and 98% specificity for the onset of DIC (Downey 
et al., 1998). The intensive care population is a very selected group of patients and the 
presence of a bTW in other patient groups needs to be interpreted alongside the clinical 
history of the patient (Luddington et al., 1997). 
As indicated above the change in light transmittance seen in association with the bTW 
takes place before min_2 is reached. Therefore, this change is not related to clot 
formation as it occurs prior to maximal thrombin generation. The molecular 
mechanisms associated with this observation have been reported (Nesheim et al., 2000). 
The drop in light transmittance is the result of the formation of a divalent metal ion 
dependent complex of C-reactive protein (CRP) and very low density lipoprotein 
(VLDL) and to a lesser extent intermediate density lipoprotein (IDL) (Nesheim et al., 
2000). The aPTT provides this divalent metal ion in the form of calcium. Elevated CRP 
levels are an essential prerequisite for the formation of this complex. CRP is an acute 
phase protein released by the liver as a consequence of inflammation and is frequently 
used to assess the presence and severity of an inflammatory response (Gabay and 
Kishner, 1999). However, a raised CRP is a poor marker of patient survival (Meisner et 
al., 1999). 
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The use of TW parameters other than the slope I measurement has been limited. Braun 
et al (1997) described the detection of severe factor deficiency using TW parameters. 
Shima et al (2002) used the TW to segregate different levels of clotting activity in 
patients previously assigned to a single grouping, i. e. less than 1.0 lU/dl, by 
conventional one-stage clotting assays. On consideration that significant clinical effect 
was noted in association with elevation of FIX levels to 0.81U/dl following gene therapy 
then it becomes important to be able to differentiate factor levels categorised as less 
than 1.0 IU/dI (Kay et al., 2000). Shima et al (2002) found that min_2 correlated with 
contrived factor levels in samples of FVIII deficient plasma spiked with recombinant 
FVIII. However, the correlation was less strong when patient plasma was tested. The 
correlation noted between the factor assay values and aPTT (derived from the time to 
min_2) was also poor at assay values less than 1.0 lU/dI. This suggests that other factors 
may affect the aPTT derived clot time and min_2. These authors commented that min-I 
may also be informative (Shima et al., 2002). As will be discussed later in this study the 
routine aPTT reagents were not optimally formulated to assess TW parameters. In 
addition the standard min_1 calculation required a complete TW trace which may not 
occur in samples with severe factor deficiency. 
1.10 Inhibition of Contact activation 
The contact system of plasma, which includes FXII, prekallikrein and high molecular 
weight kininogen, has been defined by its property to activate when exposed to 
artificial, negatively charged surfaces. This occurs because FXII 
binds and autoactivates 
when exposed to artificial, negatively charged surfaces (Silverberg et al., 
1980; Wiggins 
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and Cochrane, 1979). In the absence of FXII and a surface this system does not activate 
in citrated plasma (Schmaier et al., 1988). The sequence of events appears different on 
biological surfaces. It has been demonstrated that prekallikrein activates independently 
of FXII on human umbilical vein endothelial cells (HUVEC) (Rojkjaer et al., 1998). 
The mechanism probably being initially triggered by the binding of high molecular 
weight kininogen to specific membrane receptors (Reddigari et al., 1993; Rojkjaer and 
Schousboe, 1997). Once bound the high molecular weight kininogen acts as a major 
receptor for prekallikrein (Motta et al., 1998). The subsequent activation of 
prekallikrein to kallikrein then results in the activation of FXII. Thus the term contact 
activation is inappropriate for the activation mechanism shown on HUVEC membranes 
(Rojkjaer et al., 1998). 
However, the activation mechanism resulting from contact with foreign surfaces is very 
relevant to preparation of plasma for low tissue factor based assays. Many of the 
investigations in the field of contact activation have been performed using materials 
used in surgical implants. Here surgical procedures, such as valve or joint replacements 
result in foreign material being left in contact with circulating blood. This can result in 
the activation of various blood components. Haemostasis is activated via the intrinsic 
activation mechanism when blood makes contact with these foreign surfaces. The 
subsequent fibrin polymerisation requires platelet binding and activation of the common 
pathway of coagulation. Platelets are activated by binding either to the foreign surface 
or to fibin/fibrinogen and the complement system is also activated during blood contact 
with a foreign surface. Complement activation peptides such as sC5-9 can subsequently 
activate platelets. Hong et al (1999) examined four artificial surfaces, titanium, titanium 
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nitride coated titanium, stainless steel and PVC. They looked for contact mediated 
activation of haemostasis by assessing FXlla CI esterase inhibitor complex (FXIla- 
CIINA), FXIla antithrombin complex (FXIla-AT) and TAT complex. They 
demonstrated that titanium and titanium nitride demonstrated marked activation, 
stainless steel showed less activation, with PVC having minimal activation. PVC 
demonstrated increased FXlIa complexes but no elevation in TAT, suggesting that 
haemostasis was not triggered to the point of thrombin generation. This is difficult to 
understand in the light of the findings of Basmadjian et al (1997) who calculated that 
very small numbers of FXlla molecules were needed to trigger haemostasis. However, 
these findings are in keeping with the events seen in whole blood taken into standard 
polypropylene collection tubes containing citrate anticoagulant. 
Using whole blood in contact with a titanium surface (highest degree of activation) for 
60 minutes at 3 7'C, Hong et al (1999) found that the addition of 40ug/Ml of corn trypsin 
inhibitor CTI totally inhibited the formation of FXlla complexes and gave a 95% fall in 
TAT complex formation. They also found that platelet consumption was prevented. In 
the absence of CTI platelet counts dropped from 219+/- 2 x109/1 to 159+/-2 x109/1. 
However,, with CTI at 40ýtg/ml the drop in platelet count was minimal (219+/-2 x 109/1 
to 213+/-13 x109/1). Decreased platelet activation in the presence of CTI was also 
demonstrated, by decreased P-selectin expression, following either adenosine 
diphosphate (ADP) or collagen activation of platelets (Schneider et al., 1997). 
PVC is not a negatively charged surface and should not have prominent contact 
activating properties (Lamba et al., 2000). However, contact activation may occur as a 
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secondary event to platelet activation (Hong et al., 2001). Again these workers observed 
that contact activation through this mechanism could be minimised by the addition of 
CTI. Recent publications have suggested that any platelet contamination is 
contraindicated in assays of thrombin generation (Chantarangkul et al., 2003; 
Chantarangkul et al., 2004). 
CTI has been shown to effectively inhibit contact activation of blood through contact 
with foreign surfaces (Hong et al., 1999; Hong et al., 2001). It is one of a number of 
plant trypsin inhibitors. 
Proteins that bind tightly to mammalian trypsins and inhibit their catalytic activity are 
distributed widely in the plant and animal kingdoms. Plausible physiological roles have 
been proposed for many of the animal based inhibitors but the function of the plant 
trypsin inhibitors are not fully understood. Com is a good source of these plant trypsin 
inhibitors. In particular, the opaque-2 com which has been shown to contain about twice 
as much inhibitor as seeds of normal corn (Swartz et al., 1977). Swartz et al (1977) also 
found that the properties of the inhibitor from opaque-2 corn seeds differed considerably 
from those previously reported from unspecified maize strains. Hojima, et al (1980) 
(Hojima et al., 1980) found that the inhibitor described by Swartz (Swartz et al., 1977) 
was unique in its strong inhibition of Hageman factor fragment or trypsin, forming a 1: 1 
molar complex, with no action against kallikreins, plasmin, oc-thrombin, FXa or oc- 
chymotrypsin. They also demonstrated its ability to prolong the aPTT. These findings 
were confirmed in 1981 by Ratnoff and Moneme (Ratnoff and Moneme, 1981). They 
demonstrated the ability of the inhibitor to prolong the aPTT through inhibition of 
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FXIIa whilst not affecting other contact proteins. It was shown that the same site on the 
com inhibitor was responsible for both trypsin and FXlla inhibition (Lei and Reeck, 
1987). The amino acid sequence and secondary structure of the opaque-2 corn trypsin 
inhibitor have subsequently been determined (Mahoney et al., 1984). They found it to 
be unique in amino acid sequence and secondary structure to anything previously 
described. 
When assays utilise "subtle" triggers of haemostasis, such as physiological levels of 
tissue factor, the sample quality becomes highly significant. Contact activation of the 
sample prior to assay is recognized as a major problem and should be minimized. 
Investigators have used antibodies to FXII (Keularts et al., 200 1), polypropylene 
throughout sample handling (Dieri et al., 2002) and CTI added to the blood/plasma 
(Cawthern et al., 1998) (Rand et al., 1996) to minimize contact activation. 
The assay described by Rand et al (1996) is probably the closest that anyone has come 
to a "physiological" assay. They used native whole blood thus avoiding any interference 
from Ca2+ chelation. The use of citrate anticoagulants may interfere with CW+ - 
dependent processes such as vitamin K-dependent protein folding and binding. As these 
processes occur at a similar rate to clot formation, the chelation-recalcification 
processes may influence underlying cellular and enzymatic mechanisms. To activate the 
coagulation process Rand et al ( 1996) used TF and examined its use between 40 and 
300 pmol/l. However, they found that when they performed the experiments in the 
absence of contact inhibition activation of FV and prothrombin where seen at the same 
rates as contact inhibited blood in the presence of relipidated TF. They concluded that to 
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assess haemostasis using a low TF trigger contact inhibition was essential. They found 
that adding CTI to the whole blood gave a dose dependent prolongation of clot time up 
to a plasma level of 32ýtg/ml. Above this level no further increase was seen. The use of 
native whole blood and TAT formation as the endpoint makes this assay unsuitable for 
routine laboratory use at this time. 
The CAT assay (Hernker et al., 2003) uses a low TF trigger but relies on careful 
venepuncture and the use of polypropylene tubes to minimise contact activation. 
Although no data has been published regarding the use of CTI in this assay, the authors 
observed that in the absence of any TF trigger, thrombin generation did occur after a 
prolonged lag phase and was variable in nature. Furthermore, in their discussion they 
concluded that, even though plastics were used throughout, contact activation could not 
be avoided unless CTI inhibition of FXlla was used. 
1.11 Thesis aims 
The screening tests applied to the investigation of haemostasis have remained relatively 
unchanged for the later part of the 20th century. 
The limitations associated with the use of the PT and aPTT as preoperative screening 
tests have been recognised for some time with only 0.2% of patients benefiting from the 
test results whilst 2.3% would receive inappropriate treatment if the results were taken 
in isolation (Eisenberg et al., 1982). Other studies have equally shown that both the PT 
(Eisenberg and Goldfarb, 1976) and aPTT (Schwnan and Mushlin, 1986) offer little 
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benefit for preoperative screening or prediction of postoperative bleeding. Despite their 
limitations the PT and aPTT remain the primary screening tools available for 
haemorrhagic risk. 
Laboratory screening of thromboPhilia has been equally criticised and its clinical 
relevance questioned (Baglin et al., 2003; Greaves and Baglin, 2000; Machin, 2003). 
The requirement for a screening test that offers some clinical predictive value for 
thrombotic risk is widely recognised (Mannucci, 2002). 
The recent changes in the understanding of how haemostasis is triggered, in particular 
the central role of tissue factor, have raised questions with regards to the nature of 
laboratory screening tests. The main focus of this thesis was to examine the use of a 
physiological tissue factor concentration as a trigger for laboratory assessment of 
haemostasis. This required the use of tissue factor concentrations in the range 2-25pM 
which are believed to reflect the lower concentrations seen at the site of injury. 
The most appropriate end-point for a "global" assay of haemostasis would appear to be 
the generation of one of the end products of the reaction. 
The enzymatic endpoint of the haemostatic pathway is thrombin. The measurement of 
thrombin generation by the ETP has received much attention in the scientific literature 
as the assay has undergone many transformations, gradually evolving into the current 
CAT assay (Hemker et al., 2003). One of the main functions of thrombin is the 
conversion of fibrinogen to the insoluble fibrin mass responsible for clot formation. 
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Fibrin polymerisation has been assessed as an endpoint for many years using the 
thrombelastograph as a bedside monitor. However, recent modifications to the 
technology have made it a good candidate for a "global" screening assay using fibrin 
polymerisation as an end-point. The MDA series of instruments offer a unique feature 
in their optical capacity to measure fibrin polymerisation. Therefore, this technology 
would offer the prospect of a rapid fully automated "global" screen using a fibrin 
polymerisation end-point. 
Thus the aims of this thesis were: - 
9 To establish that physiological tissue factor could trigger an assay such that both 
hypocoagulable and hypercoagulable samples could be identified. 
* To consider the sample requirements for such an assay. 
9 To evaluate both thrombin generation and fibrin polymerisation as endpoints for 
"global" assays of haemostasis and optimise reagents for use in these assays. 
* To establish the potential of these assays by analysis of selected hypercoagulable 
and hypocoagulable patient groups. 
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2. MATERIALS AND METHODS 
2.1 Chemicals and reagents 
All chemicals and reagents were purchased from Sigma Aldrich Ltd (St Louis, MO. 
USA) or VWR International Ltd(Lutterworth, Leics., UK) unless otherwise stated. 
2.2 Sample preparation 
Platelet poor plasma was prepared from blood collected into 0.109M sodium citrate (9: 1 
v/v) using the Sarstedt monovette(k) collection system (Sarstedt, NtImbrecht, Germany). 
The samples were centrifuged at 3500g for 15 minutes and the resultant plasma stored 
at -80'C until assay. Platelet rich plasma was prepared by centrifugation at 800g for 10 
mins. 
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2.3 Assays used for patient selection. 
2.3.1 Standard assays using MDA series analyser. 
Instrumentation and consumables: 
MDA series coagulometer (bioMerieux, Lyon, France), 
Disposable cuvettes (bioMerieux, Lyon, France), 
Imidazole buffer (5 OmM Glyoxaline, I OOmM NaCl, pH 7.3) (bioMerieux, Lyon, 
France). 
D- 
Reagents: 
Simplastin HTFO (bioMerieux, Lyon, France). 
Platelin LS (bioMerieux, Lyon, France), 
Platelin LS CaC12(bioMerieux, Lyon, France) 
Factor 11 (Fll) deficient plasma (Helena BioSciences, Sunderland, UK), 
FV deficient plasma (bioMerieux, Lyon, France), 
FVII deficient plasma (bioMerieux, Lyon, France), 
FVIII deficient plasma (bioMerieux, Lyon, France), 
FIX deficient plasma (Biopool International, Ventura, CA, USA), 
FX deficient plasma (Helena BioSciences, Sunderland, UK), 
FXI deficient plasma (bioMerieux, Lyon, France), 
FXII deficient plasma (bioMerieux, Lyon, France), 
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MDA PC kit (bioMerieux, Lyon, France), comprising; PC activator and PC 
substrate. 
MDA D-dimer kit (bioMe'rieux, Lyon, France), comprising: diluent, buffer, latex 
solution, reference material and control material. 
Reference material (Technoclone, Vienna, Austria) 
Normal and abnormal control plasma. 
Assay protocol: 
Assays of PT, aPTT, PC, Fll, FV, FVII, FVIII, FIX, FX, FXI, FXII and DD were 
performed using standard MDA protocols. 
2.3.2 Assays adapted for use on the MDA series analyser. 
Instrumentation and consumables: 
MDA series coagulometer (bioMerieux, Lyon, France), 
Disposable cuvettes (bioMerieux, Lyon, France), 
Imidazole buffer (50mM Glyoxaline, I OOmM NaCl, pH 7.3) (bioMerieux, Lyon, 
France). 
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2.3.2.1 Free protein S 
Reagents: 
Liatest free PS kit (Diagnostica Stago, Paris, France) comprising: buffer and 
latex solutions. 
Reference material (Technoclone, Vienna, Austria) 
Normal and abnormal control plasma. 
Assay protocol: 
The standard latex B3 open assay was run from the analyser menu. Control or reference 
material was loaded onto row A, Imidazole buffer (50mM Glyoxaline, IOOmM NaCl, 
pH 7.3) loaded onto row B, assay buffer (50mM HEPES, 145 mM NaCl, pH 7.1) was 
loaded onto row C and latex solution was loaded onto row D. The analyser diluted 8ýd 
of plasma to 24ýtl with imidazole buffer (50mM Glyoxaline, I OOmM NaCl, pH 7.3) in a 
test cuvette, and warmed the dilution to 37'C. Following the addition of 50ýd of assay 
buffer (50mM HEPES, 145mM NaCl, pH 7.1) the mixture was incubated at 37'C for 
220 seconds. Agglutination was monitored at 540m-n for 240 seconds following the 
addition of 75ýtl of latex suspension. The free PS concentration was then calculated by 
extrapolation from a stored reference curve. 
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2-3.2.2 Activated Protein C resistance 
Reagents: 
CoatestOAPCTmResistance kit (Chromogenix, Lexington, MA, USA), 
comprising: APTT reagent, APC/CaC12, and CaC12- 
Normal and abnormal control plasma. 
Assay protocol: 
The APC and APC blank assays were run from the analyser menu. Control material was 
loaded onto row A, APTT reagent was loaded onto row C and APC/CaCl2 and CaC12 
was loaded onto row D. The analyser added 50ýd of APTT reagent to 25ýtl of plasma 
which had been warmed to 37T. Following a further 220 seconds incubation 50ýd of 
APC/CaC12 or CaC12 was added and the time to clot formation was measured. Results 
were expressed as a ratio of the clot time in the presence of APC . the clot time in the 
absence of APC. 
2.3.3 Assays using the MTX series analyser. 
Instrumentation and consumables: 
MTX series coagulometer (bioMerieux, Lyon, France), 
Disposable cuvettes (bioMerieux, Lyon, France), 
Imidazole buffer (5 OmM Glyoxaline, I OOmM NaCl, pH 7.3) (bioMerieux, Lyon, 
France) 
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2.3.3. lAntithrombin 
Reagents: 
Coarnatic*AT40OTM (Chromogenix, Lexington, MA, USA) chromogenic 
antithrombin activity kit comprising; heparin buffer, FXa and Substrate S-2772. 
Reference material (Technoclone, Vienna, Austria) 
Normal and abnormal control plasma. 
Assay protocol: 
To 2ýtl of a 50/50 mix of plasma and heparin buffer (Tris buffer, pH8.2, ionic strength 
0.25, unspecified heparin concentration), 200ýtl of FXa was added and the mixture 
incubated for 60 seconds. The absorbance change at 405mn over 60 seconds was 
measured following addition of I 00ýtl of substrate S-2772. AT levels were then 
calculated from a stored reference curve. 
2.3.3.2 Lupus anticoagulant 
Reagents: 
LA screenO and LA ConfinnO (Gradipore, Frenchs Forest NSW, Australia) 
Fumed Silica (Sigma-Aldrich Ltd, St. Louis, MO, USA) 
Bell and Alton Platelet substitute (Diagnostic Reagents Ltd. Oxford, UK) (Bell 
and Alton, 1954). 
Calcium Chloride (BDH Ltd. Poole, UK) 
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Assay protocol: 
The assays were performed as previously described (Luddington et al., 1999). Briefly 
the dilute Russel's Viper venom time (dRVVT) was performed by adding 100ýtl of LA 
screeng (a low phospholipid reagent with high lupus sensitivity) or LA confirm(t (a 
phospholipid rich reagent for correction of lupus anticoagulants) to I 00ýd of plasma that 
had been prewanned for 30 seconds at 37'C. The subsequent clot fonnation was then 
timed. The silica clot times were performed by timing the clot formation following 
recalcification with 75ýd of 0.025M CaC12 of a pre incubated mixture of 75ýd plasma 
and 75ýtl of silica (1.75g/l)/phospholipid reagent. 
2.3.4 Molecular screening for Factor V Leiden and Prothrombin G20210A 
variants. 
Instrumentation and disposables: 
M-J-Research PTC-200 peltier programmable thermal cycler (Genetic Research 
Instrumentation. Ltd. Essex. UK). 
Submarine gel tank and power pack (Bio-Rad Laboratories Ltd, Hemel 
Hempstead, UK). 
Syngene Gene Genius Bio imaging system (Genetic Research Instrumentation. 
Ltd. Essex. UK). 
TM-40 ultraviolet transilluminator (Ultra violet products Ltd, Cambridge, UK). 
Bind-ETTm Ethidium Bromide removal system (Elchrom Scientific, 
Gewerbestrasse, Switzerland). 
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200[d thin-walled tubes for PCR (Molecular Bioproducts, San Diego, USA). 
Reagents: 
Thermus aquaticus DNA polymerase (Perkin-Elmer corporation, Warrington, 
UK). 
IN PCR buffer (lOOmM Tris-HCI, 500mM KCI) (Perkin-Elmer corporation, 
Warrington, UK). 
25mM Magnesium chloride (Perkin-Elmer corporation, Warrington, UK). 
Deoxynucleotide tri-phosphates (Amersham Pharmacia Biotech, Milton Keynes, 
UK) 
PCR Primers (University Department of Biochemistry, Cambridge, UK). 
Hi-pure low EEO agarose (Sigma-Aldrich Ltd, St. Louis, MO, USA) 
ýX 174 RF DNAlHaeIII digest size markers (HT Biotechnology Ltd ) 
Mn1 I and Hind Iff (New England Biolabs Inc. Hitchin, UK) 
Spennicline (Calbiochem Corp. La Jolla, USA). 
I Ox Tris-borate buffer (Sigma-Aldrich Ltd, St. Louis, MO, USA). 
Loading buffer: 30% glycerol, 0.125% bromophenol blue w/v, 0.125% xylene 
cyanol w/v. (BDH, Poole, UK). 
Ethidium Bromide (BDH, Poole, UK). 
Assay Protocol: 
A multiplex PCR method to simultaneously screen for the factor V Leiden and 
Prothrombin G2021 OA mutations was based upon that of Gomez et al (1998) (Gomez et 
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al., 1998). Briefly, following multiplex PCR the products were simultaneously digested 
with MnI I and Hind III. The 345bp Prothrombin fragment was cleaved by MnI I to 
yield fragments of 15,58 and 272bp. In the presence of the prothrombin G20210A 
mutation the 272bp fragment was further cleaved by Hind III to yield fragments of 249 
and 23bp. The FV fragment had no Hind III restriction sites but was cleaved by Mnl I to 
yield fragments of 37,67 and 116bp. In the presence of the FV Leiden mutation a 
restriction site was lost resulting in the generation of fragments of 67 and 153bp. 
ABC DE FG HIJKL 
Figure 2.1 Gel showing enzyme digests following multiplex PCR for FV Leiden and PT 
G20210A mutations. Lane A contains molecular weight markers. Lanes B-G show 
normal DNA. Lane H shows a PT G20210A heterozygote. Lane I shows a FV Leiden 
heterozygote. Lanes J and K show homozygous FV Leiden and PT G20210A mutations 
respectively. Lane L is a blank lane containing no DNA. 
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2.4 Methods of reagent preparation and assessment. 
2.4.1 Preparation of Phospholipid vesicles 
Instrumentation and consumables: 
Extrusion device ( Avestin, Ottawa, Canada) 
Polycarbonate filters (Glen Creston, Middlesex, UK) 
Reagents: 
Synthetic phospholipids in chloroform ( Avanti polar Lipids, Alabama, USA). 
Assay protocol: 
The vesicles were prepared as described by Falls et al (2000) (Falls et al., 2000). 
Briefly, the lipids were combined in the required proportions and dried under nitrogen 
at 45'C for 30 minutes and then resuspended in HEPES buffer (50mM HEPES, 145mM 
NaCl, pH 7.1). The mixture was then passed through the extrusion device 11 times 
using a 100nm diameter polycarbonate filter. A further II passes were then perfonned 
through a 50nm diameter polycarbonate filter and the resultant vesicles stored at 4'C 
until use. 
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2.4.2 Relipidation of tissue factor 
Instrumentation and consumables: 
Extrusion device (Avestin, Ottawa, Canada) 
Polycarbonate filters (Glen Creston, Middlesex, UK) 
Assay protocol: 
Phospholipid vesicles were taken following the initial II passes through a 100nm 
polycarbonate filter (section 2.4.1). These were then mixed with the required 
concentration of recombinant tissue factor (American Diagnostica Inc. Stamford, CT. 
USA) and passed through the extrusion device a further 21 times using a 50nm diameter 
polycarbonate filter. The resultant vesicles were stored at -80'C until use. The tissue 
factor activity of the vesicles was confirtned using the tissue factor assay described 
below (Section 2.4.4) 
2.4.3 CTI activity by prolongation of aPTT 
Instrumentation and consumanubles: 
MDA series coagulometer (bioMerieux, Lyon, France), 
Disposable cuvettes (bioMerieux, Lyon, France), 
Imidazole buffer (5 OmM Glyoxaline, I OOmM NaCl, pH 7.3) (bioMe'rieux, Lyon, 
France) 
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Reagents: 
Platelin LS (bioMerieux, Lyon, France), 
Platelin LS CaC12(bioMerieux, Lyon, France), 
CTI (Cambridge Biosciences, Cambridge, UK), 
CTI buffer (20nM TRIS, 150mM NaCl, pH 8.5), 
Normal plasma pool (Technoclone, Vienna, Austria) 
Assay protocol: 
A series of CTI concentrations (0,200,400,600,800,1000,2000,3000 gg/ml) were 
prepared by dilution of reference and test lots of CTI in CTI buffer (20mM TRIS, 
150rnM NaCl, pH8.5). To 450ýd of normal pooled plasma 50ýd of the CTI dilution was 
added and allowed to stand at RTOC for 10 minutes prior to testing. Duplicate aPTTs 
(Section 2.3.1.2) were then performed for all plasma dilutions. One unit was defined as 
the concentration of CTI required to double the baseline (no CTI) APTT of the nonnal 
pooled plasma. 
2.4.4 Assay of Tissue factor activity 
Instrumentation and consumables: 
Microplate reader (Thenno Electron Corp. Basingstoke, UK) 
96 well microtitre plates (Bachem UK Ltd, St. Helens, UK) 
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Reagents: 
Actichrome*)TF (American Diagnostica Inc. Stamford, CT. USA) chromogenic 
assay for TF activity, comprising; assay buffer (unspecified constitution, pH 
8.4), TF/TFPI depleted plasma, lipidated TF, human FX, human FVlla and 
Spectrozyme(XFXa. 
Glacial Acetic Acid (BDH, Poole, UK) 
Assay protocol: 
A reaction mixture was prepared, in each well of the microtitre plate, comprising; 50ýd 
of assay buffer (unspecified constitution, pH 8.4), 25ýtl of lipidated TF standards or test 
plasma, 25ýtl of human FVII and 25ýtl human FX. Following a 15 minute incubation at 
37'C 25gl of Spectrozyme0FXa substrate was added to each well and incubation 
continued for a further 60 minutes at 37'C. The reaction was stopped by the addition of 
50ýd of glacial acetic acid and the resultant absorbance at 405nm measured. TF activity 
was interpolated from a standard curve of absorbance against lipidated TF concentration 
(PM). 
2.4.5 Gel filtered platelets 
Gel filtered platelets were prepared as previously described (Taube et al., 1999). PRP 
was applied to a C-series 16/40 gel-chromatography column packed with Sepharose 
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CL-6B (Sigma Aldrich Ltd. Poole, UK). Following elution with phosphate buffered 
saline (3. ImM NaH2PO4. ) 18.9mM Na2HP04,145mM NaCl, pH 7.2) (PBS), the 
fractions containing platelets were pooled and the platelet count adjusted to 150 x 109/1 
in PBS. 
2.5 Assav developmen 
2.5.1 Using a mechanical end point 
Instrumentation and disposables: 
KC 10 coagulometer (Sigma-Amelung, Poole, UK). 
Disposable ball bearings and cuvettes (Sigma-Amelung, Poole, UK) 
2.5.1.1 Low TF assay using mechanical end-point detection 
Reagents: 
Commercial thromboplastin tissue factor sources: 
Recombinant: 
Innovin@ (Sysmex UK Ltd, Milton Keynes, UK), 
Recombiplas@ (Ortho Diagnostics, Amersham, UK), 
Thromborel@ R (Sysmex UK Ltd, Milton Keynes, UK), 
HTFO (bioMerieux, Lyon, France). 
Rabbit derived: 
Simplastin@ Excel S (bioMerieux, Lyon, France), 
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Manchester@ reagent (Helena BioSciences, Sunderland, UK), 
PT-Fib HS+@ (Instrumentation Laboratory UK Ltd, Warrington, UK) 
Human derived: 
Thromborel@ S (Sysmex UK Ltd, Milton Keynes, UK) 
HEPES (Sigma Aldrich. St Louis, MO. USA) Buffer (50mM HEPES, 145mM 
NaCl, pH 7.1). 
Calcium Chloride (BDH Ltd. Poole, UK) 
The thromboplastins were serially diluted in Hepes buffer (50mM HEPES, 145mM 
NaCl, pH 7.1) and stored on ice. These dilutions were tested within 30 minutes of 
preparation. 
Assay protocol: 
To a KCIO cuvette containing 70ýtl of plasma previously warmed to 370C an equal 
volume of thromboplastin dilution was added. Following 220 seconds of incubation at 
37'Cý 70ýtl of 0.025M CaC12 was added and the clotting time recorded. 
2.5.1.2 Low TF assay to assess the effect ofphospholipid using mechanical end-point 
detection 
Additional Reagents: 
Bell and Alton Platelet substitute (Diagnostic Reagents Ltd. Oxford, UK) (Bell 
and Alton, 1954). 
Gel filtered freeze fractured platelets (Section 2.4.5) 
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Assay protocol: 
The assay was performed as described above (Section 2.5.1.1) with the addition of 
phospholipid as detailed in Section 3.1.3 immediately prior to the dilute thromboplastin. 
2.5.1.3 Low tissuejactor assay to assess the effect of thrombomodulin using mechanical 
end-point detection. 
Additional reagents: 
Rabbit Thrombomodulin (American Diagnostica Inc. Stamford, CT. USA) 
Assay protocol: 
The assay was performed as described above (Section 2.5.1.1) with the addition of 70ýtl 
of thrombomodulin prior to the dilute thromboplastin. 
2.5.2 Low TF assay using optical end-point detection. 
Instrumentation and consumables: 
MDA series coagulometer (bioMerieux, Lyon, France), 
Disposable cuvettes (bioMerieux, Lyon, France), 
Imidazole buffer (50mM Glyoxaline, I OOmM NaCl, pH 7.3) (bioMerieux, Lyon, 
France) 
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Reagents: 
FVIII deficient plasma (bioMerieux, Lyon, France), 
FIX deficient plasma (bioMerieux, Lyon, France), 
PC deficient plasma (Biopool International, CA, USA) and 
PS deficient plasma (Biopool International, CA, USA) 
Simplastin HTFS (bioMerieux, Lyon, France). 
Rabbit Thrombomodulin (American Diagnostica Inc. Stamford, CT. USA) 
Calcium Chloride (BDH Ltd. Poole, UK) 
Assay protocol: 
An assay was constructed using the assay editor function of the analyser. The TF/ TM 
reagent was loaded onto row C and 0.025M Calcium chloride was loaded onto row D. 
The analyser was programmed to add 50ýd of dilute thromboplastin reagent +/- TM to 
an equal volume of pre warmed plasma. Following 220 seconds of incubation at 37'C 
50ýtl of 0.025M CaCl2was added and the clotting time recorded. Clot formation kinetics 
were monitored at a wavelength of 460nm. 
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2.5.3 Calibrated automated thrombin generation assay 
Instrumentation and consurnables 
Fluoroscan Ascent (Thermolabsystems OY, Helsinki, Finland) 
Thrombinoscope software (Synapse BV, Maastricht, The Netherlands) 
96-well microplates (Greiner Bio-One Ltd. Stonehouse, UK) 
D- 
Reagents 
Fluorogenic substrate Z-Gly-Gly-Arg-AMC (Bachem, Dubendorf, Switzerland) 
Phospholipid Vesicles (Section 2.4.1) 
Recombinant human tissue-factor (American Diagnostica Inc, Stamford CT, 
USA) 
Relipidated tissue factor (bioMerieux, Lyon, France) 
Rabbit thrombomodulin (American Diagnostica Inc, Stamford CT, USA) 
Dimethyl sulphoxide (DMSO) (Sigma Aldrich Ltd, Poole, UK) 
Calcium Chloride (BDH Ltd, Poole, UK) 
Bovine Serum Albumin (BSA) (Sigma Aldrich Ltd, Poole UK) 
HEPES (BDH Ltd, Poole, UK) 
Thrombin Calibrator (Synapse BV, Maastricht, The Netherlands) 
Assay protocol 
The assay was performed as described (Hemker et al., 2003). Briefly 
20ýtl of buffer 
(20mM Hepes, 140mM NaCl, 5mg/ml BSA, pH 7.35) containing trigger reagent were 
added to each microplate well. Following the addition of 80ýtl of sample, 
20ýtl of 
substrate reagent [875ýd buffer (20mM HEPES, 60mg/ml BSA, pH 
7.35), 100ýtl IM 
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CaC12,25 W of fluorochrome in I OOmM DMSO] was added and the reaction monitored 
using thrombinoscope software. 
2.5.4 Thrombelastometry 
Instrumentation and consumables; 
ROTEMS (Pentapharm Gmbh, Munich, Germany) 
Disposable cups and pins (Pentapharm Gmbh, Basle, Switzerland) 
Relipidated recombinant tissue factor (Section 2.4.2) 
0.2M Calcium Chloride (Sysmex UK Ltd, Milton Keynes, UK) 
Assay protocol: 
The assay was performed as described (Sorensen et al., 2003). Briefly a minimal 
volume of relipidated tissue was added to the cup followed by 20gl of 0.2M CaC12- 
Following the addition of 340ýtl of platelet poor plasma the cup was located with the pin 
on the instrument and the thrombelastogram initiated. 
2.6. Statistical Analysis 
The following statistical analysis was used in this study: 
n 
Mean W == I /nI, xi 
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i=l 
Standard deviation (SD) 
SD (S) = ýS2 where s2 = variance =I /n_ I [yX2_nX2] 
Standard error (SE) 
s 
SE=ýn where n= sample size 
Coefficient of Variance (CV) 
s 
CV xX 100 
Correlation coefficient (r) 
yxy-m 
r= (n-1) sx sy 
where s,, and sy denote SDs 
Mann-Whitney U Rank Sum Test 
Ul = nln2+ R, 
n2(M±l ) 
U2 = nln2+ 2- R2 
n, = the number of observations in group I 
n2= the number of observations in group 2 
R, = the sum of the ranks assigned to group I 
R2= the sum of the ranks assigned to group 2 
U= min (U 1, U2) 
U was compared with the critical value of U at the significance level p<0.05. 
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3. RESULTS 
3.1 Development of an assay to detect hypocoagulability using a low TF trigger and 
a clot time end-point. 
Introduction 
Josso (1965) was the first to postulate that FVII could activate FIX so involving FVIII 
and FIX in the thromboplastin triggered coagulation (Josso and Prou-Wartelle, 1965). 
However, the rate of FXa generation by FIXa is 6-10 times slower than the rate of FXa 
generation from FVlIa (Jesty and Silverberg, 1979; Zur and Nemerson, 1980). 
Furthennore, FXa, which is generated in the initial stages of the extrinsic pathway, has 
also been shown to participate in the first proteolytic step in the activation of FIX in a 
highly purified system (Lawson and Mann, 1991). It was reported using a dilute (1/250) 
rabbit brain thromboplastin that FXa generation was reduced to 10% of nonnal values 
in FVIII or FIX deficient plasma (Marlar et al., 1982). This decrease was normalised 
following replacement of the deficient factor. Decreased thrombin generation was 
demonstrated in FIX and FVIII deficient plasmas by Xi et al (1989) (Xi et al., 1989) 
and severe FXI deficiency (He et al., 2001; Keularts et al., 2001) using dilute 
thromboplastin reagents. Therefore, it was reasonable to assume that by diluting 
standard commercially available thromboplastin reagents an assay sensitive to 
decreased levels of FVIII and FIX could be produced. 
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3.1.2 The ability of the low TF assay to discriminate FVIII deficiency from 
normal. 
A panel of commercially available thromboplastin reagents was tested against normal 
plasma (Technoclone, Vienna, Austria) and FVIII deficient plasma (bioMerieux, Lyon, 
France) to determine their ability to discriminate between the two (Section 2.5.1.1). The 
commercial FVIII deficient plasma chosen was a chemically depleted reagent 
containing von Willebrand factor (vWF). The results are summarised in Table 3.1.1. 
Thromboplastin Plasma 1110 V100 1/1000 1/5k 1/10k 1/50k 
lnnovin@ Ratio 1.38 1.50 1.47 1.36 1.38 1.47 
InnovinO Norm. Ratio 1.00 1.08 1.06 0.98 0.99 1.06 
RecombiplasO Ratio 1.24 1.19 1.04 1.08 1.24 1.49 
Recombiplas@) Norm. Ratio 1.00 0.96 0.84 0.86 1.00 1.21 
HTFO Ratio 0.92 0.84 0.90 1.01 1.01 1.30 
HTFO Norm. Ratio 1.00 0.90 0.98 1.10 1.10 1.41 
Thromborel@ R Ratio 1.00 0.98 1.03 1.05 1.19 1.31 
Thromborele R Norm. Ratio 1.00 0.98 1.03 1.05 1.19 1.31 
Simplastin@ Excel S Ratio 1.23 1.07 0.94 0.84 0.78 0.90 
SimplastinO Excel S Norm. Ratio 1.00 0.87 0.76 0.68 0.62 0.73 
Manchester Reagent Ratio 0.92 0.84 0.91 0.98 1.00 1.16 
Manchester Reagent Norm. Ratio 1.00 0.92 1.00 1.08 1.10 1.26 
PT-Fib HS+6 Ratio 1.10 1.10 0.94 1.01 0.97 0.97 
PT-Fib HS+@ Norm. Ratio 1.00 0.99 0.85 0.92 0.87 0.87 
Thromborel@ S Ratio 1.00 0.90 0.87 0.87 0.88 1.20 
Thromborel@ S Norm. Ratio 1.00 0.90 0.87 0.87 0.88 1.20 
Table 3.1.1 Ratios produced for dilute thromboplastins against normal and FVIII 
deficient plasmas using a mechanical end-point detection. 
Ratio = clot time for FVIII def Plasma/ clot time for normal plasma. 
Normalised Ratio = Ratio at I /x dilution. / ratio at I/ 10 dilution. 
The relationship between clotting time and dilution was most clearly demonstrated 
by 
the use of a normalised ratio (Ratio at I /x dilution. / ratio at I/ 10 
dilution). This allowed 
the relative prolongation of clotting time with increasing 
dilution to be clearly 
illustrated. Two of the thromboplastins selected demonstrated a switch in the route of 
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coagulation to the Josso loop on dilution. This was demonstrated by the progressively 
increased normalised ratio following dilution. These thromboplastins, HTFO and 
Thromborel@ R, are both recombinant products. The results are highlighted in Table 
3.1.1. The phenomenon was demonstrated to a lesser extent by Recombiplas@, 
Manchester Reagent and Thromborel@ S and not seen with the Simplastin@ Excel S 
and PT-Fib HS+@ reagents. 
3.1.3 The effect of additional phospholipid to the sensitivity of the low TF 
triggered assay to detect FVIII deficiency 
Using HTF@ at dilutions of 1/100 and 1/50000, a series of exPeriments were conducted 
to examine the effect of adding additional phospholipid to the reaction (Section 2.5.1.2). 
Phospholipid was added from 2 different sources. The first was Platelet substitute 
(Diagnostic Reagents Ltd. Oxford, UK). This was a crude phospholipid mixture 
prepared as a freeze-dried buffered emulsion of chloroform extract of brain tissue (Bell 
and Alton, 1954) (Table 3.1.2). The effect was most clearly demonstrated by 
comparison of the normalised ratios for FVIII deficient plasma against the normalised 
ratio for the normal plasma pool [Ratio (FVIII def) / Ratio (Normal)]. This is 
highlighted in the final row of Table 3.1.2. 
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Plasma Type Thromboplastin 
Dilution 
No P. lipid 1vl 1/100 
B&A 
'llal 1/10 
B&A 
1tA B&A 5gl B&A IOIA B&A 
Normal 1/100 78.50 79.10 77.90 65.50 55.70 54.60 
Normal 1/50000 424.20 335.80 275.90 233.00 233.30 234.50 
Ratio(normal) 5.40 4.25 3.54 3.56 4.19 4.29 
FVlil Deficient 1/100 69.50 68.50 66-00 58.50 52.10 48.40 
FVI II Deficient 1/50000 618.10 385.70 304.70 211.40 238.90 214.10 
Ratio(Mlldef) 8.89 5.63 4.62 3.61 4.59 4.42 
Ratio(FVllldeo 
Ratio(normal) 
1.65 1.33 
II 
1.30 
I 
1.02 
I 
1.09 
I 
1.03 
-i 
Table 3.1.2 Clot times (seconds) produced with the addition of Bell and Alton platelet 
substitute to reaction (B&A). 
Abbreviations: P. Lipid = phospholipid, B&A = Bell and Alton platelet substitute, 
FVIIIdef = factor VIII deficient plasma. 
Addition of the Bell and Alton platelet substitute (B&A) reduced the clotting times. 
However the sensitivity to FVIII deficiency, as shown by ratio (FVIII def )/ ratio 
(Nonnal) was lost with increasing phospholipid concentration. This could be the result 
of TF activity present within the phospholipid extract (Walsh and Lipscomb, 1976). 
This possibility was assessed using the ActichromegTF activity assay (Section 2.4-4) 
(American Diagnostica Inc. Greenwich, USA). The assay results confirmed that the 
reagent, when reconstituted as directed by the manufacturer, contained in excess of 
300pM TF. 
To avoid the effect of TF contamination, the experiment was repeated using freeze- 
fractured gel filtered human platelets (GFFP). GFFP were prepared by passing platelet 
rich plasma suspended in HEPES-Tyrode's buffer (I 13mmol NaCl, 2.8mmol KCI, 
4.3mmolNaH2PO4,2mmolMgCI2,2mmol CaC12.0.1% glucose, 0.1% bovine serum 
albumin, 20 mmol HEPES, pH 7.35) through a Sepharose 2B column (Yamamoto et al., 
1988). The plasma protein free platelet fraction was then subjected to 3 cycles of rapid 
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freezing at -800C and thawing at 370C to disrupt the platelet membrane and expose the 
anionic phosphoplipids (Section 2.4.5). 
The results obtained with the freeze fractured platelets (Table 3.1.3) demonstrated the 
same pattern as that seen with the B&A. The preparation was assessed for TF 
contamination again using the Actichrome*)TF activity assay (Section 2.4.4) (American 
Diagnostica Inc. Greenwich, USA). No TF activity was detected. Thus, the addition of 
phospholipids, in this form shortened the clot times but abolished the sensitivity to 
FVIII deficiency. 
Plasma 
Type 
Thromboplastin 
Dilution 
No P. lipid 1ý11 1110 
GFFP 
1[d GFFP 5gl GFFP 10gi GFFP 
Normal 1/100 78.5 77.9 68.7 58.5 58.1 
Normal 1/50k 424.2 323.1 241.4 257.9 232.7 
Ratio(normal) 5.40 4.15 3.51 4.41 4.01 
FVIII 
Deficient 
1/100 69.5 66.5 63.4 57.9 53.5 
FVIII 
Deficient 
1/50k 618.1 347.4 246.5 255.1 239.7 
Ratio(FVllldeo 8.89 5.22 3.89 4.41 4.48 
Ratio(FVlllcleý 
Ratio(nor al) 
1.65 I 1.26 I 1.11 I 1.00 I 1.12 
Table 3.1.3 Clot times produced with the addition of GFFP to the low TF triggered 
assay. 
Abbreviations: P. Lipid = phospholipid, FV111def = factor VIII deficient plasma, GFFP 
= Gel-filtered freeze fractured platelets. 
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3.1.4 The sensitivity of the low TF triggered assay to the concentration of FVIII. 
This experiment used a series of concentrations of FVIII to assess the sensitivity to 
FVIII. The 5 thromboplastins identified previously (Section 3.1.2) as enhancing 
coagulation via the Josso loop were tested. 
A series of dilutions were prepared to give a range of FVIII concentrations from 0% to 
100%. Recombinant FVIII (Helixate, Aventis, West Sussex, UK) was added to FVIII 
deficient plasma (bioMerieux, Lyon, France) to achieve the desired FVIII 
concentrations. Factor levels were determined using a one stage assay based upon the 
method of Hardisty and Macpherson (1962) using an MDA 180 automated coagulometer 
(bioMerieux, Lyon, France). The assay was performed using a standard assay protocol 
Section 2.5.1.1. 
For comparison the effect was most clearly demonstrated by use of a normalised ratio. 
In this instance the results obtained at a given FVIII concentration were compared to 
those obtained at 100% FVIII. As shown previously (Section 3.1.2) the recombinant 
human TF reagents Thromborel@ R and HTFO gave the most effective response to 
decreased FVIII levels. However, the results (Table 3.1.4) demonstrated that they were 
only sensitive to very low levels of FVIII (<10%). ThromborelS S was the only other 
reagent to give a raised nonnalised ratio at the 10% FVIII level. 
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Thromboplastin Dilution 0% FVIII 10% FVIII 20% FVIII 30% FVIII 100% 
FVIII 
Recombiplas@ 
Recombiplas@) 
Ratio 
Normalised ratio 
10.63 
1.18 
8.08 
0.92 
7.85 
0.91 
8.54 
0.85 
9.14 
1.00 
Manchester Ratio 5.59 5.69 5.63 5.64 5.50 
Manchester Normalised ratio 1.02 1.03 1.02 1.02 1.00 
Thromborelo S 
Thromborel@ S 
Thromborele R 
Ratio 
Normalised ratio 
Ratio 
7.18 
1.16 
8.06 
6.94 
1.12 
6.49 
6.31 
1.02 
5.98 
6.69 
1.08 
5.86 
6.18 
1.00 
5.62 
Thromborele R Normalised ratio 1.43 1.15 1.06 1.04 1.00 
HTFO Ratio 6.39 5.59 5.30 5.08 4.85 
HTFO Normalised ratio 1.32 1.15 1 1.09 
-1 
1.05 1.00 
_j 
Table 3.1.4 FVIII sensitivity of dilute thromboplastins. 
Ratio = Clot time at 1/5 0000 dilution. / clot time at I/ 100 dilution. 
Normalised Ratio = ratio at x% FVIII / Ratio at 100% FVIIL 
Abbreviations: FVIII = factor VIII 
3.1.5 Determination of the sensitivity of the low TF triggered assay to the 
concentration of FIX. 
This experiment used a series of concentrations of FIX to assess the FIX sensitivity. 
Again the 5 thromboplastins identified previously (Section 3.1.2) as enhancing 
coagulation via the Josso loop were tested. 
A series of dilutions were prepared to give a range of FIX concentrations from 0% to 
100%. High purity FIX (Replenine, Bio Products Laboratory, Herts, UK) was added to 
an immunologically depleted FIX deficient plasma (bioMerieux, Lyon, France) to 
achieve the desired FIX concentrations. Factor levels were determined using a one stage 
assay based upon the method of Hardisty and Macpherson (1962) using an MDA180 
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automated coagulometer (bioMerieux, Lyon, France). The assay was again performed 
as described in Section 2.5.1.1. 
Thromboplastin 
Recombiplaso 
Dilution 
Ratio 
0% FIX 
11-06 
10%y( FIX 0 
8.60 
20% FIX 
8.51 
t, 30% FIX 
7.92 
100% FIX 
9.35 
Recombiplas@ 
Manchester 
Normalised ratio 
Ratio 
1.18 
5.30 
0.92 
5.73 
0.91 
6.11 
0.85 
6.32 
1.00 
5.60 
Manchester Normalised ratio 0.94 1.02 1.09 1.13 1.00 
Thromborel@ S Ratio 9.70 7.97 7.76 7.46 7.38 
Thromborelo S Normalised ratio 1.31 1.08 1.05 1.01 1.00 
Thromborel@ R Ratio 8.09 6.99 7.17 6.24 6.18 
ThromborelO R Normalised ratio 1.31 1.13 1.16 1.01 1.00 
HTFO Ratio 6.90 5.77 5.71 5.36 5.93 
HTFO Normalised ratio -11 " 0.97 0.96 0.90 1.00 
Table 3.1.5 F IX sensitivity of dilute thromboplastins. 
Ratio = Clot time at 1150000 dilution. / clot time at 1/100 dilution. 
Normalised Ratio = ratio at x% F IX / Ratio at 100% FIX. 
Abbreviations: FIX = factor IX 
Again for comparison the effect was most clearly demonstrated by use of a normalised 
ratio. The results obtained at a given FIX concentration were compared to those 
obtained at 100% FIX. The reagents were relatively insensitive to changes in FIX over 
the range 10-100% (Table 3.1.5). The Thromborel reagents both recombinant and 
placental derived were the most sensitive to FIX deficiency as shown by raised 
nonnalised ratios. 
3.1.6 Confirmation of the factor sensitivities using clinical samples. 
To confirm the findings of the factor sensitivities determined previously (Sections 3.1.4 
and 3.1.5), 20 samples from patients with reduced FIX or FVIII were tested using the 
dilute thromboplastin assay (Section 2.5.1.1) and the endogenous thrombin potential 
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assay (Section 2.5.3). Factor levels were determined using a one stage assay based upon 
the method of Hardisty and Macpherson (1962) using an MDA180 automated 
coagulometer (bioMerieux, Lyon, France). 
Factor Level FVIII / FIX 1/100 HTF 1/50000 
HTF 
Ratio Normalised 
Ratio 
nMol Thrombin 
(ETP) 
100 Normal 83.6 438.0 5.24 1.00 1741 
2 FVIII 71.7 701.3 9.78 1.87 9 
2 FIX 69.6 634.0 9.10 1.73 42 
4 FVIII 99.4 800.0 8.05 1.54 56 
6 FVIII 69.0 385.1 5.58 1.06 411 
7 FVIII 79.1 569.0 7.19 1.37 233 
7 FVIII 66.8 414.3 6.20 1.18 1552 
7 FVIII 72.9 493.5 6.77 1.29 528 
8 FVIII 66.8 372.9 5.58 1.06 1403 
8 FIX 74.5 362.2 4.86 0.93 2123 
10 FVIII 62.9 323.7 5.15 0.98 1672 
29 FVI 11 90.9 556.3 6.12 1.17 206 
30 FIX 71.3 365.3 5.12 0.97 998 
32 FIX 74.5 371.6 5.02 0.96 1654 
33 FVIII 68.3 293.6 4.30 0.82 1027 
37 FVIII 70.7 341.3 4.83 092 1147 
38 FVIII 72.4 437.7 6.04 1.15 646 
42 FVIII 81.3 397.2 4.88 0.93 528 
43 FVIII 70.5 369.6 5.24 1.00 1972 
46 FVIII 65.4 355.4 5.43 1.04 2032 
47 FVIII 61.1 298.0 4.88 0.93 1552 
48 FVI 11 56.3 257.0 4.56 0.87 1486 
Table 3.1.6 Factor sensitivity in clinical samples. 
Ratio = Clot time at 1150000 diln. / clot time at 1/100 diln. 
Normalised Ratio = ratio at x% Factor / Ratio at 100% Factor). 
Abbreviations: FVIII = factor VIII. FIX = factor IX, ETP = endogenous thrombin 
potential. 
The data in Table 3.1.6 demonstrated a similar sensitivity to FVIII and FIX to that seen 
in the dilution experiments above (Section 3.1.4 and 3.1.5). Only samples with factor 
levels of below 7% gave raised normalised ratios. The ETP appeared to 
be more 
sensitive to decreased factor levels with the majority of samples with 
factor levels 
below 42% giving levels of thrombin generation significantly below that seen at 
100% 
80 
factor concentration. However, the results for the ETP assay were variable with some 
elevated / normal results being seen at low factor levels. 
3.1.7 Discussion. 
The working hypothesis tested, i. e. that by diluting standard commercially available 
thromboplastin reagents, an assay could be made sensitive to FVIII and FIX deficiency, 
was supported by the data generated in the present study. However, not all 
commercially available thromboplastin reagents demonstrated this effect and the 
dilutions required were much greater than the 1/250 reported by Marlar et al (1982) in 
their purified system experiments. The ability to push the system towards FXa 
generation via the Josso loop (Josso and Prou-Wartelle, 1965) appeared to be most 
pronounced in the human TF reagents, Thromborel@R, Thromborel@S and HTFO. In 
contrast to the data published by Marlar et al (1982) the rabbit brain products, 
Simplastin@ excel S, Manchester reagent and PT-Fib HS+@ did not show good 
sensitivity to FVIII and FIX deficiency even at the higher dilutions tested. 
The assays were performed using a semi-automated KCIO coagulometer (Sigma- 
Amelung, Poole, UK) with clot times for the 1150000 dilution predominantly greater 
than 400 seconds. To bring the assay within the remit of fully automated systems such 
as the MDA180 (bioMerieux, Lyon, France) clot times would need to be reduced to 
below 250 seconds. Attempts to achieve this by the addition of phospholipid were 
successful but the sensitivity to FVIII and FIX was lost. 
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The degree of factor sensitivity achieved was not sufficient for clinical use and was 
generally below that seen in the ETP assay. However, the purpose of the exercise was to 
demonstrate that dilution of these reagents could favour FXa generation via the Josso 
loop. The reagents themselves had not been optimised for use at these high dilutions. 
Therefore, it was reasonable to assume that the performance of a TF based assay for 
detection of FVIII and FIX deficiency could be further improved. 
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3.2 Development of an assay to detect defects within the PC pathway using a dilute TF trigger. 
3.2.1 Introduction 
The presence of a hypercoagulable state has been suggested from measurement of 
markers of thrombin generation or fibrin degradation. These activation markers have 
been shown to be elevated in hereditary thrombophilias (Bauer et al., 1988; Demers et 
al., 1992; Simioni et al.,, 1996; Zoller et al., 1996) and acquired prothrombotic states 
(Ginsberg et al., 1995; Ginsberg et al., 1993). The levels of various activation markers 
have been shown to increase in relation to the number of risk factors present (Arkel et 
al., 2002). However there is considerable overlap between affected individuals and the 
normal population. These assays are both time consuming and expensive and do not 
lend themselves to routine practice. 
Attempts have been made to develop assays capable of screening for defects within the 
PC pathway using either snake venom activation of the patients PC or addition of 
exogenous PC coupled with either contact or venom activation of coagulation. These 
assays have been shown to be very sensitive to the detection of the FV Leiden defect 
but less so to PC and particularly limited in the detection of PS deficiency (Dragoni et 
al., 2001; Haas et al., 1998). A multicentre trial using the proC@ Global assay 
confirmed these findings and also demonstrated considerable overlap between patient 
and normal populations with 40% of individuals with no detectable defect of the PC 
pathway falling below a cut-off determined by receiver operator characteristics analysis 
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(Toulon et al., 2000). The proC@ Global assay has also been shown to be affected by 
the presence of liver disease (Toulon et al., 2001), oral anticoagulant therapy (Toulon et 
al., 2001), lupus anticoagulant (Rimmer et al., 2000) and elevated FVIII levels (Rimmer 
et al., 2000). The limitations of sensitivity and specificity of these screening tests has 
led to a poor take-up for routine screening. A recent Medical Devices Agency 
evaluation evaluated four kits designed to screen the PC pathway: Acticlot@V-Out, 
Diagen PCA test, GradiThrom PCP test and Dade Behring ProC@ Global. Their 
conclusion confirmed the findings reported above. All kits demonstrated excellent FV 
Leiden sensitivity but poor sensitivity to PS deficiency and only moderate sensitivity to 
PC deficiency. PC sensitivity was higher with those kits that used activation of 
endogenous PC (Diagen PCA, GradiThrom PCP and Dade Behring ProC@). Even with 
the 100% sensitivity to the FV Leiden mutation the poor specificity did not replace the 
need to genotype the individual. None of the methods tested was reliable in the presence 
of unfractionated heparin, oral anticoagulants or lupus anticoagulants. It is recognised 
that a global test of thrombobotic risk is desirable but as yet unavailable (Tripodi and 
Mannucci, 2001), particularly as the results of tests currently available do not correlate 
with risk of recurrence of venous thromboembolism (Baglin et al., 2003). 
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3.2.2 The ability of low TF assay to discriminate PC deficiency from normal. 
A panel of commercially available thromboplastin reagents was tested against normal 
plasma (Technoclone, Vienna, Austria) and commercial immunodepleted PC deficient 
plasma (Biopool International Ltd, CA, USA) (Section 2.5.1.1). The relationship 
between clotting time and dilution was most clearly demonstrated by the use of a 
nonnalised ratio (Ratio at I /x dilution. / ratio at I/ 10 dilution). This allowed the relative 
shortening of clotting time with increasing dilution to be clearly illustrated. The results 
are surnmarised in Table 3.2.1. 
Thromboplastin 1110 1/100 1/1000 1/5k 1/10k 1/50k 
InnovinO Ratio 1.23 1.21 1.3 1.35 1.28 0.92 
NR 1.00 0.98 1.07 1.11 1.05 0.76 
HTFO Ratio 1.17 1.13 1.32 1.36 1.43 1.06 
NR 1.00 0.96 1.12 1.16 1.22 0.90 
Thromborel@ R Ratio 1.35 1.40 1.58 1.52 1.52 
NR 1.00 1.03 1.17 1.17 1.12 
SimplastinO Excel S Ratio 1.06 1.15 1.10 1.13 1.13 1.03 
NR 1.00 1.08 1.04 1.06 1.06 0.97 
Manchester Reagent Ratio 1.03 1.13 1.16 1.13 1.10 1.07 
NR 1.00 1.09 1.12 1.09 1.06 1.03 
PT-Fib HS+@ Ratio 1.15 1.15 1.16 1.03 0.97 0.89 
NR 1.00 1.00 1.01 0.89 0.84 0.77 
ThromborelO S Ratio 1.00 1.06 1.20 1.15 1.08 0.81 
NR 1.00 1.06 1 1.20 1 1.15 1.08 0.81 
Table 3.2.1 Ratios of PC deficient plasma / normal plasma produced for dilute 
thromboplastins. 
Ratio= clot time for PC def, plasma / clot time for normal plasma. 
Normalised ratio = Ratio at I /x dilution / ratio at I/ 10 dilution. 
Abbreviations: NR = normalised ratio 
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Detection of the PC deficiency was poor with only three of the reagents demonstrating a 
decreased ratio at greater dilution of thromboplastin reagent. These being the Innovin@, 
PT-Fib HS+@ and Thromborel@S reagents. The results are highlighted in table 3.2.1. 
3.2.3 The ability of a low TF assay to discriminate PS deficiency from normal. 
The same panel of commercially available thromboplastin reagents were tested against 
normal plasma (Technoclone, Vienna, Austria) and PS deficient plasma (Biopool 
International. CA, USA) to determine their ability to discriminate between the two 
groups (Section 2.5.1.1). Again the relationship between clotting time and dilution was 
most clearly demonstrated by the use of a normalised ratio (Ratio at I/x dilution. / ratio 
at 1/10 dilution). The results are summarised in Table 3.2.2. 
All of the thromboplastins tested demonstrated decreased ratios with progressive 
dilution of the thromboplastin trigger. The poorest response was seen when the 
Manchester reagent was used. 
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Thromboplastin 1/10 11100 1/1000 1/5k 1/10k 1/50k 
Innovine Ratio 
NR 
1.23 
1.00 
1.23 
1.00 
1.17 
0.95 
1.07 
0.87 
0.89 
0.72 
0.89 
0.52 
HTFO 
ThromborelOR 
_Simplastin@ 
Excel S 
Ratio 
NR 
Ratio 
NR_ 
Ratio 
1.16 
1.00 
1.21 
1.00 
0.94 
1.04 
0.89 
1.09 
0.90 
1.03 
1.01 
0.87 
1.02 
0.84 
0.75 
0.83 
0.71 
0.90 
0.74 
0.63 
0.80 
0.68 
0.88 
0.72 
0.50 
0.62 
0.53 
0.52 
NR 1.00 1.09 0.80 0.67 0.53 0.55 
Manchester Reagent Ratio 1.02 0.94 0.76 0.67 0.80 0.83 
NR 1.00 0.92 0.74 0.66 0.78 0.81 
PT-Flib HS+@ Ratio 0.92 1.00 0.92 0.69 0.60 0.58 
NR 1.00 1.08 1.00 0.75 0.65 0.63 
ThromborelOS Ratio 1.05 1.00 0.83 0.68 0- 60 0.40 
NR 1.00 0.95 0.79 0.64 
ý. 
57 0.38 
Table 3.2.2 Ratios of PS def. plasma / normal plasma produced for dilute 
thromboplastins 
Ratio= clot time for PS def. plasma / clot time for normal plasma. 
Normalised ratio = Ratio at I /x dilution / ratio at I/ 10 dilution. 
Abbreviations: N-R=normalised ratio 
3.2.4 The effect of the addition of TM to the low TF assay. 
It is reasonable to assume that the addition of TM to the assay system would increase 
sensitivity to the action of the PC pathway. This approach has been used in preliminary 
experiments to look at the action of the lupus anticoagulant (Mohri et al., 1997). By 
diluting the TF component of the reaction the potential effect of the TM should be 
enhanced (Varadi et al., 1999). 
The same panel of commercially available thromboplastin reagents used previously 
(Section 2.5.1.3) was tested against normal plasma (Technoclone, Vienna, Austria) and 
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PC deficient plasma (Biopool International, CA, USA) in the presence of lunit/ml 
rabbit TM (American Diagnostica Inc. Greenwich, CT. USA). The relationship between 
clotting time and dilution was demonstrated by the use of a normalised ratio (Ratio at 
I /x dilution. / ratio at I/ 10 dilution). The results are summarised in Table 3.2.3. 
Thromboplastin 1/10 1/1k 1/5k 1/10k 1/50k 
lnnovin@ Ratio 1.06 1.30 0.79 1.18 0.98 
Normalised Ratio 1.00 1.22 0.75 1.11 0.92 
HTFO Ratio 1.12 1.35 1.59 1.67 1.12 
Normalised Ratio 1.00 1.20 1.41 1.49 1.00 
ThromborelOR Ratio 2.24 1.91 2.19 1.02 0.75 
Normalised Ratio 1.00 0.85 0.97 0.45 0.33 
Simplastin@ Excel S Ratio 0.90 0.77 0.62 0.48 0.77 
Normalised Ratio 1.00 0.85 0.68 0.53 0.85 
Manchester Reagent Ratio 1.03 1.21 0.91 0.81 0.80 
Normalised Ratio 1.00 1.17 0.88 0.78 0.77 
PT-Fib HS+@ Ratio 1.10 1.21 0.60 0.56 0.53 
Normalised Ratio 1.00 1.10 0.55 0.51 0.48 
ThromborelOS Ratio 1.06 1.25 1.43 1.38 1.10 
Normalised Ratio 1.00 1.17 1.34 1.30 1.04 
Table 3.2.3 Ratios of PC def, plasma / non-nal plasma produced for dilute 
thromboplastins in the presence of I unit/ml TM. 
Ratio= clot time for PC def, plasma / clot time for normal plasma. 
Normalised ratio = Ratio at I /x dilution / ratio at I/ 10 dilution. 
Detection of the PC deficiency, as seen by decreased norinalised ratios at higher 
dilutions of thromboplastins, was improved. The mix of thromboplastins which gave the 
better response was different to that seen previously for hypocoagulable samples 
(Section 3.1.2). PT-Fib HS+ and Thromborel R gave the better discrimination from 
normal when defined as a progressively lower ratio with increasing thromboplastin 
dilution. However, performance of the assay in this way is not practical as clot times at 
the 1150000 dilutions were in the range 1000 to 1500 seconds. 
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3.2.5 Discussion. 
The results of the present study support the hypothesis that by diluting standard 
commercially available thromboplastin reagents an assay could be made sensitive to 
defects within the PC pathway. Both deficiencies of PC and PS were shown to give 
normalised ratios of less than 1. These results were distinguishable from the results of 
the haemophilias, which gave normalised ratios of greater than 1. 
The addition of TM did enhance assay performance in combination with some of the 
thromboplastin reagents as could have been expected from the work of Mohri et al 
(1997). However to achieve separation of the hypercoagulable plasmas results from 
those of a reference population the assay clot times were in excess of 1000 seconds 
which was beyond the reading frame of most laboratory automation and thus unsuitable 
for routine applications. 
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3.3 Development of an assay to detect both hyper- and hvpo- coagulability using a 
low TF trigger and a kinetic measure of clot formation. 
3.3.1 Introduction 
The use of a clot time end-point has limited practical use due to the very long reaction 
times involved consequently the use of a kinetic end-point was considered as an 
alternative to the clot time. Most automated laboratory coagulometers monitor clot 
formation by a mechanical detection system or the use of optical end-point detection. 
The optical systems rely upon the fact that when plasma clots there is an associated 
increase in turbidity resulting from fibrin polymerisation. This change in turbidity is 
most commonly monitored by an increased in absorbance at a fixed wavelength. To 
detect this change in turbidity a relatively unsophisticated optical sensor is required. 
In contrast the MDA series of analysers were built around a very sensitive optics 
system. The MDA series analyser was chosen for this study because it allowed the 
optical changes, in terms of light transmittance, which occur during fibrin 
polymerisation to be closely monitored. The instrument collects 5 sets of data per 
second over a spectrum of wavelengths. This is achieved by the use of a holographic 
diffraction grating rather than specific wavelength light filters. Therefore, this 
instrument provided accurate measurement of light transmittance (1200 data points over 
4 minutes) which allowed for subsequent mathematical manipulation of the resultant 
trace. Additionally, the development work was not restricted in tenus of optical 
wavelength. 
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Two variables were assessed, the maximum velocity of clot formation and the 
maximum rate of acceleration of clot formation. The maximum velocity of a clotting 
reaction is given by the minimum value of the Is' derivative (dT/dt) from a plot of light 
transmittance (T) observed over time (t). The maximum rate of acceleration is given by 
the minimum value of the second derivative (d, T/dt2) from the same light transmittance 
plot (Braun et al., 1997) (Figure 1.8). 
3.3.2 The ability of the MDA series coagulation analyser derived clot time to 
discriminate between deficiencies of coagulant and anticoagulant proteins. 
Commercially available deficient plasmas were evaluated using a low tissue factor 
triggered assay on the MDA series coagulation analyser. The assay was configured 
around an open assay format available within the analyser menu and is detailed in the 
methods section (Section 2.5.2) 
Five plasma samples were tested; an in-house normal pooled plasma, FVIII deficient 
plasma (bioMerieux, Lyon, France), FIX deficient plasma (bioMe'rieux, Lyon, France), 
PC deficient plasma (Biopool International, CA, USA) and PS deficient plasma 
(Biopool International, CA, USA). The assay was initiated using dilutions of HTFO 
(bioMerieux, Lyon, France). 
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Diln Normal FVIII DP FIX DP PC DP PS DP 
11100 97 76 80 71 75 
11500 180 143 145 117 123 
111000 211 191 189 132 148 
1/5x1 03 nc nc nc 209 224 
lilXl04 nc nc nc nc nc 
Table 3.3.1: Mean clot times (seconds) achieved using various dilutions of HTF as a 
trigger. 
Abbreviations: FVIII = factor VIII, FIX = factor IX, DP = deficient plasma, PC 
protein C, PS = protein S, nc = no clot detected, Diln = dilution of HTF. 
Diln Normal FVIII DP FIX DP PC DP PS DP 
11100 1 1 1 1 1 
11500 1.85 1.88 1.81 1.65 1.64 
111000 2.18 2.51 2.36 1.86 1.97 
1/5x1 03 nc nc nc 2.94 2.98 
111X104 nc nc nc nc nc 
Table 3.3.2: Ratio (A) of clot time at 1/x clot time at 1/loo achieved using various 
dilutions of HTF as a trigger. 
Abbreviations: FVIII = factor VIII,, FIX factor IX, DP = deficient plasma, PC 
protein C, PS = protein S, nc = no clot detected, Diln = dilution of HTF. 
Diln Normal FVIII Def. FIX Def. PC Def. PS Def. 
1/100 1 1 1 1 1 
1/500 1 1.02 0.98 0.89 0.89 
, 1/1000 1 1.15 1.08 0.85 0.9 
Table 3.3.3: Ratio (B) of ratio A (test) at ratio A (normal) at 
'/,, achieved using 
various dilutions of HTF as a trigger. 
Abbreviations: FVIII = factor VIII, FIX factor IX, DP = deficient plasma, PC 
protein C, PS = protein S, nc = no clot detected, Diln = dilution of HTF. 
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1.2 
1.15 
1.1 
1.05 
Ratio B1 
0.95 - 
0.9 
0.85 
0.8 - 
1/100 11500 1/1000 
HTF Dilution 
Figure 3.3.1: Ratio B (Mean ± SEM, n=3) for Normal ( ), FVIII deficient (0), FIX 
deficient (A), PS deficient (o) and PC deficient (A) samples with differing HTF 
dilutions. 
Examining the clot times alone (Table 3.3.1) both the procoagulant deficiencies (FVIII 
and FIX) and the anticoagulant deficiencies (PC and PS) gave shorter clot times than 
the non-nal reference pool. If the change in clot time with dilution, as given by ratio A 
(clot time at a given dilution of thromboplastin divided by the clot time at 1/loo dilution 
of thromboplastin), and shown in Table 3.3.2, was considered the results at the 1/looo 
dilution started to segregate either side of the normal reference pool result. This was 
seen more clearly when ratio A for the test plasma against ratio A for the normal 
reference pool, as shown in Table 3.3.3 and Figure 3.3.1, were compared. Here a 
segregation of hypercoagulable samples and hypocoagulable samples either side of the 
normal reference pool was clearly seen. 
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3.3.3 The ability of the MDA clot kinetic parameters to discriminate between 
deficiencies of coagulant and anticoagulant proteins. 
The same sample set and reaction conditions were used as described in the previous 
expenment (Section 3.3.2). In this experiment the minima of the first (min-1) and 
second derivatives (min_2) of the curve light transmittance against time were 
calculated. The ratio B was calculated for each variable and the results shown in Table 
3 
3.3.4. 
Ratio B= result at 1/x ; result at 
1/100 for the test plasma 
result at 1/x --: - result at 
1/100 for the normal plasma 
Diln Normal FVIIIDP FIXDP PC DP PS DP 
11100 1 1 1 1 1 
11500 1 0.85 0.62 1.02 1.25 
111000 1 0.65 0.47 0.86 1 
Table 3.3.4: Ratio (B) for min 
-I 
achieved using various dilutions of HTF as a trigger. 
Abbreviations: FVIII = factor VIII, FIX = factor IX, DP = deficient plasma, PC 
protein C, PS = protein S, Diln = dilution of HTF. 
Using minj allowed the segregation from normal of the hypocoagulable samples 
(FVIII and FIX deficiency) but not of the hypercoagulable saMPles (PC and PS 
deficiency). The assay was repeated with the addition of I OnM TM. From the results 
shown in Table 3.3.5 and Figure 3.3.2 it can be seen that this enhanced the 
differentiation of both hyper- and hypocoagulable samples from the normal reference 
pool. 
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Diln Normal FVIII Def. FIX Def. PC Def. PS Def. 
11100 1 1 1 1 1 
11500 1 0.56 0.48 1 1.2 
111000 1 0.3 0.1 1.38 1.2-8--1 
Table 3.3.5: Ratio (B) for min 
-I 
achieved using various dilutions of HTF as a trigger in 
the presence of I OnM TM. 
Abbreviations: FVIII = factor VIII, FIX = factor IX, DP = deficient plasma, PC 
protein C, PS = protein S, Diln = dilution of HTF. 
2 
1.5 
1 
0.5 
0 
-0.5 
1/100 1/1000 1/500 
HTF Dilution 
Figure 3.3.2 Ratio B (Mean ± SEM, n=3) for min_l, in the presence of 10nm TM, for 
Normal ( ), FVIII deficient (m), IX deficient (A), PS deficient (1: 1) and PC deficient 
samples with differing dilutions of HTF. 
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The calculation of min_2 again allowed the segregation of the hypocoagulable samples 
from the normal reference pool. However, the hypercoagulable samples also gave ratios 
of less than one. The values obtained for the hypercoagulable samples would classify 
them alongside the hypocoagulable group (Table 3.3.6). Therefore, it was not possible 
to differentiate hypo- from hypercoagulant samples. 
Diln Normal FVIII Def. FIX Def. PC Def. PS Def. 
1/100 1 1 1 1 1 
1/500 1 0.6 0.51 0.89 1.04 
[-1/1000 1 0.47 0.56 0.69 0.38 
Table 3.3.6: Ratio (B) for min 
-2 
achieved using various dilutions of HTF as a trigger. 
Abbreviations: VIII = factor Vlll,, IX = factor IX, DP = deficient plasma, PC = protein 
C5 PS = protein S,, Diln = dilution of HTF. 
The assay was repeated in the presence of lOn. M TM. The results (Table 3.3.7, Figure 
3.3.3) demonstrated that the hypercoagulable samples now gave a positive ratio. 
However, the differentiation of the hypocoagulable group was lost with these samples 
giving ratios close to the values of the normal reference pool. The FIX deficient plasma 
gave a ratio >I at an HTF dilution of I/ 1000 making the interpretation 
hypercoagulable. 
Diln Normal FVIII Def. FIX Def. PC Def. PS Def. 
11100 1 1 1 1 1 
11500 1 0.65 1.39 0.89 --- 
1.1 
- h111000 0.71 1 1.13 1 1.34 1.33 j [ 
Table 3.3.7: Ratio (B) for min_2 achieved using various dilutions of HTF as a trigger 
in 
the presence of I OnM TM. 
Abbreviations: FVIII == factor VIII, FIX = factor IX, DP = 
deficient plasma, PC 
protein C, PS = protein S, Diln = dilution of 
HTF. 
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Figure 3.3.3: Ratio B (Mean + SEM, n=3) for min 
- 
2, in the presence of I OnM TM, for 
Normal (, ), FVIII deficient (m), IX deficient (A), PS deficient (0) and PC deficient 
samples with differing dilutions of HTF. 
To calculate the min_1 and min_2 variables the MDA required a full TW trace to be 
produced. This required clot formation to reach completion within the 240 second read 
window of the analyser. These experiments provided evidence that the use of clot time 
and min_1 could discriminate hypocoagulable, hypercoagulable and the normal 
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reference samples when assessed on the MDA. However, from the previous 
experiments performed using a mechanical endpoint (Sections 3.1.2,3.2.2) it can be 
seen that better discrimination would be achieved at greater thromboplastin dilutions. 
This problem was discussed with bioMerieux and two solutions were suggested, an 
alternative algorithm for minj rate calculation and a change in the optical wavelength 
used. 
3.3.4 An algorithm for calculation of minj rate. 
Firstly a new algorithm was produced to calculate min_l. The new calculation 
quantitated the maximum rate of change in light transmittance after the start of clot 
formation (initial reduction in light transmittance). The data was fitted by a cosine 
model and slopes computed from a reconstructed model. This maximum rate calculation 
was found to be in close agreement with the min_1 value when this was calculated by 
the MDA software. 
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3.3.5 Effect of optical wavelength on minj rate. 
The second proposal followed experiments to examine the min_l value produced when 
the endpoint was assessed at different optical wavelengths (Figure 3.3.4). 
It was found that at lower wavelengths the min_1 rate increased. Therefore by using a 
wavelength lower than the default 580nm used by the MDA, an increased min_1 rate 
could be calculated. A wavelength of 460nm was selected for the low TF assay. At this 
wavelength there was optimal differentiation of the normal, hypercoagulable and 
hypocoagulable samples whilst maintaining minimal optical interference from other 
proteins. The MDA performed a blank reading on each sample and this was set at 100% 
light transmittance. At wavelengths below 460nm any bilirubin present in the plasma 
would interfere with the assay due to decreased initial light transmission. 
300 
250 
200 
150 
100 
50 -------- 
0t----- J- - -- - --- -- -- -1 
405 460 520 580 640 
Wavelength (nm) 
Figure 3.3.4: Min_l rates calculated using different optical wavelengths for clot 
detection. o= hypercoagulable sample, x= normal sample, m= hypocoagulable sample. 
(Data supplied by bioMerieux). 
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3.3.6 Elimination of interference from VLDL-CRP complex formation. 
The association of an atypical biphasic waveform (Section 1-9) and the presence of DIC 
was first described in 1997 (Downey et al., 1997). The observation was then confirmed 
in a much larger prospective study (Downey et al., 1998) but also shown not to be 
specific for DIC (Luddington et al., 1997). The mechanism producing the biphasic 
waveform has been identified. It was the consequence of the formation of a divalent 
metal ion dependent complex of CRP and VLDL and to a lesser extent, IDL (Nesheim 
et al., 2000). In the low TF assay described above (Section 2.5.2), the formation of the 
VLDL-CRP complex could be triggered by the addition of the divalent cation Ca2+ in 
the form of calcium chloride. The formation of this complex resulted in a reduction in 
light transmission. 
The new algorithm for calculation of min_l required a stable precoagulation phase to 
the TW. In the presence of VLDL-CRP complex this did not occur. The algorithm 
would then calculate the maximum rate of change in light transmission associated with 
the formation of the VLDL-CRP complex rather than the rate of fibrin polymerisation. 
During the development of an assay for VLDL-CRP (Perez et al., 2001) bioM6rieux 
had found that the presence of phosphory1choline (PPQ in a reagent forraulation 
inhibited the formation of the VLDL-CRP complex. It was found that the presence of 
ImM PPC in the CaC12 reagent completely eliminated the biphasic waveform 
phenomenon. To assess the effect of the added PPC on min-I rate, VLDL-CRP 
complex was generated in a VLDL rich plasma sample by the addition of CRP and 
min_1 rates calculated in the presence and absence of PPC in the CaC12 reagent (Table 
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3.3-8). This work was carried out on my behalf by bioMerieux using VLDL rich plasma 
which was spiked with purified CRP at the concentrations indicated in Table 3.3.8). The 
resultant TWs are shown in Figures 3.3.5 - 3.3-7. Again this data was generated by 
bioMerieux on my behalf 
Conc. of CRP Min_I rates Clot times 
[tg/ml PPC noPPC PPC noPPC 
0 120 117 80 80 
100 120 119 79 79 
200 117 115 80 81 
300 112 81 80 nc 
400 121 54 79 80 
500 105 39 82 nc 
Table 3.3.8: Min 
-I 
rates and clot times (seconds), in CRP spiked plasma, in the 
presence and absence of PPC in the CaC12 reagent. Assay triggered using 1/1000 
dilution of HTF. 
Abbreviations: C-reactive protein (CRP), phosphory1choline (PPQ. (Data supplied by 
bioMerieux). 
The results (Table 3.3.8) show that minj rate calculations were affected by the 
presence of a biphasic waveform. In the presence of PPC the min_l rate remained 
relatively constant giving the same result as that obtained from the plasma in the 
absence of PPC and CRP. In the presence of PPC the TW seen in the absence of 
additional CRP (Figure 3.3.5) remained unchanged with the progressive addition of 
CRP and subsequent VLDL-CRP complex formation (Figures 3.3.6 & 3.3.7). This 
observation was true for results in either the presence or absence of TM. However, in 
the absence of PPC the TW traces became progressively biphasic and gave erroneous 
min_1 rate results (Table 3.3.8). It was concluded that, although VLDL-CRP complex 
fonnation would rarely be seen in the patients groups under investigation, lmM PPC 
would be incorporated into the calcium chloride reagents for subsequent experiments. 
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Figure 3.3.5: Comparison of TWs comparing PPC and CaC12 in the presence and 
absence of TM. (Data supplied by bioM6rieux). 
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Figure 3.3.6: Comparison of TWs comparing PPC and CaC12 in the presence and 
absence of TM and VLDL-CRP complex generated by the addition of 200[tg/ml CRP. 
(Data supplied by bioM6rieux). 
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Figure 3.3.7: Comparison of TWs comparing PPC and CaC12 in the presence and 
absence of TM and VLDL-CRP complex generated by the addition of 400ýtg/ml CRP. 
(Data supplied by bioM6rieux). 
3.3.7 Sample stability 
Healthy donor blood was collected in the presence and absence of CTI. At intervals up 
to 4 hours, 5 aliquots with and without CTI were centrifuged at 30OOg for 10 minutes. 
The aliquots were loaded onto the MDA analyser and min_1 rates measured using a 
2pM TF trigger (Figure 3.3.8). 
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Figure 3.3.8. Min_I rates following storage at RTT (mean ± SEM, n--5). 
The min_1 rate fell by 8% over the 4 hour test period in the absence of CTI. This 
finding is in agreement with studies of aPTT stability carried out at the Addenbrookes 
haernostasis unit (data not shown). Over the same period the presence of CTI resulted in 
a stable min_1 measurement. For the purposes of this study samples for measurement of 
min_l rate were centrifuged and PPP prepared within 2 hours of venepuncture. This 
was found to be comfortably within the limits of sample stability. 
3.3.8 Optimisation of the TF and TM concentrations for detection of hyper- and 
hypo- coagulable samples using the min-I rate. 
It has previously been demonstrated (Section 3.3.3) that the min_l rate (minimum of 
the I" derivative of the TW) can be used to detect patients with either defined 
thrombophilic defects or severe haemophilia. To better evaluate the clinical 
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effectiveness of such a test, a small cohort of well defined patients was selected. The 
cohort consisted of 3 hypocoagulable patients, 3 healthy individuals and 3 
hypercoagulable patients. The hypocoagulable individuals were selected from mild or 
moderate haemophiliacs who were not on routine prophylaxis but required replacement 
therapy following trauma. The healthy individuals were selected with no history of 
bleeding or thrombosis who where found to have haemostatic profiles within the normal 
reference range (Table 3.3.9). The hypercoagulable individuals were selected from the 
CVTE study (Baglin et al., 2003) as having a clinical and family history of recurrent 
venous thrombo-embolism associated with a detectable defect as shown in the table 
below (Table 3.3.9). 
A matrix of reagent combinations was tested (Table 3.5.1) to determine the optimum 
reagent combination for detection of hypo and hyper coagulability. 
Group Hype r-coagula ble Contro l Hypo-coagu lable Reference 
Donor No. 2 3 9 10 5 6 4 7 8 Ranges 
PT(secs) 12.7 12.7 12.5 12.5 11.9 12.3 11.8 12.8 14.5 11 to 14 
aPTT(secs) 28.3 26 23.6 32 26.4 24.3 39.9 40.4 57.5 22.5 to 34.5 
1 
APCsr 2.2 1.6 2.7 2.9 2.8 2.4 >4 >4 3.4 >2.2 
PC (0/0) 52 106 90 133 110 148 209 96 85 >73 
PS (0/0) 121 127 136 99 149 160 75 110 75 >71 
AT (%) 88 124 100 120 135 108 94 116 97 >80 
Lupus Neg Neg N eg Neg Neg Neg Neg Neg Neg 
FVL Neg Het Neg Neg Neg Neg Neg Neg Neg 
PTGM Neg Neg neg Neg Neg Neg Neg Neg Neg 
FVIII (iu/dl) 154 158 1 291 291 75 133 140 12 18 135 45 to 149 
FIX (iu/dl) 91 129 
] 
132 132 106 137 146 125 85 2 55 to 158 
FXI (iu/di) 112 105 99 99 81 146 88 101 97 52 70 to 150 
DD(u g FEUM 1) 874 1372 1251 1251 353 176 869 248 129 100 <500 
Plts(xlo9/1) 237 246 286 286 285 271 242 262 
t 
175 1 269 150 to 400 
Table 3.3.9: The haemostatic profile for 9 selected donors. Abnormal results are shown 
in red. Abbreviations used: prothrombin time (PT), activated partial thromboplastin 
time (aPTT), activated protein C sensitivity ratio (APCsr), protein C (PC), protein 
S 
(PS), antithrombin (AT), lupus anticoagulant (Lupus), factor V Leiden mutation 
(FVL), 
prothrombin gene mutation (PTGM), factor VIII (FVIII), factor 
IX (FIX), factor XI 
(FXI), D-dimer (DD), platelet count (Plts), negative (Neg), Heterozygous (Het). 
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Each reagent combination was tested in triplicate against the 9 donor panel. The mean 
minj rate result for each reagent tested can be seen in Appendix 1. The results 
demonstrated that at a final TF concentration of I pM the hypercoagulable patients could 
be distinguished from those of the other groups. This is illustrated in Figures 3.3.11 and 
3.3.12. This effect could not be demonstrated from clot time alone (Figures 3.3.9 and 
3.3.10). However at no point could all of the mild haemophiliacs be differentiated from 
the control group by either clot time or clot kinetics. At no point was the clot time able 
to differentiate the three patient groups, results shown in Appendix 2. Indeed at TF 
concentrations above 2pM donor 4 fell within the hypercoagulable group of results 
(Figures 3.3.9 and 3.3.10). It would appear that the optimum reagent for identification 
of hypercoagulable samples was the IpM TF / 0.5nM TM combination (Figure 3.3.12). 
At this combination the best discrimination of the hypocoagulable patients from the 
control group was also seen, although this was still poor. 
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Figure 3.3.9. The effect of increasing TF concentration on the mean clot time in the 
absence of TM. The donors tested fell into one of three categories hypercoagulable (X), 
normal () or hypocoagulable 
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Figure 3.3.10. The effect of increasing TF concentration on the mean clot time at 0.5nM 
TM. The donors tested fell into one of three categories hypercoagulable (X), normal 
() or hypocoagulable (EI). 
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Figure 3.3.11. Figure to show the effect of increasing TF concentration on the mean 
minj rate in the absence of TM. The donors tested fell into one of three categories 
hypercoagulable (X), normal () or hypocoagulable (EI). 
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Figure 3.3.12. Figure to show the effect of increasing TF concentration on the mean 
min_l rate at 0.5nM TM. The donors tested fell into one of three categories 
hypercoagulable (X), normal (zý, ) or hypocoagulable (LI). 
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3.3.9 Assay precision 
Three donor CTI-citrate anticoagulated plasma pools were collected. The first was 
collected from 5 healthy donors, the second from 5 carriers of the FV Leiden mutation 
and the final pool from 5 patients with haernophilia A. Each pool was tested on ten 
occasions using a 2pM TF trigger reagent in the presence and absence of I nM TM. 
The assay coefficient of variance from the mean (CV) was generally good with values 
predominantly below 10% (Table 3.3.10). The notable exception being the 2pM TF/ 
InN4 TM reagent when testing the haemophilia pool. The calculation of min_1 rate 
when the values fall below 50 %T/sec was felt to be unreliable. 
Pool 2pM TF 2pM TF II nM TM 
Normal 6.8 12.1 
FV Leiden 3.9 7.8 
Haemophilia 12.3 41.2 
Table 3.3.10. Coefficient of variance from the mean (%) for min_ I rate using a 2pM TF 
reagent in the presence and absence of I nM TM. 
Abbreviations: TF = Tissue factor,, TM = Thrombomodulin, FV = Factor V. 
3.3.10 Discussion. 
The results of the present study have demonstrated that the effects previously noted 
using the semi-automated mechanical clot detection of the KC 10 (Section 2.5.1) could 
be replicated using the fully automated MDA (Section 2.5.2). The use of kinetic 
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measurements of fibrin polymerisation gave an alternative end-point which allowed 
measurement to be achieved within the 240 second read window of the MDA. 
The use of fibrin polymerisation rates and clot strength as end point markers has been 
used for many years in the thrombelastograph (Section 1.7). The use of this technology 
has been largely restricted to the monitoring of blood component therapy (Salooja and 
Perry, 2001). The use of this form of endpoint as a more subtle screen of haemostasis is 
a relatively recent phenomenon. This is largely due to the fact that the equipment to 
accurately assess reaction rates is relatively new. 
Attempts have been made to use the overall degree of fibrin polymerisation as a screen 
for hypercoagulability (Andresen et al., 2002). However, although a difference between 
the hypercoagulable and the control samples could be seen, the assay gave considerable 
overlap between patient and control values. This problem was seen in the 
thrombelastograph assay which also used rather crude measures of fibrin polymerisation 
(Section 3.6.3). 
The use of the MDA kinetic variables to assess coagulation factor levels was first 
postulated by Braun et al (1997) (Braun et al., 1997). However, little has been 
published on the subject since most research involving the TW has centred around the 
biphasic TW finding (Downey et al., 1997). Recently the use of min_2 in 
hypocoagulable patients has been reported (Shima et al., 2002). The authors 
demonstrated that the min_2 value could potentially provide increased sensitivity over 
the clot time end-points at very low factor levels. Although data was not shown they 
postulated that min_1 estimation may provide even greater sensitivity. 
Their 
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experiments were presumably limited by the MDA software. The revised algorithm for 
min_l . developed for the low tissue factor assay (Section 3.3.4), is expected to 
overcome some of these problems. 
In addition to the improved min_1 algorithm and the reduction in wavelength (Figure 
3.3.4) have both improved the sensitivity of the assay. The addition of PPC to the CaC12 
reagent ensures a stable precoagulation phase (Table 3.3.8). This removes the 
possibility of erroneous results resulting from the presence of a bTW. Pretest variables 
associated with sample handling can be minimised by preparation of PPP within 2 hours 
of venepuncture. Good sample stability was demonstrated for up to 4 hours in the 
presence of CTI (Figure 3.3.8). 
Having demonstrated that clot kinetics could differentiate, hypercoagulable, 
hypocoagulable and normal samples (Section 3.3.3) the next step was to optimise the 
reagent concentrations (Section 3.3.7). 
A matrix of 42 TF and TM concentrations was assessed in the range IpM TF with no 
TM to 15pM tissue factor and 7nM TM. Ten donors were bled into citrate tubes 
containing CTI (final concentration in whole blood 18.3ý1g/ml). The first was rejected as 
the haemophiliac bled had recently received FVIII concentrate. Donors 2,3 and 9 were 
selected from the CVTE study cohort (Baglin et al., 2003). All three 
had a defined 
thrombotic defect (Table 3.3.9), donor 2 was protein C deficient, donor 3 was 
heterozygous for the FV Leiden mutation and donor 9 had a persistently elevated FVIII. 
All three had persistently raised D-dimer levels. A panel of "normal" control 
donors 
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was screened and three (donors 5,6, and 10) were selected for the study. All had 
repeatable normal results (results within the laboratory normal reference ranges), 
however at the time of sampling donor 6 had a transiently elevated DD (Table 3.3.9). 
Donor 6 gave similar results to the other control donors at all TF/TM combinations 
tested. In contrast to the earlier development work, which used totally deficient plasma, 
mild / moderate haernophiliacs were bled for the study, donors 4 and 7 had haemoPhilia 
A and donor 8 haemophilia B. Donor 8 had a transiently low FXI at the time of 
sampling. The optimisation study demonstrated that the hypercoagulable donors could 
be segregated from the control donors using minj rate (Appendix 1) but not clot time 
(Appendix 2). This was most marked at lower tissue factor concentrations (Figures 
3.3.11 and 3.3.12). The hypocoagulable donors did not all segregate from the controls. 
However at low TF concentrations in the presence of TM two of the three were 
distinguishable from the controls when the min_1 rate was used (Figure 3.3.12). This 
finding was not unexpected as earlier work had suggested poor differentiation from 
normal for mildly deficient haemophiliacs (Table 3.1.6). The application of the assay to 
the detection of hypocoagulabilty was further compromised by the poor precision seen 
at low min_1 rates. 
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3.4 Elimination of contact activation 
3.4.1 Introduction 
When assays utilise "subtle" triggers of haemostasis, such as physiological levels of TF, 
the sample quality becomes highly significant. Contact activation of the sample prior to 
assay is recognized as a major problem and should be minimized. Investigators have 
used antibodies to FXII (Keularts et al., 2001), polypropylene throughout sample 
handling (Dieri et al., 2002) and CTI added to the blood/plasma (Cawthern et al., 1998) 
(Rand et al., 1996) to minimize contact activation. The aim of these experiments was to 
investigate the extent of contact activation interference in low TF triggered assays and 
examine ways of minimising these effects. In the following experiments a low TF 
trigger was applied to the assay of thrombin production using the ETP (Hemker and 
Beguin, 1995; Hernker et al., 2000) and the assay of fibrin polymerisation using clot 
kinetics (Braun et al., 1997) in the presence of CTI to inhibit contact activation (Hojima 
et al., 1980; Swartz et al., 1977) 
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3.4.2 Effect of the addition of CTI to a citrated blood collection tube (Sarstedt, Leicester, UK) using the ETP. 
CTI was supplied in a TRIS buffer solution (20mM Tris, 150mM NaCl, pH 8.5). To 
evaluate the contribution of the buffer to any reduction in background thrombin 
generation, experiments were performed with TRIS buffered citrate in the presence and 
I nk absence of CTI using 5 sets of samples. A mean background ETP of 845nM. min (SD 
658) was reduced to a mean of 729nM. min (SD 574) following the addition of the TRIS 
buffer solution to the citrate (p=0.675). However, following the addition of TRIS 
containing CTI this background ETP was completely abolished (p<0.02). The volume 
of CTI and/or buffer added to 3ml of whole blood was 50[d in all cases and 
consequently there was no dilutional effect to consider. 
3.4.3 Effect of CTI on the functional levels of coagulation factors. 
It has been widely reported that the action of CTI is specific to the inhibition of trypsin 
and FXIIa (Hojima et al., 1980; Rand et al., 1996; Ratnoff and Moneme, 1981). To 
confirin these findings one-stage assays of coagulation factors, Fll, FV, FVII, FX, 
FV1115 FIX, FXI and FXII were perfonned. Assay values were not significantly different 
for any of the factors assayed (Figure 3.4.1). However, assays using contact activation 
as the triggering mechanism (FVIII, FIX, FXI and FXII) required greater sample 
dilution to overcome the inhibitory effect of the CTI. 
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Figure 3.4.1 Effect of the addition of CTI on the one-stage assay of clotting factors. The 
results are the mean (± SEM) of triplicate assays performed on a pooled normal plasma. 
Open columns are factor assays performed in the absence of CTI. Filled columns are 
factor assays performed in the presence of CTI. 
Further evidence of the specific nature of CTI was shown by examining the effect of 
CTI on FXII deficient plasma. The addition of CTI to a plasma sample reduced the ETP 
estimation of that sample (Section 3.4.7). However when this experiment was 
performed using FXII deficient plasma no such reduction in thrombin generation was 
seen (Figure 3.4.2). 
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Figure 3.4.2 Effect of CTI addition on the potential for thrombin generation by FXII 
deficient plasma. The results are the mean (± SEM)of triplicate assays performed on a 
single plasma sample. 
3.4.4 Effect of CTI concentration on the clotting times of plasma. 
CTI has been reported to inhibit the clotting times of plasma in the aPTT assay in a dose 
dependent manner whilst having no effect on assays using a tissue factor trigger (He et 
al., 2001; Rand et al., 1996). To confirm these findings PT and aPTT were measured 
using a pooled normal plasma sample on an MDA 180 automated coagulation analyser 
(bioMerieux, Lyon, France). These data confinned the earlier findings. They also 
demonstrated that not only were the aPTT clot times prolonged in the presence of CTI 
but the rate and velocity of the clotting reaction were proportionally affected (Figures 
3.4.3-3.4.7). This effect on the reaction rate was not seen in the TF based assays (Figure 
3.4.7). 
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Figure 3.4.3 TWs for the PT (a) and APTT (b) in the presence of increasing 
concentrations of CTI. 
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Figure 3.4.4 Effect of the addition of CTI on clot time. Results (mean +SEM) of 5 
samples are shown. Open columns are in the absence of CTI, filled columns are in the 
presence of CTI. Statistical significance was determined using student paired t-test. 
Abbreviations: PT = prothrombin time, APTT = activated partial thromboplastin time, 
ns = not statistically significant. 
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Figure 3.4.5 Effect of the addition of CTI on the velocity (minl) of clot formation. 
Results (mean +SEM) of 5 samples are shown. Open columns are in the absence of CTI, 
filled columns are in the presence of CTL Statistical significance was determined using 
student paired t-test. 
Abbreviations: PT = prothrombin time, APTT = activated partial thromboplastin time, 
ns = not statistically significant. 
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Figure 3.4.6 Effect of the addition of CTI on the acceleration (min2) of clot formation. 
Results (mean+SEM) of 5 samples are shown. Open columns are in the absence of CTI, 
filled columns are in the presence of CTL Statistical significance was determined using 
student paired t-test. 
Abbreviations: PT = prothrombin time, APTT = activated partial thromboplastin time, 
ns = not statistically significant. 
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Figure 3.4.7 Effect of CTI on the reaction rates in the APTT compared to a 
low TF 
triggered assay. Results shown are from samples taken from a 
healthy donor. 
Abbreviations: CTI = corn trypsin inhibitor, APTT = activated partial thromboplastin 
time, TF = tissue factor. 
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3.4.5 Effect of CTI concentration upon the thrombin generation of plasma. 
In order to eliminate thrombin generation due the activation of FXII which occurred 
during sample handling it was necessary to investigate the dose effect of CTI. Samples 
from 3 consenting healthy individuals were tested. Blood was taken into 3ml Sarstedt 
citrate tubes containing CTI (I. Img/ml) added in the range 0-100ýtl. The assay of ETP 
in the absence of a TF trigger demonstrated that background contact activation was 
eliminated with the addition of >50ýtl of CTI. Maximal effect was seen following the 
addition of 50ýtl therefore no benefit was seen with the addition of greater than 50ýtl of 
CTI. When a 5pM tissue factor trigger was used the addition of greater than 50ýtl of CTI 
did not effect the degree of thrombin generation (Figure 3.4.8). This demonstrated that 
once the effect of the FXlla had been eliminated CTI had no finther effect on the assay 
results. 
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Figure 3.4.8 Thrombin generation curves (TGC) generated by the addition of different 
concentrations of CTI on the peak thrombin generation in a normal plasma. TGC are 
shown in the presence and absence of tissue factor (TF). 
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3.4.6 Effect on thrombin generation of the timing of the addition of CTI. 
Samples from 5 consenting healthy individuals were tested in the absence of CTI, 
following the addition of 60ýtg/rnl CTI to the plasma post venepuncture and using blood 
taken into 3ml Sarstedt citrate tubes containing 50ýfl CTI (I. Img/ml)(equivalent to 
18.3[tg/ml whole blood). It is worth noting that the CTI added to plasma post 
venepuncture was approximately double the plasma concentration used when blood 
drawn into CTI-citrate. ETP was assayed in the presence and absence of TF and the 
results are summarized in Figure 3.4.9. The results indicated that in the absence of 
contact inhibition significant thrombin generation was noted in the absence of a tissue 
factor trigger (mean 1425nM. min, SD 582). This was reduced on addition of CTI to the 
plasma (mean 403nM. min, SD 483, p<0.05) but virtually abolished when blood was 
drawn directly into citrate, containing CTI (mean InM. min, SD 2.23, p<0.01). In all 
cases the lagtime to start of thrombin generation was longer when no activator was 
present. In the presence of a low TF trigger the addition of CTI to either the plasma or 
collection tube reduced the ETP (Figure 3.4.9). Figures 3.4.10-3.4.12 gives examples of 
the typical thrombin generation curve seen at different times of CTI addition. Figure 
3.4.10 demonstrates that the TF signal seen in untreated plasma would be difficult to 
interpret given the degree of contact triggered thrombin generation. 
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Figure 3.4.9 Effect of the timing of CTI addition on the potential for thrombin 
generation in 5 healthy donor plasmas (mean + SEM). Filled boxes triggered with TF 
and clear boxes represent sample related thrombin potential. 
Abbreviations: ETP = endogenous thrombin potential, CTI = corn trypsin inhibitor. 
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Figure 3.4.10 Example of typical thrombin generation curve when no CTI was added to 
the sample. Blue line results from activation with 5pmM TF. Red 
line results from 
sample activation alone (no activator added). 
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Figure 3.4.11. Example of typical thrombin generation curve when CTI was added to 
the plasma sample. Blue line resulted from activation with 5pmM TF. Red line resulted 
from sample activation alone (no activator added). 
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Figure 3.4.12. Example of typical thrombin generation curve when CTI was added to 
the sample tube at the time of collection. Blue line resulted from activation with 5pmM 
TF. Red line resulted from sample activation alone (no activator added). 
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3.4.7 Studies on the influence of the method of sample collection. 
The Sarstedt blood collection system allows the sample collection tubes to be used 
either pre-evacuated or using a syringe draw method of blood collection. For research 
purposes it is therefore possible to carefully control the process of blood collection. 
Indeed all of the experiments described above were performed using blood drawn using 
a syringe draw technique with minimum trauma. However, when tests are performed 
later using clinical samples then the limitations of the blood collection process need to 
be evaluated. To evaluate the effect of using either of these methods blood was drawn 
using either syringe draw or pre-evacuated collection in the presence or absence of CTI. 
The samples were stored as whole blood for 2 hours at ambient temperature and then 
centrifuged at 30OOg for 15 minutes. The separated platelet poor plasma was then kept 
at ambient temperature for 4 hours before being stored frozen at -800C. The samples 
were then thawed at 37'C immediately prior to testing. 
Samples were collected from 12 consenting donors, 5 healthy donors (2 male and 
3 
females oral contraceptive users were excluded), 3 with mild factor deficiencies, 
3 
heterozygous for the FV Leiden mutation and one with persistent elevated FVIII. 
Tests of thrombin generation (Section2.5.3) and clot kinetics 
(Section 2.5.2) were 
performed using a 5pM TF trigger or no trigger to assess the 
degree of sample 
activation. 
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Mild factor defi ciency -- Control Factor V leiden High VIII I 
Donor Donc 
Sam m ple le 
1 3 12 5 6 7 10 11 4 8 2 9 mean 
Syringe No CTI 
E 
75 78 112 91 111 90 98 90 75 75 74 
1 
87 87.5 
Syring CTI 74 82 122 105 1 126 108T -107 92 7-5 , 79 79 107 95.9 V Evacuated . V No C TI No C 74 78 118 89 114 90 98 86 74 74 75 88 87.8 
. d Evacuat d e CTI CT 77 4 
Table 3.4.1. Clot times (secs) for donors bled using either syringe draw or pre- 
evacuated blood taking method into tubes containing citrate anticoagulant with or 
without CTI. The assays were activated using 5pM TF. Samples are divided into, factor 
deficient, normal, heterozygous FV Leiden or elevated FVIII. 
Mild factor defi ciency Control Factor V leiden 1 1-ligh Vill 
Dono 1 3 12 5 6 Sample 7 10 11 4 8 2 9 mean 
Syringe No CT 
I 
-0.10 -0.12 -0.09 -0.12 -0.10 -0.11 -0.15 -0.11 
I 
-0.11 -0.18 -0.16 -0.16 
1 
-0.13 
Syringe CTI -0.061 -0.08 -0.06 -0.071 -0.06 -0.061 -0.07 -0.08 -0.111 -0.12 -0.10 
1 
-0.09 -0.08 
Evacuated No CTI 
' -0.10 
] -0.12 -0.09 -0.13 -0.09 -0.11 -0.15 -0.11 -0.13 -0.20 -0.16 -0.16 -0.13 
Evacuated, CTI -0.06 -0.08 -0.05 -0.081 -0.05 -0.061 -0.09 -0.0 -0.11 
1 
-0.11 -0.10 -0.09 0.09 -0.08 
Table 3.4.2. Min 
-I 
rates (%T/sec) for donors bled using either syringe draw or pre- 
evacuated blood taking method into tubes containing citrate anticoagulant with or 
without CTI. The assays were activated using 5pM TF. Samples are divided into, factor 
deficient, normal, heterozygous FV Leiden or elevated FVIII. 
Mild factor deficienc Control Factor V leiden High VII vil 11 
Donor 1 3 
I 
12 5 
1 
6 71 10 11 4 8 2 
1 
9 mean 
Sa ple 
] 
Syringe 
Syringe 
No CTI 
CTI 
1 
326 
0 
0 
0 
0- 
0 
1 
21681 
0 
0 
0 
8911 
01 
924 
0 
0 
0 
10 
0 
1900 
0 
0 
0 
888 
0 
591 
0 
Evacuated 
Evacuatedl 
No CTI 
CT 
397 
0 
0 
0 
0 
0 
2821 
0 
0 
0 
462 
0 
1 241 
0 01 
864 
0 
367 
0 
1678 
0 
883 
01 
960 
210 
724 
18 
Table 3.4.3. ETPs (m-nol. min) for donors bled using either syringe draw or pre- 
evacuated blood taking method into tubes containing citrate anticoagulant with or 
without CTI. The assay was run with no activator. Samples are divided into, factor 
deficient, normal, heterozygous FV Leiden or elevated FVIII. 
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I Donor 
Mild factor defi 
1 
ciency Control Factor V leiden High VIII 
Sam )Ie 
3 12 5 5 6 7 10 11 4 8 2 9 
1 
mean 
Syringe No CTI 
1 
1026 988 742 2445 2445 93T 691 1559 1263 1549 
1 
2331 1847 1126 
1 
1370 
Syringe CTI 790 782 4466 1660099 1 523 6301 815 908 1183 1906 1218 964 981 
Evacuatedl No CTI err 988 601 2880 887 7661 1200 1182 1340 1951 1507 
1 
1337 1330 
Evacuated l CTI 808 768 425 1 299 689 03 1036 1322 1938 1182 970 970 996 
Table 3.4.4. ETPs (nmol. min) for donors bled using either syringe draw or pre- 
evacuated blood taking method into tubes containing citrate anticoagulant with or 
without CTI. The assay was activated using 5pM TF. Samples are divided into, factor 
deficient, normal, heterozygous FV Leiden or elevated FVIII. Abbreviations: err--error 
in software calculation. 
There was little difference between the syringe draw and pre-evacuated methods when 
assessing them using the 5pM tissue factor activation (Tables 3.4.1,3.4.2 and 3.4.4). 
However, in the untriggered ETP assay donors 2,, 4 and II were active only in the 
evacuated tubes without CTI and donor 9 demonstrated persistent activation in the CTI 
containing evacuated tube (Table 3.4.3). With the exception of the elevated factor 
sample taken with pre-evacuation, no thrombin generation in the absence of activator 
when CTI was present in the collection tube (Table 3.4.3). When tissue factor was used 
as the activator an effect of the presence of CTI was demonstrated in all of the assays. 
With CTI the clot times lengthened, rate of clot formation slowed and the amount of 
thrombin generated fell. This was probably a reflection of the elimination of the 
contribution from FXlla to the activation process. Thus, the results are a more realistic 
reflection of the effect of the TF trigger alone. 
It was interesting to note that despite these donors being non-symptomatic individuals 
the carriers of the FV Leiden mutation all presented with raised thrombin generation, 
more rapid fibrin polymerisation and shorter clot times than the normal population 
when the 5pM TF trigger was used. Control donor 5 had elevated thrombin generation 
129 
and a high background sample activation. These findings are not reflected in the fibrin 
polymerisation assay results. This was a persistent finding in this individual although no 
other haematological abnormality was found (data not shown). 
3.4.8 Effect of CTI on thrombin generation in clinical samples. 
Samples were collected from 10 healthy donors, 10 haemophilia patients and 20 patients 
with a history of idiopathic (that is unprecipitated) venous thrombosis. The 10 patients 
with haernophilia had baseline factor levels below 0.02 IU/ml and had been treated in 
the 72 hours before blood sampling. FVIII/FIX levels ranged from 0 IU/ml to 0.29 
IU/ml at the time of ETP measurement. The 20 patients with a history of idiopathic 
venous thrombosis all had objectively documented evidence of thrombosis and had 
completed all anticoagulant therapy at least 3 months before blood sampling. Seven of 
20 patients had laboratory evidence of thrombophilia (4 FV Leiden, 2 AT deficiency 
and I PS deficiency). The unactivated ETPs and low tissue factor triggerd ETPs were 
measured on samples taken into tubes with CTI (18.3gg. ml final concentration in whole 
blood) and tubes without CTI. 
In the absence of CTI the unactivated ETP was detectable in 9 of 10 normal samples 
(Mean of 9 samples 13921nmol. min, SD335), 2 of 10 haemophilia samples 
(I 52nmol. min and 540nmol. min), and 17 of 20 samples from patients with venous 
thrombosis (mean of 17 samples 1980nmol. min, SD617). In the presence of CTI the 
ETP was not detectable in any sample. 
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When the ETP was triggered with 2pM TF ETPs were significantly lower in the 
presence of CTI (p<0.001). The difference (no CTI minus CTI) between results ranged 
from -1 to 2159nmol. min (median -754) and so the thrombin generation attributable to 
contact activation was often greater than that attributable to the TF-ETP at this 
concentration of TF. 
3.4.9 Standardisation of CTI activity 
CTI was supplied at a standard concentration of 1.1 mg/ml and a specific activity was 
quoted by the manufacturer. The activity was based upon the definition that one unit 
would prolong the aPTT two fold. 
As the aPTT is a very variable test in terms of machine/reagent combinations the 
specific activity of the individual reagent lots were checked using an aPTT assay 
developed for the present studies (Section 2.4.3). From the original work performed it 
was found that 50ýd of CTI to a 3ml collection tube inhibited contact activation and that 
using concentrations above this level gave no additional benefit. Using the activity 
assay this corresponded to an activity of LOU. Therefore subsequent reagent Lots were 
standardised to use LOU concentrations of CTI. 
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3.4.10 Discussion 
The use of low level TF to trigger haernostasis in the laboratory is an attractive way of 
producing an assay more closely resembling the physiological model. The level of TF 
used is critical to both the pathway by which thrombin is generated and the amount of 
thrombin that is produced (Cawthern et al., 1998). However, in the physiological setting 
contact activation is not an activator as no natural anion surface has been identified. 
This is not the case in samples collected and transported to the laboratory. The act of 
blood withdrawal and manipulation triggers contact activation of coagulation. Therefore 
it is very difficult, in vitro, to produce a TF activated system in the absence of contact 
activation although attempts have been made to minimise the effect (Keularts et al, 
200 1; Dieri et al, 2002; Cawthem et al, 1998; Rand et al, 1996). 
These studies have demonstrated that, in the absence of a contact inhibitor, contact 
activation occurs in blood drawn into citrate. The magnitude of the thrombin generation 
seen however is not insignificant (Figure 3.4.10) and must be considered sufficient to 
influence test results. Current practice in haemostasis departments is increasingly 
looking to assess minimal changes in factor levels (Shima et al., 2002) or subtle 
interactions of multifactorial conditions (Mannucci, 2002). Assessment of clot 
kinetics 
at factor levels below I. Oiu/dl has identified a variation in phenotype which may 
have 
clinical relevance (Shima et al., 2002) particularly in the setting of gene therapy where 
minimal changes have been associated with modest clinical 
improvement (Kay et al., 
2000). If low TF assays are to be applied to this type of patient, the 
background contact 
activation would be a significant problem. Equally the quest 
for an assay to assess 
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hypercoagulability is likely to include low TF assays and again contact activation would 
be a significant concern. 
The lagtime to initial thrombin generation is considerably longer for the background 
activation compared to that seen using a TF trigger. However, it is not acceptable to 
simply "gate-out, " or subtract, this contact element as the compound contribution 
cannot be estimated. 
Addition of CTI to separated plasma does reduce this effect. Indeed in 40% of samples 
tested activation was negated. However, 60% of samples still demonstrated sample 
activation which was not eliminated by CTI addition. It would therefore be 
inappropriate to use CTI addition to plasma as a means of contact inhibition in all 
samples. 
In this study the benefits of taking blood directly into citrate anticoagulant containing 
CTI was investigated. It was found that the background thrombin generation due to 
contact activation within the sample was found to be eliminated in samples bled directly 
into CTI (Figure 3.4.9.3.4.12). CTI added at the rate of 50ýtl (I. I mg/ml CTI) to 3ml of 
whole blood (I 8.3ug/ml approx plasma final concentration) appeared to be the optimum 
concentration for FXIIa inhibition. At this level the aPTT was doubled with minimal 
effect on the PT (Figure 3.4.4) being noted. Here it was demonstrated that 
CTI not only 
prolonged the time to clot formation in the contact activated aPTT 
but also affected the 
kinetics of the clotting reaction. Both the acceleration phase of clot 
formation (min2) 
and the velocity of clot formation (minl) were reduced in the same order of magnitude 
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as the clot time. The clot kinetics along with the clot times were unaffected in the TF 
activated PT. 
The thrombin generation measured in the samples bled into CTI and assayed using a 
low TF trigger was around 1785nM. min (Figure 3.4.8). This response within a non-nal 
plasma allows discrimination of both hyper- and hypocoagulable samples as this result 
falls centrally within the reading capacity of the instrumentation. From the results of 
these experiments it is clear that samples should be collected directly into citrate 
containing CTI when they are to be used in assays triggered with a low TF 
concentration, where contact activation is undesirable. The addition of CTI at any stage 
following sample withdrawl and manipulation will not inhibit contact activation in all 
samples and is thus unreliable. 
The use of CTI will render the assay insensitive to levels of FXII. Consequently, where 
FXII is to be assessed a contact based assay (Dieri et al., 2002) should be used and the 
use of CTI is contraindicated. 
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3.5 Endoizenous thrombin potential 
3.5.1 Introduction 
There is great Interest in the ETP assay with over 100 papers published using the assay. 
Half of these have appeared in the past 2 years. To date it is the only method that 
appears to offer a global screening capability. It is difficult to assess the claims for the 
sensitivity of the assay as the term ETP has been used throughout the development of 
this technology. As such the methodology has changed from a subsampling amidolytic 
assay using defibrinated plasma (Hemker et al., 1986) to a continuous registration 
fluorescent assay capable of using platelet rich plasma (Hem-ker et al., 2003). The 
calibrated automated thrombin generation method (CAT) (Hemker et al., 2003) was 
used throughout this study. Although the CAT method has only recently been described, 
a research license was granted to use the assay prior to its publication and general 
release. Therefore there has been continuity of assay throughout this study. 
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3.5.2 Sample stability. 
The assay components are well defined but the sample stability prior to assay is not. It 
was therefore necessary to investigate this prior to clinical studies. Citrated blood 
samples were collected from 3 healthy individuals in the presence and absence of CTI 
(18.3 [tg/ml final concentration in whole blood). PPP was generated following 1,2,3,4, 
5,6,7,8 and 24 hours of incubation at ambient temperature (Section 2.2). An ETP 
assay using either 2pM TF or no activator was then performed on the plasma samples 
(Figure 3.5.1). 
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Figure 3.5.1. The mean (±SEM) ETP from 3 samples stored as whole blood at RTOC for 
up to 24 hours. 0 show samples taken into citrate containing CTI triggered by 2pmol 
TF and 0 show samples taken in the absence of CTI with no activator. 
In the absence of CTI there was a progressive rise in unactivated thrombin generation 
reaching a peak at 6 hours (mean 1898nmol. min, SD 438) followed by a decline to a 
mean ETP of 1142 nmol. min (SD209) at 24hours. In the presence of CTI no 
background activation was seen at any of the time-points as indicated by the absence of 
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thrombin generation in the unactivated ETP up to an assay time of 60 minutes. In the 
presence of CTI the TF-triggered ETP (2pmol TF) was constant throughout the 24 hour 
period (mean 1601 nmol. min, SD 498, ANOVA F=0.225, p=0.981). This finding 
suggests that sample handling times are not critical when CTI is used in the collection 
tube. This has implications within the routine hospital setting where delays in sample 
transport are a common problem. 
3.5.3 Optimisation of TF and TM concentrations for detection of hyper- and 
hypo- coagulable samples using thrombin generation. 
The measurement of thrombin generation as a means of assessing haemostatic status has 
been proposed as a means of recognising a prethrombotic state, correlating with 
bleeding tendency and indicating anticoagulant treatment levels (Hemker and Beguin, 
2000). The literature confirms that thrombin generation can identify both thrombophilic 
and haernophilic individuals (Hernker and Beguin, 1995). The use of the specific 
contact inhibitor, CTI, has enabled the assay to be performed with confidence using 
frozen PPP (Section 3.4.5). Using the sample cohort described earlier (Table 3.3.9) the 
assay (Section 2.5.3) was assessed using 48 combinations of TF and TM (Table 3.5.1). 
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TF (pM 
TM (nM) 123 4 5 6 8 15 
0 Tested Tested Tested Tested Tested Tested Tested Tested 
0.5 Tested Tested, Tested Tested Tested Tested Tested Tested 
I Tested Tested 1 Tested 
' 
Tested Tested Tested Tested Tested 
2 Tested Tested Tested Tested Tested Teste-di Tested 
3 Tested Tested Tested Tested Tested Tested, 
4 Tested T Tested Tested Tested 
5 rested Tested Tested 
7 Tested 
I 
Tested Tested 
Table 3.5.1: The final reaction concentrations of tissue factor (TF) and thrombomodulin 
(TM) used to assess the thrombin generation. 
The results of thrombin generation assays are shown in Appendices 3-5. The use of 
lagtime measurements did not provide sufficient discrimination between the 3 patient 
groups (hypercoagulable, healthy controls and hypocoagulable). However, both the 
thrombin peak and total thrombin levels were able to discriminate between the groups. 
At concentrations 3-15pM TF in the absence of TM, the hypocoagulable group could be 
distinguished from the other two groups (Figures 3.5.4). As the TF concentration 
increased the hypocoagulable group continued to be easily distinguished from the other 
two patient cohorts. However as the TF concentration rose this segregation of the 
hypocoagulable group became apparent even in the presence of TM. With increasing 
TM concentration there was a requirement for higher TF levels to maintain the degree 
of segregation of the hypocoagulable group (Figures 3.5.2 and 3.5.3). 
With respect to the hypercoagulable group a different pattern emerged. Only at the 
highest TF/TM concentration did the hypercoagulable samples segregate from the 
control population (Figures 3.5.2 and 3.5-3). 
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The use of the ETP gave a similar pattern of results. Again the hypocoagulable group 
segregated at 3pM TF in the absence of TM (Figures 3.5.8). The requirement for higher 
TF concentrations as the TM concentration increased was again evident (Figures 3.5.5- 
3.5.7). As with the thrombin peak estimation differentiation of the hypercoagulable 
group from the normal population was best demonstrated at the 15pM TF/7nM TM 
combination (Figure 3.5.7). At this reagent combination it was possible to clearly 
differentiate all 3 populations, hypocoagulable, control and hypocoagulable. 
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Figure 3.5.2. Effect of increasing TM concentration on the mean peak thrombin 
estimation at 8pM TF. The donors tested fell into one of three categories 
hypercoagulable (X), normal () or hypocoagulable (L 1). 
139 
700- 
--4-600- 3x 
, E500- xx x 
.E 400 -x 
E 300- 
0A a» 200 - 
100 - Es 0 
A012345 
'TM(nf4 
6 
x 
x 
Figure 3.5.3. Effect of increasing TM concentration on the mean peak thrombin 
estimation at 15pM TF. The donors tested fell into one of three categories 
hypercoagulable (X), normal () or hypocoagulable 
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Figure 3.5.4. Effect of increasing TF concentration on the mean peak thrombin 
estimation in the absence of TM. The donors tested fell into one of three categories 
hypercoagulable (X), non-nal () or hypocoagulable (D). 
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Figure 3.5.5. Effect of increasing TM concentration on the mean ETP at 6pM TF. The 
donors tested fell into one of three categories hypercoagulable (X), normal or 
hypocoagulable (--). 
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Figure 3.5.6. Effect of increasing TM concentration on the mean ETP at 8pM TF. The 
donors tested fell into one of three categories hypercoagulable (X), normal or 
hypocoagulable (D). 
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Figure 3.5.7. Effect of increasing TM concentration on the mean ETP at 15pM TF. The 
donors tested fell into one of three categories hypercoagulable (X), normal or 
hypocoagulable (7). 
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Figure 3.5.8. Effect of increasing TF concentration on the mean ETP in the absence of 
TM. The donors tested fell into one of three categories hypercoagulable (X), normal 
() or hypocoagulable (FI). 
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3.5.4 Extended matrix 
From the results described above the 15pM TF/ 7nI\4 TM combination gave the best 
differentiation of the patient populations. However, it was possible that increasing the 
TF/TM concentrations further would provide better differentiation. Three further 
reagent combinations were tested 20pM TF/ 0 TM, 20pM TF/ 9nM TM and 25pM 
TF/12riM TM. 
The assay was performed as described previously (Section 2.5.3) using half volumes 
throughout to keep the fluorescent signal within optimum for the reader. 
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Figure 3.5.9 ETP results for the nine donor panel described in Section 3.5.3 using 20pM 
TF in the absence of TM as the triggering reagent. 
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Figure 3.5.10 ETP results for the nine donor panel described in Section 3.5.3 using a 
20pM TF/9nM TM triggering reagent. 
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Figure 3.5.11 The ETP results for the nine donor panel described in section 3.5.3 using 
a 25pM TF/12n-M TM triggering reagent. 
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The results are shown above (Figures 3.5.9-3.5.11). At 20pM TF/O TM there was good 
discrimination between the control and thrombophilia populations. However, there was 
no differentiation of the haemophilia group from the control group (Figure 3.5.9). 
Following addition of 9nM TM to this reagent the haemophiliacs could easily be 
differentiated but overlap between the thrombophilia and normal populations was seen 
(Figure 3.5.10). The loss of differentiation between the thrombophilia and nonnal 
populations was more marked as the TF concentration was increased further to 25pM 
(Figure 3.5.11). The presence of TM in the reagent maintained the differentiation of the 
haernophilia population. 
3.5.5 Assay precision 
Three plasma pools were tested on ten occasions to assess assay precision. Each pool 
consisted of 5 donor samples of CTI-citrate anticoagulated plasma. The first pool was 
derived from individuals carrying the FV Leiden mutation, the second from healthy 
individuals and the third from patients with haemophilia A. The ETP assay was 
performed using a 15pM TF / 7nM TM trigger reagent. CVs of between 5 and 13% 
were obtained for the normal and FV Leiden pools. The normal pool returning CVs of 
6.97%5 5.46% and 5.05%. for the lagtime, ETP and peak values respectively. While the 
FV Leiden pool gave CVs of 6.95%, 6.5 1% and 12.28%, for the lagtime, ETP and peak 
values respectively. However, the CVs for the haemophilia pool were poor with values 
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of 37.28%, 51.7% and 41.3%, for the lagtime, ETP and peak values respectively. These 
were improved using a 4pM TF trigger in the absence of TM (CVs 18.9%, 25.7% and 
26.2%, for lagtime, ETP and peak respectively). 
3.5.6 Discussion 
It was established that following the addition of CTI samples were remarkably stable 
throughout the 24 hour test period (Figure 3.5.1). However, as samples have been 
shown to be unstable after delays of more than 3 hours prior to centrifugation and PPP 
preparation (Section 3.6.2) a2 hours maximum time between venepuncture and sample 
separation was used throughout. 
Low TF levels produced weak thrombin generation curves particularly in the presence 
of TM and TF concentration of less than 3pM often failed to give a thrombin generation 
curve in the hypocoagulable and some of the control individuals. Discrimination of the 
3 patient groups improved as higher TF concentrations were used with separation of all 
3 groups being seen above 6pM TF particularly when TM was added. It was possible to 
clearly identify the hypocoagulable samples at low levels of TF. The addition of high 
TM concentration reduced the separation from the control group as a result of thrombin 
inhibition in the normal group. The ability of the reagent combinations to segregate the 
hypercoagulable samples from normal appeared to be a function of TF/TM 
concentration. At higher TF concentration higher TM concentrations could be used 
without compromising the assay through thrombin inhibition. This effect appeared to 
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have a maximum threshold at 15pM TF with 7nM TM. The sub matrix experiments of 
section 3.5.4 demonstrated that the use of higher levels gave no benefit over the 15pM 
TF / 7nl\4 TM reagent combination. The 15pM TF / 7nM TM reagent was therefore 
selected for use against the VTE patient (Section 3.7). The 15pM TF / 7n-M TM reagent 
combination demonstrated good assay precision for normal and hypercoagulable 
samples. However, a lower TF reagent in the absence of TM may be favoured for 
hypocoagulable screening. Therefore additionally the 4pM TF reagent was selected for 
evaluation of the haernophilia samples (Section 3.8) 
147 
3.6 Rotational thrombelastometrv. 
3.6.1 Introduction 
The TEG / ROTEM allows the user to examine the speed of formation and subsequent 
stability of a blood clot (Mallett and Cox., 1992). The technology is applicable to whole 
blood, platelet rich plasma and platelet poor plasma. Early applications were in the field 
of blood component monitoring in a theatre setting (Kang et al., 1985; Spiess et al., 
1987), where the TEG was used to assess the need for plasma or platelet administration 
during surgery. This is still its main use today. However, a few reports have suggested a 
role for the TEG / ROTEM in thrombophilia screening (O'Donnell et al., 2004)(Handa 
et aL . 1997). Others have described the use of the TEG / ROTEM in the monitoring of 
replacement therapy for haemophiliacs with inhibitors to FVIII (Sorensen et al., 2003). 
In this study the ROTEM was assessed for its ability to act as a global screen for 
haemostasis. In particular its capability in terms of haemophilia and thrombophilia 
detection was assessed. 
3.6.2 The effect of CTI concentration on the ROTEM. 
The native ROTEM involved the use of native whole or citrated blood. However, it was 
not practical to perform analysis on whole blood for the patient group being tested due 
to the limited sample stability as the sample was only stable for a period of 90 minutes 
(Sorensen et al., 2003; Vig et al., 2002) (Section 3.6.3). The activation of the ROTEM 
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occurs from intrinsic sample activation and mechanical activation through contact with 
the cup and pin. The use of the ROTEM using a low TF trigger has been described 
previously (Sorensen et al., 2003). However, no attempt was made to eliminate the 
sample related contact activation. In order to standardise sample collection and allow a 
TF activated ROTEM assay the effect of CTI was investigated. 
Blood was collected from 6 healthy volunteers into sodium citrate anticoagulant to give 
a final plasma CTI concentrations of 18.3,27.45 and 36.6 ýtg/ml assuming a PCV of 
0.45 1/1. The ROTEM results using recalcification of the plasma, with no additional 
activator, are shown in Table 3.6.1 
CTI concentration No CTI 18.3ug/ml 27.45uq/ml 36.6ug/ml 
r time 31.8 131.95 119.1 147.7 
Maximum Amplitude 24 10.75 14 11.67 
, Alpha angle 20.6, nc Inc nc 
Table 3.6.1. Mean ROTEM results of 6 healthy volunteers bled into different 
concentrations of CTI. The assay was triggered by recalcification of the plasma. The 
values shown indicate final concentrations of CTI. 
Abbreviations: nc= not calculated 
The results show inhibition of coagulation following the addition of 18.3ýtg/ml of CTI 
(Mann Whitney U test for r time and maximum amplitude p<0.05). The addition of 
higher concentrations of CTI was without further effect. 
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3.6.3 Sample stability and assay precision. 
Sample stability was not an issue when the TEG / ROTEM was used at the bedside with 
native whole blood. However, when the technology moved into the laboratory there was 
a need to use an anticoagulated sample. This has led to the problem of sample stability. 
This has been examined using both the Haemoscope (Vig et al., 2002) and Pentapharm 
(Sorensen et al., 2003) instruments with similar findings. The reports suggest a window 
between 30 minutes and 2 hours post venepuncture, into citrate anticoagulant, when the 
TEG / ROTEM variables gave "reliable results". 
Blood was collected in the presence and absence of CTI from 3 healthy individuals and 
was left at RTT for up to 9 hours before testing. The assay was perfonned as 
previously described (Section 2.5.4) except that whole blood was tested rather than 
plasma. The results obtained using a lpM TF trigger demonstrated a steady decrease in 
r-time in all samples tested , with a 
fall of around 30% over the 7 hour test period. In 
contrast the NIA was stable in all samples throughout the same period. The angle was 
stable up to 2 hours in the recalcified ROTEM in the absence of CTI but then increased 
by 40% over the next 5 hours. The CTI containing samples gave an overall increase of 
10% over the same period. 
The stability of samples for analysis of the ROTEM in plasma was also assessed. Blood 
was taken from 3 healthy individuals into citrate anticoagulant containing CTI and left 
for up to 7 hours as whole blood at RTOC. At hourly intervals PPP was prepared 
(Section 2.2) and the samples stored at -80T until assayed. Figure 3.6.1 shows that the 
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ROTEM analysis was stable up to 3 hours post venepuncture. Over the following 4 
hours the r-time fell by an average of 22%, MA fell by 12% and the alpha angle rose by 
10%. 
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Figure 3.6.1. ROTEM results using aI pM TF trigger (Mean ± SEM) for PPP prepared 
from whole blood, containing CTI, stored at RTOC for up to 7 hours. Symbols: E] r- 
time, A alpha angle and X maximum amplitude (MA). 
Two plasma pools were assayed on ten occasions to assess assay precision. The first 
was derived from CTI-citrate anticoagulated plasma collected from individuals carrying 
the FV Leiden mutation. The second plasma pool was derived from CTI-citrate 
anticoagulated plasma collected from healthy individuals. Five donors were included in 
each pool. Using aI pM TF trigger reagent the CVs were less than 10% for all variables. 
The healthy donor pool gave CVs of 8.43%, 6.22% and 4.82%, for the r-time, MA and 
alpha angle respectively. Similarly, the FV Leiden plasma pool gave CVs of 7.69%, 
5.53% and 4.75%, for the r-time, NIA and alpha angle respectively. 
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3.6.4 Assessment of TF concentration. 
It has been found that maximal inhibition of sample contact activation could be 
achieved using 18-3ýtg/rnl CTI in the collection tube (Section 3.4.5). Contact activation 
could not be totally eliminated when using the ROTEM (Table 3.6.1). An assay using 
low levels of TF as a trigger with minimal influence of sample activation was therefore 
evaluated. At higher TF concentrations the reaction would be driven via prothrombinase 
activation from the XaNlIa/TF complex. Under those conditions ROTEM results in the 
presence or absence of CTI would be similar. As the TF concentration is lowered 
prothrombinase activation would switch to lXa mediated activation via the Josso loop 
(Josso and Prou-Wartelle, 1965). 
Blood was collected from 3 healthy individuals into citrate anticoagulant in the presence 
and absence of CTI. ROTEM analysis (Section 2.5.4) was performed on PPP using 
progressively lower levels of TF activator. The results were comparable between the 
CTI and non-CTI containing samples down to a TF concentration of 2pM. Below 2pM 
there was a marked increase in r-time and decrease in angle seen in the CTI containing 
samples (Table 3.6.2). At IpM TF the r-time increased by 47% and the angle fell by 
63% relative to the sample without CTI. Below IpM TF the r-times became 
progressively longer (results not shown). 
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r-ti me Maximum amplitude Alpha angle 
TF conc. CTI no CTI CTI no CTI CTI no CTI 
2pM 7.7 6.9 22 21.6 43.3 45.6 
1 PM 18.3 12.4 20 21.6 26.3 44 
Table 3.6.2. Mean ROTEM results of PPP from 3 healthy donors in the presence and 
absence of CTI at I or 2pM TF. 
The experiment was then repeated using samples taken into CTI from normal 
individuals and haernophiliacs (Table 3.6.3). 
Control Haemophilia A 
TF conc r-time MA alpha angle r-rime MA alpha angle" 
8pM 6.9 27 69 13.1 21 53 
4pM 7.2 28 51 21.6 20 26 
ipm 17 1 30 36 43.2 19 nr 
Table 3.6.3. Mean ROTEM results of PPP from 3 healthy donors and 3 haemophiliac in 
the presence of CTI using different TF concentrations. 
The difference between the control and severe haemophilia samples became more 
pronounced as the TF concentration decreased. The variables most affected were the r- 
time and alpha angle. 
The IpM TF triggered ROTEM was further assessed using the selected 9 donor panel 
previously described (Table 3.3.9). The r-time was uninformative with no separation of 
control, hypercoagulable or hypocoagulable samples. The results for the MA and alpha 
angle are shown in Figures 3.6.2 - 3.6.3. 
To enhance the effect of the PC pathway, TM was incorporated into the reagent. 
The 
addition of TM to the 1 pM TF reagent resulted in a very weak 
ROTEM response. 
Increasing the TF concentration to 2pM allowed the addition of 0.5nM TM to the 
153 
reagent. This reagent resulted in the differentiation of hypercoagulable samples from 
control group. However, the haemophilia and control samples were indistinguishable 
using this reagent combination. The r-time and alpha angle were uninformative with no 
separation of control, hypercoagulable or hypocoagulable samples. The results for the 
MA against the selected 9-donor panel (Table 3.3.9) for the 2pM TF/ 0.5nM TM 
reagent are shown in Figure 3.6.4. 
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Figure 3.6.2. Maximum amplitude (MA) results for 9 donor panel previously 
described 
(Table 3.3.9) using a IpM TF trigger. 
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Figure 3.6.3. Angle results for 9 donor panel previously described (Table 3.3.9) using a 
I pM TF trigger. 
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Figure 3.6.4. Maximum amplitude (MA) results for 9 donor panel previously described 
(Table 3.3.9) using a 2pM TF/0.5nM TM trigger. 
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3.6.5 Discussion 
Sample stability was more of an issue for the use of the ROTEM in the laboratory 
setting rather than bedside. The results were in agreement with those published 
(Sorensen et al., 2003; Vig et al., 2002) in that the period between 30 minutes and 2 
hours post venepuncture was the most stable for whole blood analysis. However, even 
during this period a shortening of the r-time was seen. When considering the assay for 
discrimination of hypercoagulable samples from normal the MA and angle have been 
found to be more informative than r-time (Zuckerman et al., 1981). Therefore the 
shortened r-time was not an important factor for this application. Using the ROTEM the 
addition of CTI inhibited clot formation but did not abolish it. The addition of greater 
than 50ýil of CTI (I. Img/ml) had no further effect on the rate of clot formation (Table 
3.4.1). As background activation assessed by the ETP is abolished at this level of CTI 
addition it is reasonable to assume that the clot formation seen in the ROTEM is due to 
activation of the plasma in the test cup and is therefore constant for each sample. The 
addition of CTI did increase the sample stability of the angle measurement beyond 2 
hours but did nothing to limit the progressive shortening of the r-time. The use of a PPP 
based assay offered greater sample stability with whole blood being stable up to 3 hours 
prior to centrifugation in the presence of CTI (Figure 3.6.1). The use of PPP limited the 
assay to the assessment of plasma components and could not assess the contribution of 
the cellular components of blood. This compromise was accepted for this study as it 
offered a direct comparison with the ETP and clot kinetic assays. It was found that the 
lowest concentration of TF that could be used to activate contact inhibited plasma was 
IpM (Tables 3.6.2 and 3.6.3). At this level assay precision was good with CVs < 10%. 
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Lower TF concentrations have been used by others in a whole blood analysis (Sorensen 
et al., 2003) However, it has been shown that the presence of the patients own platelets 
resulted in much lower levels of TF being required for sample activation (Hemker et al., 
2003). The nine donor panel confirmed that IpM TF could differentiate the selected 
thrombophilia patients from the control individuals. However, as with the clot kinetics 
(Section 3.3), another assay using a fibrin polymerisation end-point, differentiation of 
mild / moderate haemophilia was poor (Figures 3.6.2 - 3.6.3). 
The addition of TM to the reagent was achieved using a 2pM TF concentration. This 
allowed 0.5nM TM to be incorporated into the reagent whilst maintaining sufficient 
thrombin generation to initiate fibrin polymerisation. The results of this reagent against 
the 9-donor panel gave excellent separation of the hypercoagulable group from either 
the control or hypocoagulable samples (Figure 3.6.4). 
The data from the ROTEM was further analysed as described by Sorenson et al (2003). 
The shape of the ROTEM curve is a similar sigmoid curve to that seen in the TWF of 
the MDA (bioMerieux, Lyon, France). Therefore, by taking the first derivative of the 
amplitude against time data it was possible to calculate the maximum velocity of the 
ROTEM reaction (Max Vel). In addition the time to this event was calculated 
(tMax. Vel). Finally the area under the first derivative curve was calculated (AUC). The 
results for Max. Vel and tMax. Vel were uninfonnative with respect to the 9-donor panel 
giving considerable overlap between all groups. The AUC gave the same pattern of 
results to the MA and thus provided no additional information. These finding are in 
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keeping with those of Sorenson et al. (2003) who demonstrated close correlation 
between the AUC and MA. 
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3.7 Evaluation of assays against a cohort of patients who had suffered a venous 
thrombotic event. 
3.7.1 Patient selection 
Patients were selected from the Cambridge Venous Thromboembolism Study (CVTE) 
(Baglin et al., 2003). Since August 1997 all consecutive patients referred for oral 
anticoagulation therapy at Addenbrooke's Hospital, Cambridge, after a first episode of 
objectively confirmed VTE had been registered on a clinical outcome database. This 
database was registered with the hospital Clinical Audit and Effectiveness Unit 
(Appendix 6). The study had full ethical approval (Appendix 6). Deep vein thrombosis 
was diagnosed by compression ultrasound or contrast venography. Pulmonary embolus 
was diagnosed by ventilation-perfusion lung scanning, computed tomography or 
pulmonary angiography. Patients with an indication for prolonged anticoagulation were 
excluded: these were patients with antiphospholipid activity, malignancy, thrombosis in 
an unusual site and those with an additional indication, for example atrial fibrillation. At 
the time of registration clinical risk factors were recorded and patients were categorised 
into 4 groups: 
Group A: patients with surgery in the previous 6 weeks 
Group B: women with pregnancy-associated VTE, including post-partum events up to 
2 
months after delivery. 
Group C: patients with unprecipitated venous thromboembolism in whom there was no 
identifiable clinical risk factor. 
Group D: patients with non-surgical risk factors for VTE. 
Some of these patients had 
absolute risk factors such as a fracture or application of a plaster cast, oestrogen- 
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containing oral contraceptive use, whilst others had unquantifiable risk factors such as 
immobilisation, a non-specific transient illness or a history of travel. 
Samples previously banked for these patients were not suitable for this study as they 
were taken in the absence of CTI. Therefore, patients from groups A and C were 
recalled and samples collected in citrate anticoagulant containing CTI. Fifty-four 
patients (17 post surgical -group A, 37 unprecipitated -group Q attended for sample 
collection. 
3.7.2 Determination of reference ranges. 
Healthy donors were selected on the basis of PT, aPTT, factor activity levels and 
thrombophilia screen results being within the laboratory reference ranges (Section 2.3). 
No abnormal results were found in 25 individuals (14 female, II male, age range 22-64 
years). Blood was taken, from these 25 individuals, into citrate anticoagulant (0.109M) 
containing CTI (final conc. in whole blood 18.3ýtg/rnl) and PPP prepared (Section 2-2). 
All samples were stored in aliquots at -80'C until assay. Min_I rate (Section 2.5.2), 
ETP (Section 2.5.3) and ROTEM (Section 2.5.4) were perfonned on freshly thawed 
PPP samples. The results are shown in tables 3.7.1-3.7.3. 
min_l rate (%T/sec 
TF conc. (pM) 1 1 1 2 2 
TM conc. (nM) 0 0.25 0.5 0 1 
Mean 57 41 42 78 50 
Mean+/-2SD 44-70 1 11-71 0-81 58-99 1 33-68 
Table 3.7.1. Reference range data for min -I 
rate at different TF / TM combinations. 
Abbreviations: tissue factor (TF), thrombomodulin (TM). 
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ETP (n ol. min) 
TF conc. (pM) 15 15 
TM conc. (nM) 0 7 
Mean 1999 1168 
, Mean+/-2SD 1623-2375 1 102-2234 
Table 3.7.2. Reference range data for ETP using 15pM TF in the presence and absence 
of 7n-M TM. Abbreviations: tissue factor (TF), thrombomodulin (TM), endogenous 
thrombin potential (ETP). 
1pM TF /0 TM 2pM TF/0.5nM TM 
r-time (mm) MA (mm) Angle (degrees) MA (mm) 
Mean 10.5 22 55.9 9.94 
Mean+/-2SD 1 6.7-14.3 13.6-30.5 20.4-81.6 0-21.2 
Table 3.7.3. Reference range data for ROTEM using lpM TF and 2pM TF/ 0.5nM TM 
reagents. 
Abbreviations: tissue factor (TF), thrombomodulin (TM), maximum amplitude (MA). 
3.7.3 Results using ETP 
Seventy- nine samples (17 post surgical thrombosis, 37 idiopathic thrombosis and 25 
control) were assayed in triplicate using the calibrated automated throm in generation 
assay (Section 2.5.3). The assay was activated using a final TF concentration of 15pM 
with or without 7nM TM (Sections 3.5.3 and 3.5.4). Both figures 3.7.1 and 
3.7.2 show a 
trend towards higher ETP values for the patients in both the surgical group and the 
idiopathic group relative to the control samples. In the absence of TM 
(Figure 3.7.1) 
32% of the idiopathic group and 32% of the post surgical group 
had ETP results higher 
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than the reference range. When TM was present (Figure 3.7.2) 24% of the idiopathic 
group and 27% of the surgical group gave values greater than the reference range. There 
was little between the idiopathic and surgical groups with only 3 patients using the 
TF/TM reagent and 2 patients using the TF only reagent giving higher results in the 
idiopathic group relative to the post surgery group. In the presence of TM the patient 
samples were significantly higher than the control group (P<0.05). In the absence of TM 
the results failed to reach statistical significance (p=0.09). 
4500- 
0 
4000- 
3500- 0 
ETP 
- 3000- nmol. mm 
2500- 
2000- 
1500- 
1000- 
500- 
0- 
Idiopathic Surgery Control 
Figure 3.7.1. ETP for post-surgical and idiopathic patients groups and controls using 
15pM TF in the absence of TM as a trigger. Median values are shown 
for each group. 
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Figure 3.7.2. ETP for post-surgical and idiopathic patients groups and controls using 
l5pM TF / 7nM TM as a trigger. Median values are shown for each group. 
3.7.4 Results using the clot kinetic parameter min-1. 
From the reagent optimisation experiments for min_l (Section 3.3.8) 5 reagents were 
used against the patient samples (Section 3.7.2) and controls (Section 3.7.3). The 
reagents selected were a IpM TF with and without TM (0.25nM and 0.5nM) and a 2pM 
TF reagent with and without I nM TM. These were selected as a low TF was shown to 
give the better discrimination of the thrombophilia samples from the control samples 
tested. The TM concentrations were selected as the maximum concentration that would 
allow clot formation of the normal / thrombophilia samples within the 240 second 
window of the MDA analyser. When the clot times exceed 200 seconds the calculation 
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of min_1 becomes unreliable as incomplete TW were seen. The reproducibilty of results 
using the lpM TF/ 0.5nM TM reagent was poor and consequently only the IpM TF/ 
0.25nM TM data is shown. Using the IpM TF in the absence of TM (Figure 3.7.3) 65% 
of the idiopathic group and 60% of the post surgical group had results above the upper 
limit of the reference range. When 0.25nM TM was included in the reagent (Figure 
3.7.4) 22% of the idiopathic group and 20% of the post surgical group had results above 
the upper limit of normality. The 2pM TF reagent gave similar findings. In the absence 
of TM (Figure 3.7.5) 51% of the idiopathic and 27% of the post surgical group gave 
values above the upper limit of the reference range. When I nM of TM was added to the 
reagent (Figure 3.7.6) the values fell to 30% in the idiopathic group and 20% in the 
post surgical group. 
As was shown in the ETP data there was little difference between the idiopathic and 
post surgical groups. In the absence of TM, 2 and 3 patients with the IpM and 2pM 
reagents respectively gave higher results in the idiopathic group relative to the surgical 
group. When TM was present there where 0 and 4 patients for the lpM and 2pM TF 
reagents respectively. 
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Figure 3.7.3. Min 
-I 
rate for post-surgical and idiopathic patients groups and controls 
using lpM TF in the absence of TM as a trigger. Median values are shown for each 
group- 
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Figure 3.7.4. Min 
-I 
rate for post-surgical and idiopathic patients groups and controls 
using IpM TF / 0.25nM TM as a trigger. Median values are shown 
for each group. 
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Figure 3.7.5. Min 
-I 
rate for post-surgical and idiopathic patients groups and controls 
using 2pM TF in the absence of TM as a trigger. Median values are shown for each 
group. 
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Figure 3.7.6. Min I rate for post-surgical and idiopathic patients groups and controls 
using 2pM TF /I nM TM as a trigger. Median values are shown for each group. 
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3.7.5 Results using the ROTEM. 
It was found that IpM TF and 2pM TF/0.5nM TM were the lowest final reagent 
concentrations that could be used in a PPP sample in CTI inhibited samples (Section 
3.6.3). These reagents were used to activate the patient (Section 3.7.2) and control 
(Section 3.7.3) samples using the ROTEM (Section 2.5.4). The MA (Figure 3.7.7 and 
3.7.9) gave the better discrimination between the thrombotic and normal groups. 
Twenty-two percent of the idiopathic and 15% of the post surgical patients gave values 
above the upper limit of normality with the IpM TF reagent and 27% and 33% 
respectively with the 2pM TF/0.5nM TM reagent. None of the thrombophilia patients 
gave an angle value outside the reference range (Figure 3.7.8). Again there was little 
difference between the idiopathic and post surgical groups with only 3 patients from the 
idiopathic group having MA values higher than those of the surgical group. 
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Figure 3.7.7. MA of ROTEM for post-surgical and idiopathic patients groups and 
controls using IpM TF as a trigger. Median values are shown 
for each group. 
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Figure 3.7.8. Angle of ROTEM for post-surgical and idiopathic patients groups and 
controls using I pM TF as a trigger. Median values are shown for each group. 
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Figure 3.7.9 MA of ROTEM for post-surgical and idiopathic patients groups and 
controls using 2pM TF and 0.5nM TM as a trigger. Median values are shown for each 
group. 
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3.7.6 Discussion 
Each of the 3 screening assays was able to identify a group of VTE patients that gave 
results above the limits defined by the reference range. Using the Mann Whitney U test 
statistically significant differences were seen between the VTE groups and the control 
group using ETP 15pM TF / 7nM TM, Min_l rate in the absence of TM and ROTEM in 
the presence of TM (P<0.05). However, each of the assays identified >20% of the VTE 
patients with values above the upper limit of normality. This figure is in keeping with 
the findings of others that have applied a "global assay" to thrombophilia screening 
(O'Donnell et al., 2004) (Faber et al., 2003). 
The spread of results was greater when TM was used in the reagent indicating a high 
variance between samples in their susceptibility to the effects of TM in contact inhibited 
plasma activated with physiological TF concentrations. This was highlighted by the 
broad normal range of the 15pM TF / 7nM TM with the high sensitivity of some normal 
individuals affecting the lower end of this range. 
Within the patients selected 30% of the idiopathic group and 12% of the surgical group 
had an identified abnormality in the routine thrombophilia screen (3 AT deficiencies, 2 
PS deficiencies, 1 heterozygous for the PTG20210A mutation and 7 heterozygous for 
the FV Leiden mutation). The detection of these abnormalities is shown below (Table 
3.7.4). The detection rates were generally higher than those seen for the DD assay 
which is seen currently as the best marker of hypercogulability. 
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Assay ET P Min_l rate ROTEG-MA D-Dimer 
t TF (pM) 
15 15 1 1 2 2 1 na Reagen TM (nM) 0 7 0 0.25 0 1 0 
Antithrombin deficiency 66% 66% 100% 33% 33% 66% 0% 0% 
Protein S deficiency 0% 0% 50% 1 0% 100% 50% 50% 50% 
PT20210 heterozygous 0% 0% 100% 0% 0% 0% 0% 0% 
FV Leiden Heterozygous 114% 129% 43% 
1 
43% 43% 43% , 43% 1 43% 1 
Table 3.7.4. Percentage detection of thrombophilic defects for the WE patient samples. 
Abbreviations: Tissue factor (TF), Thrombomodulin TM, endogenous thrombin 
potential (ETP), Factor V (FV), not applicable (na). 
These detection rates were similar to those reported (Kyrle et al., 1998; O'Donnell et al., 
2004) but below those for the PC pathway screening assays such as ProC*Global 
(Toulon et al., 2001). The detection rate for the IpM TF reagent using the min_l rate 
appears very high but the fact that over 60% of patient samples gave values above 
the 
upper reference limit would suggest that this assay may 
be too sensitive. When the 
reagent was compared to the 2pM TF /I nM TM reagent only 
2 additional samples, with 
recorded defects, gave positive results. With the 2pM 
TF / lnM TM only 20-30% of 
patients fell above the reference range. This means that to 
detect these 2 individuals 17 
extra patient samples would be considered to 
have a positive result when the IpM TF 
reagent was used. 
There was some degree of overlap between the patients 
identified by the different 
assays (Tables 3.7.5 and 3.7.6). 
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Min 1 ETP D-Dimer MA 
Min 1 75% 64% 89% 
ETP 39% 14% 56% 
D-Dimer 39% 17% 56% 
MA 35% 17% 
1 
36% 
1 
Table 3.7.5 Percentage of samples giving high results with more than one assay in the 
absence of TM. Min 
-I 
assay used 2pM TF. The table is read along the top and then 
down the side, i. e. 75% of patients with abnormal ETP have an abnormal min-I 
whereas 39% of patients with an elevated min_1 have and abnormal ETP. 
Abbreviations: endogenous thrombin potential (ETP), maximum amplitude (MA). 
Min 1 ETP D-Dimer MA 
Min 1 30% 43% 11% 
ETP 21% 21% 33% 
D-Dimer 43% 30% 56% 
MA 7% 30% 36% 
Table 3.7.6 Percentage of samples giving high results with more than one assay in the 
presence of TM. Min 
-I 
assay used 2pM TF. The table is read along the top and then 
down the side, i. e. 30% of patients with abnormal ETP have an abnormal min-I 
whereas 21% of patients with an elevated min_l have and abnormal ETP. 
Abbreviations: enclogenous thrombin potential (ETP), maximum amplitude (MA). 
An overlap between the assays using fibrin polymerisation endpoints would probably be 
expected. Indeed the closest agreement was for the positive MA group and the min-l 
group in the absence of TM, at 89%. The opposite relationship was not as striking with 
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only 35% of positive min_l results having an abnormal MA. This reflects the number of 
patients registering above the upper reference limit. One possible conclusion is that the 
min_l rate was more sensitive to factors affecting fibrin polymerisation than the 
ROTEM NIA measurement. 
The angle parameter for the ROTEM proved uninformative in the VTE patients. The 
finding that the MA parameter was the best marker of hypercoagulabilty confirmed the 
findings of O'Donnel et al (2004). Additionally they found 5/87 patients with a 
shortened r-time as the only abnonnaility. R-time was not included in the above 
analysis as it showed poor discrimination of recurrent VTE patients from the controls in 
the reagent optimisation experiments (Section 3.6). However one patient had a reduced 
r-time. This patient also had abnormal min_1 and ETP results in the presence of TM. 
The assays of fibrin polymerisation and thrombin generation identified different 
populations, albeit with some overlap, that may be at increased risk of recurrent VTE. If 
both assay types identify an increased thrombotic risk one question that should be 
addressed in future studies is whether patients with abnonnalities in both assay types are 
at any greater risk of thrombosis. 
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3.8 Application of assays of ETP and Min I to the detection of haemODhilia. 
3.8.1 Introduction 
The assay of factor levels in haemophilia patients is a routine procedure in haemophilia 
centres. However, the clinical utility of the results has recently been questioned 
(Keeling et al., 1999). These authors described an individual with inherited mild 
haemophilia associated with a one-stage FVIII assay repeatedly within reference limits. 
This was attributed to the molecular defect within the A3 domain of the FVIII gene 
causing the haemophilic defect in this patient. When the assay was performed using a 
two-stage technique the factor level was found to be low. Other genetic lesions within 
the FVIII gene have been described which also produce this phenotype (Mazurier et al., 
1997; Rudzki et al., 1996). These patients are however very rare. 
Problems associated with the assay of FVIII also occur following replacement therapy, 
particularly when recombinant products are used. The introduction of a B-domain- 
depleted recombinant FVIII, ReFaCtOTM, highlighted problems associated with one- 
stage laboratory assays of FVIII to assess levels of recombinant therapeutic products. 
Recovery levels of FVIII were found to be 30-50u/dl lower when a one-stage rather than 
a two-stage or chromogenic assay was used (Hay et al., 2000). It was found that it was 
the use of a plasma standard in assays of ReFactoTM that caused the gross 
underestimation of circulating product (Mikaelsson et al., 2001). This finding resulted 
in the introduction of a product specific standard (Mikaelsson et al., 2001) which 
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corrected this discrepancy (Hay et al., 2000; Sukhu et al., 2003). Further work carried 
out by the National Institute for Biological Standards and Control (NIBSC) supported 
the use of product specific standards (Hubbard et al., 2001). These authors 
demonstrated 45-53% differences in recovery FVIII levels following the infusion of 
full-length recombinant FVIII between chromogenic and one-stage assays when plasma 
standards were used. They concluded that the discrepancies were caused by the 
difference in thrombin and FXa generation observed between the plasma standards and 
product specific standards (Hubbard et al., 2001). The plasma standard had a slightly 
more rapid thrombin generation and markedly slower FXa generation (Hubbard et al., 
2001). In this chapter the effect of infusion of recombinant factor concentrates upon 
thrombin generation and fibrinogen polymerisation is investigated. 
3.8.2 Patient selection. 
Thirteen previously diagnosed severe haemophiliacs (seven Haemophilia A and six 
haemophilia B) were selected for the study. The patients attended the haemophilia clinic 
for routine assessment of post infusion recovery or full half-life studies following their 
change from plasma derived to recombinant factor concentrate. Where half life studies 
were performed samples were collected in the presence and absence of CTI over a 
period of 72hours (pre-dose, 15mins post infusion, 4hrs post infusion, 8hrs post 
infusion,, 24hrs post infusion, 32hrs post infusion, 48hrs post infusion and 72 hrs post 
infusion). Factor assays (Section 2.3.1.4) were performed within 2 hours, using citrated 
plasma prepared in the absence of CTI. CAT (Section 2.5.3) and min_1 assay (Section 
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2.5.2) was performed on frozen PPP (Section 2.2) prepared from blood drawn into 
citrate containing CTI. 
3.8.3 Assessment of ETP pre-infusion of factor concentrate 
ETP was initiated using a final concentration of 4pM TF in the absence of TM and a 
final concentration of 15pM TF trigger containing 7nl\4 TM. Both of these reagents 
previously gave good differentiation of the haemophilia samples from the control 
population (Figures 3.5.7 and 3.5.8). Poor assay precision was demonstrated using the 
15pM TF / 7nM TM reagent against severe haemophilia samples (Section 3.5.5). 
Therefore testing was perfonned in quadruplicate when this reagent was used. Any 
correlation of ETP with factor level was assessed for those patients registering a factor 
concentration >I u/dl (Figure 3.74). 
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Figure 3.8.1 Correlation of endogenous thrombin potential (ETP) against baseline 
factor 
level for patients with factor levels >lu/dI. M= ETP triggered using a 
final 
concentration of 15pM TF and 7nM TM. * = ETP was triggered using a 
final 
concentration of 4pM TF. 
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Although there was a tendency for the ETP to rise as the baseline factor levels rose, the 
correlation between factor level and ETP was poor whichever reagent was used (Figure 
3.8.1) and the relationship between factor levels and ETP was not significant. 
Seven patients had baseline factor levels below I u/dI. The ETP results ranged from 0- 
534 nmol. min (mean 180) using the reagent containing TM and 0-637 nmol. min (mean 
243) in the absence of TM. 
3.8.4 Assessment of minj pre-infusion of factor concentrate 
None of the reagents tested previously segregated all of the haemophilia samples from 
the control group (Section 3.3.8). As better segregation was observed at lower TF 
concentrations IpM TF and 2pM TF were selected for further analysis of haemophilia 
samples. The signal from the IpM TF reagent was found to be too weak for 
reproducible min_1 calculation therefore data is shown for the 2pM reagent only. Any 
correlation of min_1 with factor level was assessed for those patients registering a factor 
concentration >I u/dl (Figure 3.8.2). 
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Figure 3.8.2 Correlation of min_1 against baseline factor level for patients with factor 
levels >I u/dl. 
As previously seen with the ETP (Figure 3.8.1) although there was a tendency for the 
min_1 to rise as the baseline factor level rose, the correlation between baseline factor 
level and min_1 was poor and the relationship between factor level and min-1 was not 
significant. 
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3.8.5 Assessment of ETP and minj rate post-infusion of factor concentrate 
Following infusion of recombinant factor concentrate the ETP was again assessed. The 
contribution of the infused factor concentrate to the ETP was calculated as thrombin 
generation per unit rise in factor level (ETP/uFactor). A good correlation was observed 
between baseline ETP (ETP pre inftision of factor concentrate) and the ETP/ufactor 
(Figure 3.8.3). However, when the data was analysed using only those patients with 
baseline factor levels <lu/dl the correlation was improved further (Figure 3.8.4). The 
same analysis performed using the min_1 end-point gave no correlation between 
baseline min_1 and min_l/ufactor (r--0.0022). No improvement was seen when the 
analysis was restricted to patients with baseline factor levels <lu/dI. However a 
significant relationship was seen between post infusion factor level and min_1 in this 
group of patients (r--0.8416, p=0.01) 
When the ETP was measured 4 hours post infusion of factor concentrate, the direct 
contribution of the infused factor to the change in ETP was reduced. This was 
demonstrated by a reduced correlation between the baseline ETP and the ETP/uFactor, 
in patients with a baseline factor level <lu/dI, (r-- 0.8525 and 0.7329 for the reagents 
with and without TM respectively). 
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Figure 3.8.3 Correlation of endogenous thrombin potential (ETP) against baseline factor 
level. 0= ETP triggered using a final concentration of 15pM TF and 7nM TM. * 
ETP was triggered using a final concentration of 4pM TF. 
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3.8.6 Calculation of FVIII half-life 
Samples were collected from six patients registered with the Addenbrooke's 
haemophilia centre as severe haemophilia A (baseline FVIII <lu/dl) for detennination 
of in-vivo half life of FVIII: C. The half-life was calculated from the results of one-stage 
FVIII: C assays and ETP. The ETP was triggered using either a final TF concentration of 
4pM or a final TF concentration of 15pM in combination with TM at a final 
concentration of 7n. M. 
Most studies have shown that FVIII activity-time curves follow a two-compartment 
model (Kjellman, 1984). The plasma activity falls rapidly after the infusion followed by 
a much slower rate of decline. The early phase is called the distribution phase and the 
latter, the elimination phase. The distribution phase is characterised by the distribution 
half-life, also called the initial half-life and is believed to depend on equilibration of 
FVIII with the extravascular compartment. The elimination phase or elimination half- 
life is often referred to as the biological half-life. 
In this analysis the half-life was calculated using both one-compartment and two- 
compartment models. These calculations generally give similar but not the same result 
when FVIII: C measurements are used (Hay et al., 2000) (Table 3.8.1). When the ETP 
was used for calculation of half-life the one-compartment and two-compartment half- 
life calculations were in agreement in 4/6 cases (Table 3.8.1). This was not the case 
when TM was omitted from the reagent (Table 3.8.1). 
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Generally the half-life determinations using the ETP data were longer than those 
calculated using the FVIILC results. The differences were not statistically significant 
although the sample size was limited. 
One-co partment half-life Two-c partment half-life 
FVIII: C ETP 4 ETP 15/7 FVIII: C ETP 4 ETP 15/7 
Patient 1 16.5 27 16.3 17.1 24.9 14.1 
Patient 2 14.6 83.5 56 17.8 63.8 84 
Patient 3 11 36.9 18.7 13.7 13.4 13.3 
Patient 4 16.7 27.1 13.1 17 82.8 11 
Patient 5 13.3 58.7 77.9 13.5 43.4 33 
Patient 6 13.6 113.6 14.1 10.8 432.6 21.5 
Mean 14.28 57.8 32.68 14.98' 110.15 29.48 
Table 3.8.1. In-vivo FVIII half-life (hours) for six severe haemophiliacs following 
infusion of recombinant FVIII. The half life was calculated from either FVIII: C levels 
(FVIII: Q, ETP triggered with a final concentration of 4pM TF (ETP 4) or ETP 
triggered with a final concentration of 15pM TF and 7nM TM (ETP 15/7). 
Half-life calculations using the min_1 rate gave very prolonged estimates (I- 
compartment 141-881 hrs, mean 349 hrs; 2-compartment 117-1078 hrs, mean 384 hrs). 
3.8.7 Discussion 
The ETP assay has been used to assess the degree of hypo-coagulability in cases of 
haernophilia (AlDieri et al., 2002; Chantarangkul et al., 2003). It has also been applied 
to the monitoring of activated prothrombin complexes following their use in 
haemophilia patients with specific factor inhibitors (Varadi et al., 2002). To date the 
ETP has not been used to assess haemostasis post infusion of factor concentrate. A 
modified thrombin generation assay was recently used to assay factor concentrates 
following their addition to factor deficient plasma (McIntosh et al., 2003). The authors 
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concluded that the assay had a potential role in assessing thrombin generation at very 
low factor levels. This conclusion was drawn largely from the observation that some 
factor deficient plasmas could "generate significant amounts of thrombin". The findings 
of the present study suggest that the observations were probably the result of contact 
activation during the preparation of the factor deficient plasma. Their conclusion is 
probably correct as in clinical trials of gene therapy there have been some individuals 
who have shown a decreased requirement for factor concentrate despite there being no 
measurable increase in FVIII (White, 2001). The results of the present study have 
shown a marked difference in the baseline ETP measurements in patients with factor 
levels <lu/dl with levels as high as 534 and 637 nmol. min being seen in the presence or 
absence of TM respectively (Section 3-8.3). This variation was not the result of sample 
activation as CTI was used to eliminate contact activation. These results further support 
the conclusions of McIntosh et al (2003) (McIntosh et al., 2003). 
It has been reported that when a hypercoagulable defect such as the FV Leiden mutation 
exists alongside the haemophilia there can be an increase in thrombin generation (Veer 
et al., 1997a). These findings were demonstrated in a reconstituted model and shown to 
be related to the levels of FV Leiden present (Veer et al., 1997a). However, most 
haernophilia patients with a heterozygous FV Leiden still have a severe bleeding 
diathesis (Lee et al., 2000). Other factor levels such as vWF (Keularts et al., 2000) and 
circulating FIXa (Keularts et al., 2000) have been shown to influence the ETP and maY 
influence the ETP seen in haernophiliacs. 
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Following the infusion of factor concentrate the subsequent rise in ETP can be largely 
attributed to the increase in the specific functional factor activity. This was clearly seen 
in the patients with <lu/dl factor baseline values (Figure 3.8.4). When residual, 
circulating factor was present the relationship between ETP and infused factor was less 
marked (Figure 3.8.3). When the ETP was measured on samples taken four hours post 
infusion of factor the relationship seen between ETP and infused factor was not as clear 
as seen immediately post infusion. This finding would suggest that over time the 
infusion of factor concentrates have influences on other aspects of haemostasis. Further 
work will establish which other events were influencing the ETP following factor 
concentrate infusion. 
The half life calculations following infusion of recombinant FVIII gave much longer 
times when the ETP results were used in the calculation (Table 3.8.1). This was the case 
irrespective of the model used for the calculation (I -compartment or 2-compartment 
model). There was closer agreement between the 1-compartment and 2-compartment 
models when TM was incorporated into the ETP trigger reagent. This would 
be 
expected as this reagent combination accounts for the influence of the PC system and 
is 
thus a more physiological measure. The results suggest that the patients retain an 
increased potential to generate thrombin long after the detectable FVIII 
levels have 
fallen. Again further work is required to explain this finding. 
The use of min_1 as a means of monitoring haemostatic potential post 
infusion of factor 
concentrate would appear to be uninformative. Although a correlation was seen 
between 
post infusion FVIII and min_l, the half-life studies generated results 
(mean half-life 
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>14 days) that could not be reflecting the clinical state of the patient. Previously it has 
been shown that the assays using fibrin polymerisation as the end-point (ROTEM and 
clot kinetics) are relatively insensitive to hypocoagulability (Sections 3.3.8 and 3.6.4). 
The results of this study confinn this insensitivity. 
The results of this study demonstrated that the ETP assay can be used to monitor the 
effect of the infusion of recombinant factor concentrates and that the assay is providing 
additional information to that seen by the assay of the specific clotting factor alone. The 
longer half-life calculated using thrombin generation as the end-point may suggest that 
haemophiliacs retain an enhanced haemostatic function beyond the time suggested by 
the measurement of FVIII alone. 
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4 DISCUSSION 
The assessment of haemostasis in terms of screening assays has been largely unchanged 
for the past 40 years. However, since the turn of the century there has been renewed 
interest in the way that patient samples can be screened for haemostatic defects. There 
have been a number of assays using fibrin polymerisation as the end point, 
thrombelastography (Hartert, 1948) and the recently launched development of this assay 
the ROTEM (Calatzis et al., 1996), the sonoclot analyser (Laforce et al., 1992), platelet 
mediated force (Carr and Zekert, 1991) and free oscillation rheometry (Ramstrom et 
al., 2002). An alternative end-point is to monitor the generation of thrombin (Hemker 
et al., 1986). This assay has evolved over the past 25 years to its current form, 
calibrated automated thrombin generation (Hemker et al., 2003). 
This study examined assays of fibrin polymerisation ROTEM (Sorensen et al., 2003) 
and thrombin generation (Hemker et al., 2003) for use as global screening tools of 
haemostasis. In addition a novel assay using clot kinetics (Braun et al., 1997) was 
developed. 
4.1 Thrombin generation assay. 
The assay of thrombin generation assay has been extensively investigated 
in terms of 
sensitivity to haernostatic defects. It has been shown to be sensitive to 
hypothrombotic 
states, deficiencies in the procoagulant clotting factors (Dieri et al., 
2002)(Keularts et 
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al., 2001) including von Willebrand factor (vWF) (Beguin et al., 1999), the presence of 
anticoagulants (AlDieri et al., 2003; Sarich et al., 2002) and anti-platelet drugs (Altman 
et al., 2000; Kessels et al., 1994) and platelet disorders (Beguin et al., 1999). In addition 
the ability of the thrombin generation measurements to assess hypercoagulability has 
been reported. Abnormal results have been shown in AT deficiency (Wielders et al., 
1997), in association with the prothrombin gene mutation G20210A (KyrIe et al., 1998) 
as well as defects of the PC pathway (Duchemin et al., 1994; Rosing et al., 1997). 
The term ETP has been used for many years in the published literature to indicate the 
area under a thrombin generation curve. Over the past 25 years there has been a 
considerable change in the assay format. Early reports using the thrombin generation 
assay refer to an amidolytic assay utilising a subsampling technique (Hemker et al., 
1986) but later assays used an amidolytic assay with continuous registration of thrombin 
generation in plasma (Hernker et al., 1993). Both of these assays use a defibrinated 
plasma. More recently assays utilise a fluorescent substrate which allows the use of 
whole plasma (Hemker et al., 2003). This later development has important implications 
as the assay not only assesses fluid phase thrombin but is also influenced by fibrin 
bound thrombin which is biologically active and capable of activating FV, FVIII, FXI 
and FXIII and platelets (Kumar et al., 1994). Additionally, the fluorescent assay allows 
for the assay of platelet rich plasma as opposed to the platelet poor restriction of the 
amidolytic assays. Although initial work for this study used the subsampling amidolytic 
assay (data not shown), the work was repeated and subsequent assay 
development used 
the fluorescent substrate technique (Section 2.5.3). As a result of the 
diversity in assays 
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using the term ETP care should be taken when reviewing published claims of assay 
sensitivity. 
Another important consideration when reviewing the published ETP data is the 
differences in reagent composition. The reagents vary primarily in terms of lipid 
composition and tissue factor concentration. Lipids vary from patients own platelet lipid 
to vesicles containing phosphatidy1choline and phosphatidylserine with or without 
phosphatidylethanolamine. Phosphatidylethanolamine has been shown to be a critical 
component of vesicles for the vesicles to support activated PC anticoagulant activity 
(Smirnov and Esmon, 1994). Thus, for optimum sensitivity to the PC pathway it would 
appear that phosphatidylethanolamine is an essential component and was incorporated 
into the vesicles used in the present study (Section 2.4.1). Lipid concentration is also an 
important consideration as it has been shown that assay imprecision occurs at lipid 
concentrations below 1.5ýtM (Chantarangkul et al., 2003). They concluded that lipid 
concentrations above 5ýM were optimal, although they did not test in the range 1.5- 
5ýM Other investigators have shown that 3ýM is the critical point above which the 
phospholipid concentration is not rate limiting (Hemker et al., 2003). The imprecision at 
very low lipid concentration demonstrated was largely attributable to platelet debris 
within the sample. Raising the lipid concentrations above 1.5ýM overcame this effect. 
An altemative approach suggested was to remove the platelet debris by microfiltration 
of the plasma through a 0.22ýtm cellulose filter (Chantarangkul et al., 2004). This 
approach is not suitable for routine use as the filters can remove vWF and 
bound PS 
(Blackie, 2003). If concentrations above 10ýM are used then contact activation 
properties of negatively charged lipids start to play a role (Keularts et al., 
2001). These 
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can be minimised by the use of CTI (Schneider et al., 1997). As CTI is incorporated 
into the assays used here this would not have presented a problem. However, as there 
was no benefit in using high lipid concentrations, a final phospholipid concentration of 
4ýM was used throughout this study. 
Another major variable in the published data relating to ETP is the concentration of TF 
used. A ten-fold difference in tissue factor requirement between the PRP and PPP 
assays have been reported (Hemker et al., 2003). Where dilutions of commercial 
thromboplastin reagents are used, tissue factor concentrations are often not quoted and 
largely discrepant dilutions are quoted (Bostrom et al., 2003; Siegemund et al., 2003). 
There are often I 000-fold differences in tissue factor concentrations when these type of 
reagents are used (Lawrie et al., 2003). 
ILRAeagents for this study were optimised for detection of hyper- and hypo-coagulability. 
The final lipid concentration was fixed at 4ýM using a synthetic mix of 
phosphatidylserine, phosphatidylethanolarnine and phosphatidylcholine in the 
proportion of 20/20/60 (M/M) (Section 2.4.1). The optimal tissue factor concentration 
was assessed against a carefully selected plasma panel taken from the CVTE study 
cohort (Baglin et al., 2003), the Addenbrooke's Hospital haemophilia centre and 
healthy control volunteers (Section 3.5.3). All samples were collected into citrate 
anticoagulant containing CTI (final concentration 18.3ýtg/ml). TM was incorporated to 
provide activation of the PC pathway with subsequent reduction in thrombin generation 
and back activation (Veer et al., 1997b). Indeed it has been shown in a reconstituted 
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model that TM is essential for the optimum influence of PC and PS (Butenas et al., 
1999). 
The results of the reagent matrix are shown (Section 3.5.3). The use of low TF 
concentrations (below 3pM TF) failed to give a thrombin curve with the mild / 
moderate haemophiliacs. With increasing TM concentration the low thrombin 
generation was again a problem with this patient group. When I pM TF was used 2/3 of 
the hypercoagulable and normal individuals also failed to give a thrombin curve 
(Appendices III-V). 
Of the thrombin generation parameters lag-time was least informative giving no 
discrimination between groups at any of the tested reagent combinations. The peak 
height and area under the curve (ETP) gave similar patterns of results. In the absence of 
TM the hypocoagulable samples differentiated better at lower TF concentrations. This 
finding is in agreement with van't Veer et al (1997c). These authors demonstrated that 
in a severe haemophiliac plasma prothrombinase complex formation was progressively 
normalised as the TF concentration rose (Figure 4.1) 
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Figure 4.1. Calculated maximal effective prothrombinase concentration as a function of 
factor VIla: TF concentration. 0 Absence of FVIII, N normal FVIII (Adapted 
from 
(Veer and KG, 1997c)) 
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A similar finding was also described in FXI deficient plasma (Cawthern et al., 1998). 
The hypercoagulable samples differentiated at higher TF concentrations (Figure 3.5.8). 
At intermediate levels of TF (6 and 8pM) it was possible to separate the 3 groups by 
ETP (Figures 3.5.5,3.5.6 and 3.5.8) but not peak height (Figures 3.5.2). With the 
addition of TM the higher TF / TM concentrations gave the best discrimination (Figure 
3.5.7). Taking the TF concentration above 15pM gave no increased discrimination even 
in the presence of TM (Section 3.5.4). 
TM has been applied to the ETP previously by Duchemin et al (1994). They found that 
at lower TF concentration the effect of TM at I Ou/ml could be seen in the thrombin 
generation of PC and PS deficient Plasmas. The TF concentration used,, however, was 
not defined as a dilution of commercial thromboplastin was quoted. However, from data 
in this study, tissue factor concentrations would need to be significantly higher than 
those tested here to support thrombin generation in the presence of I Ou/ml TM. Again, 
from the data shown in this study the effect of the TM can be titred against TF 
concentration. When high TF and no TM are used the APC system is bypassed (Hemker 
and Beguin, 2000). 
4.2 Clot end point 
An alternative end-point to thrombin generation is the assessment of clot formation. 
Clot end-points, that is the time at which fibrin polymerisation first occurs, have 
been 
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applied in haemostasis screening for the past half century. The reagents and automation 
have evolved to produce this end-point in as short a period of time as possible. To this 
end, non-physiological triggers of the intrinsic and extrinsic pathways have been 
manufactured. There is no doubt that interpretation of these screening tests allows the 
detection of procoagulant factor deficiencies. However, the 2 pathway model of 
haemostasis (Davie et al., 1991) has been shown to be incorrect as mounting evidence 
supports the role of tissue factor initiated haemostasis with back activation of the 
"intrinsic pathway". As a result the use of reagents closer to the physiological situation 
should allow screening via the tissue factor pathway consistent with the current model 
of haemostasis. 
The KC 10 coagulometer detects the clot end-point through mechanical interference. 
When fibrin forms between a moving plastic cup and a stationary ball bearing the 
bearing is moved with the cup. This is detected electromagnetically and the timer is 
tripped. This technology was used as it provides total flexibility in tenns of reagent 
composition / volume and an infinite detection window for clot formation. Initially a 
panel of commercially available thromboplastin reagents were screened for their ability 
to detect deficiencies associated with the "Josso loop"(Josso and Prou-Wartelle, 1965). 
The present study demonstrated that not all reagents would drive the production of Xa 
via the "Josso loop" and were not able to detect FVIII or FIX deficiency. Human TF 
sources were found to be superior for this purpose (Tables 3.1.4 and 3.1.5). These 
findings were in contrast to other reports (He et al., 2001; Marlar et al., 1982) where 
rabbit brain derived reagents where successfully used. The same panel of commercial 
thromboplastin reagents was assessed against commercial PC and PS deficient plasmas 
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(Section 3.2). As expected (Butenas et al., 1999), the addition of TM enhanced the 
assay sensitivity. Again the commercial reagents performed differently with 3/8 
reagents giving better discrimination (Section 3.2.4). The composition of the 
commercial reagents is unknown in terms of TF concentration, lipid composition and 
additives such as heparin neutralisers. Thus it is not unexpected that there are 
differences in performance between reagents. PS detection in particular has been shown 
to be lipid concentration dependent, with high phospholipid levels masking PS 
deficiency. 
The clot times generated using the mechanical end-point method were prohibitive for a 
46routine" application being in excess of 20 minutes. To overcome this a photo-optical 
detection was assessed which allowed, not only, clot time to be measured but also rates 
of fibrin polymerisation. 
4.3 Clot waveform kinetics 
Information on the dynamics of clot formation may be extracted from the optical 
profiles generated when performing PT or aPTT assays on the MDA series analysers 
(Braun et al., 1997; Givens et al., 1998). Using standard laboratory reagents it has been 
shown that different patterns are associated with certain clinical conditions (Downey et 
al., 1997). However, these reagents are optimised for rapid clot formation in minimal 
time as required for basic PT and aPTT screening and as such are only capable of 
detecting gross changes in the reaction kinetics. The optical capability of the analyser 
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allows for a more subtle use of these kinetic parameters. The instrument collects optical 
data at 0.2 second intervals for 240 seconds. This allows for a smoothed curve to be 
generated. Following first and second derivative transformations information is 
available relating to the rate and velocity of the clotting process. Using this capability 
linked to the ability to select the optical wavelength allows for reaction conditions to be 
optimised for the kinetic reaction rather than clot end-point. The first objective was to 
produce a reagent that would be sensitive to both hyper- and hypo-coagulable samples 
within the 4 minute read time of the analyser. This work followed on from the 
mechanical end-point experiments described above (Section 3.1). Using the optical clot 
end-point commercially available deficient plasmas were run against a crude low TF 
reagent (Section 3.3.2). As expected from the mechanical end-point observations it was 
not possible to use a dilution of thromboplastin greater than 1/1000 and maintain an 
end-point within the 240 second read frame of the instrument. At this dilution, clot time 
is not able to differentiate commercially available deficient plasmas from control (Table 
3.3.1). However, if the change in clot time related to dilution is assessed by comparison 
of the results obtained at a 1/1000 dilution against the clot time at a 1/100 dilution, the 
sample groups could be differentiated. Ratios for PC and PS deficient plasmas fell 
below those of the control and ratios for FVIII and FIX deficient plasmas fell above the 
upper reference limit of the control (Figure 3.3.1). Leading on from this the clot kinetic 
variables were assessed (Section 3.3.3). In the presence of TM the min_1 rate (the 
maximum reaction velocity) was found to discriminate hypercoagulable, 
hypocoagulable and reference groups. The min_2 (the maximum acceleration in 
reaction rate) measurement did not separate the 5 plasmas tested. When considering 
other assay components it was found that decreasing the optical wavelength to 460nm 
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and using a modified algorithm the sensitivity of the min_l rate measurement could be 
increased (Sections 3.3-4, and 3.3.5). 
A main clinical utility of the TW at present is the detection of a biphasic pattern which 
has been shown to be an early marker of sepsis related DIC (Downey et al., 1997). 
However, the presence of a non-linear precoagulation phase would make it impossible 
to apply the new mathematical model to the reaction curve. It had previously been 
recognised that the addition of phosphory1choline to the reaction eliminated the 
-I- abnonnal slope I associated with the bTW (Perez et al., 2001). The addition of ImM 
PPC to the reagent was found to abolish the abnormal slope I and allow accurate 
measurement of the min_l rate (Section 3.3.6). 
The work to this point was performed using commercially available thromboplastin 
reagents and deficient plasmas. The next development was to produce a reagent to make 
optimum use of the kinetic measurements and to test it using patient samples. Samples 
were collected into citrate anticoagulant containing CTI (final concentration 18.3ýtg/ml). 
Three hypercoagulable patients, 3 hypocoagulable patients and 3 healthy control 
individuals were selected as previously described (Section 3.3.8). The assay (Section 
2.5.2) was run using a selection of reagents containing TF and TM in varying 
combinations (Table 3.5.1). At higher TF levels the assay was not able to differentiate 
the 3 groups of samples even in the presence of TM. At TF levels of 2pM or below the 
hypercoagulable samples could be separated from the normal samples using min_l rate 
but not clot time. Differentiation of the hypocoagulable samples was poor. 
This finding 
was not unexpected. Fibrin formation occurs when approximately l0nM thrombin 
has 
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been generated (Brummel-Ziedins et al., 2003) and as such is a threshold triggered 
event. From the ETP optimisation study (Section 3.5.3) it was found that the rate of 
thrombin formation increases rapidly as the strength of the trigger reagent is increased. 
Thus, it is reasonable to assume that once a TF concentration of greater than 2pM is 
used, the speed of thrombin generation is such that, the rapid fibrin polymerisation 
decreases the sensitivity of the clot kinetics measurements. 
4.4 The use of the contact inhibitor CTI. 
One of the major potential problems of low TF triggered assays in clinical practice is 
interference from contact activation (Rand et al., 1996). This can be minimised by 
taking blood with a free-flowing technique without a tourniquet (Hemker et al., 2003). 
In clinical practice this approach is unlikely to be sufficiently robust to prevent 
imprecision due to pre-analytical variation. The first aim of this study was to identify 
the degree of sample activation that occurred in samples obtained in a routine 
haemophilia and thrombophilia clinic environment. The second aim was to determine if 
CTI could abolish contact activation in a low TF triggered assay. 
This study demonstrated that in the absence of contact inhibition thrombin generation 
due to contact factor activation was detectable using the calibrated automated 
thrombograrn (Section 3.4.5). It was also shown that the addition of CTI to a plasma 
sample following separation was not sufficient (Section 3.4.6) and that 
blood must be 
drawn into tubes containing CTI if in-vitro contact factor-activated thrombin generation 
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was to be abolished. The minimum concentration of CTI in whole blood above which 
contact factor-activated thrombin generation was maximally inhibited was determined 
at 50ýtl of I. Img/ml CTI in a 3ml blood sample or 18.3ýtg/ml final concentration in 
whole blood (Section 3.4.5). 
CTI is a specific inhibitor of FXIIa (Hojima et al., 1980). As such it has no effect upon 
extrinsically activated coagulation assays but inhibits assays using a contact trigger such 
as silica (Section 3.4.4). It was found that not only were clot times of the aPTT affected 
but that the reaction rates were proportionally affected (Figures 3.4.4 - 3.4.6). This 
observation has not been previously made. Elimination of in-vitro contact activation 
within the sample was shown in the presence of 18.3ýtg/ml CTI. However, using the 
ROTEM it was not possible to achieve the zero assay baseline levels seen with the ETP 
or clot kinetic assay (Section 3.6.2). As the activation was not intrinsic to the sample, 
the action of the cuvette and pin must have triggered the clot process in some way. 
This study has established that a low tissue factor triggered assay can be performed 
without concern for the effect of interference from in-vitro contact factor activation. It 
has further been shown that the action of CTI is sufficient for use in samples taken in a 
clinical setting. Furthermore, it has been shown that the method of sample collection 
could influence the results. There was little difference in the results obtained from the 
use of pre-evacuated tubes versus a syringe draw technique of blood collection (Section 
3.4.7). However, 25% of the samples tested demonstrated thrombin generation in the 
unactivated ETP in the pre-evacuated tubes only. Therefore, a syringe 
draw 
venepuncture should be adopted for all sample collection. 
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4.5 ROTEM 
The ROTEM is primarily designed as a whole blood analyser. However, the use of 
whole blood has limitations in clinical practice. Sample stability is an issue when 
dealing with whole blood analysis. The ROTEM assay has been shown to have a sample 
stability of 30-120 minutes for the use of citrated whole blood (Sorensen et al., 2003). 
These findings were confinned in this study. When blood taken into CTI was used 
recalcification as the trigger gave no result or at best a grossly pronged r-time. When a 
combination of CTI and TF activation was used there was some improvement in the 
stability of the ROTEM parameters. The r-time continued to shorten as before, the MA 
was relatively unchanged but the increase in angle was lessened considerably. However, 
as there was still progressive sample activation with a resultant tendency towards 
hypercoagulabilty, the addition of CTI proved to be of little benefit in the whole blood 
assay. Previous studies using whole blood and low TF trigger have started analysis at a 
set period following venepuncture (30 minutes) to minimise the sample ageing effect 
(Ingerslev et al., 2003). These studies were carried out by the same group who 
advocated the 90 minute window (Sorensen et al., 2003). The fact that the same group 
chose to standardise the assay interval serves to emphasise the unstable nature of whole 
blood samples for ROTEM analysis. 
For the purposes of this study it was decided that whole blood analysis at a set time 
interval from venepuncture or even within a 90-minute window was not practical and 
that PPP would be used for the analysis. It was found that samples taken into CTI could 
safely be handled over a 3-hour period prior to sample separation without affecting the 
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ROTEM parameters (Figure 3.6.1). This allowed a good quality sample to be separated, 
frozen and assayed in a controlled process. 
Titration of TF and TM resulted in the selection of final concentrations of IpM TF and 
2pM TF / 0.5nM TM to be taken forward to the analysis of the main patient cohort 
(Section 3.7). 
4.6 Evaluation of three "global assays" against a selected cohort of patients 
previously investigated for thrombopbilia. 
The patients were selected from the CVTE study of consecutive patients seen at 
Addenbrookes thrombophilia clinic following an objectively confirmed first episode of 
VTE. The original strategy for this study was to use the samples taken at the time of 
recruitment into the study. However, during the course of this study it was discovered 
that sample contact activation had serious implications when assays utilised 
physiological TF concentrations as a trigger mechanism (Section 3.4). It was therefore 
necessary to recall patients for blood collection using citrate anticoagulant tubes 
containing the specific FXlla contact factor inhibitor CTI. This led to a patient selection 
bias in the study as the patients at highest risk, those with recurrent VTE, were excluded 
from the sample collection. This patient group would have been returned to 
anticoagulant therapy following their second event, thus excluding them from analysis 
in the study described here. Following the discovery of the effect of sample activation 3 
patients were seen following recurrence of their VTE- Samples from these patients were 
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used for reagent optimisation and clearly gave greater separation from control values 
than the patient cohort used in the final analysis. 
The patients unavailable for re-sampling using CTI due to recurrence of WE would 
have been predominantly from the idiopathic group. Therefore the differences seen 
between the idiopathic and surgical groups were less than would otherwise have been 
expected. 
As discussed earlier (Section 3.7.6) the assays measured different endpoints of 
haemostasis. The ROTEM and min_1 assays utilised clot kinetics whereas the ETP 
quantitated thrombin generation. It was therefore not surprising that they identified 
different patient groups with some degree of overlap. When it comes to evaluation of 
results from a study of global assays it is difficult to know what to judge the results 
against. One option is to look at the ability to detect known defects. However, not C, 
everyone with a diagnosed thrombophilic state using the current panel of assays will 
develop a thrombosis. Therefore is it a good result or a bad result for an assay not to 
detect all of the current abnonnalities? 
Clearly the defects assessed as part of thrombophilia screens in hospital laboratories are 
associated with increased occurrence of VTE but not all carriers of the abnormality will 
have a thrombotic event. Some defects are hypothesised as increased risk factors based 
upon observed incidences in thrombotic populations compared to normal. 
Hyperhomocyctsteinemia is one such condition. Studies of these patients have given 
negative results when assessed with ETP assays (Bos et al., 1998). It is possible that an 
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assay studying fibrin polymerisation would yield different results. The ETP was also 
used to investigate the suggested increased thrombotic risk associated with elevated 
FVIII (Kraaijehhagen et al., 2000), FIX (Vileg et al., 2000) and FXI (Meijers et al., 
2000). Elevated ETP levels relative to a control population were shown in patients with 
elevated FIX and FXI but not FVIII (Siegemund et al., 2004). Elevated factor levels 
have been associated with an elevated MA in the thrombelastograph in earlier studies 
carried out in the Addenbrookes Hospital haemostasis unit (data not shown). 
Assays using physiological triggers do not swamp the coagulation system as is seen in 
PT and aPTT type assays. As such there is time during the reaction for multiple factors 
to influence the outcome. As a result it is possible for a hypocoagulant defect to be 
compensated by a hypercoagulant defect producing a normal result. This normal result 
may better reflect the clinical picture. This type of compensation has been seen in 
haernophiliacs with milder bleeding diatheses than would be predicted from their factor 
levels (Ettingshausen et al., 2001; Vianello et al., 2001). The converse is almost 
certainly true in thrombophilia when hypocoagulable conditions such as von 
Willebrands disease (VWD) are thought to have an incidence of I% in the general 
population. Neonatal haemostasis is a classic example of abnormal (compared to adult) 
levels of haemostatic proteins but a normally functioning haemostatic mechanism 
(Cvim et al., 2003). 
Few reports have looked at the detection of hypercoagulability in patient samples. 
Those that there have been have looked at sensitivity to the PC pathway defects using 
assays such a ProCSGlobal (Dragoni et al., 2001; Toulon et al., 2001). Others 
have 
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looked at the detection rates of carefully selected patients (Andresen et al., 2004). These 
reports are difficult to interpret. The ProC*Global assay has consistently shown good 
detection of PC pathway defects with the exception of protein S (Toulon et al., 2001). 
When patient groups have been studied the same observations have been made as seen 
in this study. That is a proportion of the patients with defined thrombophilia were 
detected but also a proportion of thrombophilia patients gave negative results (Andresen 
et al., 2004; O'Donnell et al., 2004). An interesting report used thrombin generation to 
look at a family with the prothrombin 20210 gene mutation (Kyrle et al., 1998). They 
found that even within the same family only 40% of the heterozygous members were 
positive and gave thrombin generation above the upper reference limits. 
The present study has demonstrated that global screening assays could be applied to 
thrombophilia screening. The results raise more questions than answers as there is no 
standard against which to judge the results. This study has identified four groups of 
patients; those with negative global assays, those with positive results using fibrin 
polymerisation assays, those with positive results using assays of thrombin generation 
and those giving positive results with both types of endpoint detection. Only time will 
tell which groups, if any, are at greater risk. 
The fact that prediction of recurrence of VTE does not appear to be related to positive 
results associated with current thrombophilia testing (Baglin et al., 
2003; Greaves and 
Baglin, 2000) poses the question, namely are the global assays selecting an at risk 
population? Equally novel mechanisms to explain increased thrombotic risk are 
still 
being reported (Bombeli et al., 2004). Therefore positive results 
for "global screening" 
201 
assays in patients negative for the currently identified thrombotic risk factors does not 
necessarl y in cate a false positive result. Only a prospective cohort study will answer 
this question. To date the only assay that has been documented as correlating with 
increased risk is the assay of Rosing et al (1997) which was applied to the samples from 
the Leiden population-based case-control study (LETS) (Tans et al., 2003). This assay 
used a combination of thrombin generation and PC activation. Both of these factors 
were investigated in this study. 
Following on from the results of the present studies reported here, a prospective case 
control study has been initiated between Addenbrookes Hospital haemostasis unit and 
the haemostasis and thrombosis research centre at Leiden University. The study will 
investigate the clinical significance of abnonnal results in the global tests of ETP, clot 
kinetics and thrombelastometry. This may be the first step to answer many of the 
questions surrounding global assays of haemostasis. 
4.7 Evaluation of CAT and min I against selected haemophilia patients 
The assay of specific factor levels as a means of monitoring replacement therapy 
has 
been common practice in haemostasis laboratories for many years. The introduction of 
recombinant products in place of plasma derived factor concentrates 
has resulted in 
discrepancies between laboratory assays of circulating product and the predicted levels 
based upon amount of product infused (Hay et al., 2000). The suggested solution was 
to 
assay the recombinant products against a matched recombinant standard 
(Hubbard et 
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al., 2001). These assays will indeed give a measure of the circulating levels of the 
infused pharmacological product but will not given an indication of the overall effect on 
the haernostasis of the patient. 
The ETP assay has been used to monitor the haemostatic effect of blood products for 
which there is no direct assay. An example of this is the monitoring of activated 
prothrombin complexes in haemophiliacs with a specific FVIII inhibitor (Varadi et al., 
1999). Fibrin polymerisation has also been used in this context (Hayashi et al., 2004) 
and in the assessment of severe haemophilia (Shima et al., 2002). 
In this study the fibrin polymerisation assays were able to detect severe factor 
deficiencies (Section 3.3.3) they were however found to be insensitive to mild / 
moderate factor deficiencies. The ROTEM assay was unable to differentiate moderate 
haemophilia samples from normal control samples (Figures 3.6.2 - 3.6.4). At low TF 
concentrations the min_1 assay was able to differentiate 2/3 of the mild / moderate 
haemophilia samples from normal (Figures 3.3.9 - 3.3.12) therefore this assay was 
further evaluated against a group of severe haemophiliacs following treatment with 
recombinant factor concentrate. Min_1 levels were very low in the pre-infusion samples 
and correlation with factor levels as assessed using a one-stage assay was poor (r = 
0.19). Assay precision was also an issue when min-I values fell below 50 %T/sec. Good 
correlation was seen between the factor levels post infusion and min-I (r = 0.84) 
however the assay could not be applied to the calculation of product half-life as the 
results were wildly discrepant from the clinical findings (Section 3.8.6). The assay may 
have a role in the demonstration of an immediate effect of an infused product 
in a 
203 
similar way to that reported using the ROTEM (Hayashi et al., 2004; Sorensen et al., 
2003). The poor performance of the fibrin polymerisation assays in the assessment of 
hypocoagulability is probably a combination of the threshold nature of fibrin formation 
(Brummel-Ziedins et al., 2003) and the impain-nent of fibrin-fibrin interaction at very 
low thrombin levels (Wilf and Minton, 1986). 
The CAT assay gave excellent differentiation of mild / moderate haemophiliacs from 
normal controls at low TF and higher TF in the presence of TM (Figures 3.5.7 and 
3.5-8) therefore offered an excellent opportunity to apply a "global" assay to the 
assessment of infused recombinant factor concentrate. The first observation was that 
there was a marked difference in the baseline ETP for patients with no detectable factor. 
Some haernophiliacs had levels up to 637nM. min (Section 3.8.3). These findings were 
not sample related as they were found to be reproducible within an individual at 
subsequent sample collections. These observations have been made previously 
(McIntosh et al., 2003) but in the absence of contact inhibition it is difficult to interpret 
the data from these authors. Following infusion of FVIII to severe haemoPhilia A 
patients the increase in ETP could be almost entirely explained by the increase in the 
FVIll: C levels measured by a one-stage factor assay (Figure 3.8.4). However, this 
relationship was not as strong when the 4-hour infusion samples were analysed (Section 
3.8.5). These results suggest that although the immediate presence of the FVIII can be 
reflected in the CAT assay after a period of time there is a systemic effect of the product 
unrelated to circulating FVIII that is being detected by the CAT assay. By 4-hours post 
infusion the ETP is higher than would be expected from the detectable FVIII. These 
findings are reflected in the half-life calculations, which are generally longer than those 
204 
calculated using the FVIII levels (Table 3.8.1). Further studies will need to carried out 
to ascertain the factors contributing to this discrepancy. 
4.8 Future work 
The results of this thesis have persuaded the group at the haemostasis research unit at 
the University of Leiden to allow analysis of samples from the Leiden case -control 
study (474 patients with a first episode of deep vein thrombosis and 474 age matched 
control subjects). These samples were not taken in the presence of CTL As the influence 
of sample contact activation is most pronounced at lower TF levels the fibrin 
polymerisation assays are not suitable for this analysis as they require very low TF 
levels. At higher TF levels the effect of sample contact activation is markedly reduced 
(data not shown) therefore this patient cohort will be tested using the CAT assay only, 
using 15pM TF / 7nM TM. 
In addition a prospective randomised clinical trial in patients with a first episode of 
VTE to investigate the usefulness of thrombophilia screening has been initiated. THE- 
WE (Thrombophilia, hypercoagulability, enviromnent and venous thromboemolism) is 
a joint collaboration between Addenbrookes haernostasis unit and the haernostasis 
research unit at the University of Leiden. Sample collection will follow 6 months 
routine anticoagulant therapy and will include sampling into CTI at a 
final 
concentration of 18.3ug/ml. The first samples will be collected in October 
2004 and 
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sample collection is expected to be completed within 2 years. Analysis will include the 
CAT and min_1 rate assay developed in this study. 
A study to investigate the discrepancy between half-life calculations using factor assays 
and the CAT assay is to be carried out. Samples are being collected from all 
haemophiliacs undergoing routine assessment of in vivo half-life. In addition to the 
assay of ETP other haemostatic proteins will be assayed to assess other changes which 
are having an influence on the ability to generate thrombin. 
4.9 Conclusions 
This study has demonstrated that assays using physiological levels of TF can be adapted 
for use in a routine clinical setting. By careful selection of reagents these assays can be 
used to screen for both hypercoagulability and hypocoagulabilty. 
Sample quality was found to be an important factor in the validity of results when using 
low TF levels. It was important to identify the limits of sample stability. It was shown 
that the incorporation of CTI into the collection tube allowed samples to be handled at 
RTT for at least 2 hours without adversely affected the assays. CTI was found to be 
essential to eliminate contact activation resulting from sample collection and subsequent 
manipulation. This data has been accepted for publication in the Journal of Thrombosis 
and Haemostasis. 
206 
Fibrin polymerisation has been assessed using thrombelastography for many years. An 
alternative assay monitoring the rate of fibrin polymerisation measured using the change 
in light transmittance was developed. This assay used the advanced optics system of the 
MDA series analyser. The rate of fibrin polymerisation was measured as the minimum 
value of the first derivative of the light transmittance over time data (min_1 rate). This 
assay proved to be equally as informative as ROTEM analysis and offered the 
advantage of full automation. 
Optimisation of TF and TM concentration allowed the selection of reagents to screen 
for hypercoagulabilty and hypocoagulabilty. This study was able to identify a group of 
patients from within the Cambridge WE cohort as hypercoagulable. It was 
demonstrated that the assays of thrombin generation and fibrin polymerisation selected 
distinct patient groups with approximately 30% of abnormal individuals having both 
enhanced fibrin polymerisation rates and thrombin potential. A prospective clinical trial 
has been initiated to assess the usefulness of these "global" screening assays in the 
prediction of thrombotic risk. 
It was found that severe haemophiliacs retained an enhanced ability to generate 
thrombin beyond that suggested from routine factor assay following infusion of 
recombinant factor concentrate. Furthermore a sub-population of severe haemophiliacs 
were found to be able to generate significant quantities of thrombin 
in the apparent 
absence of clotting factor (either FVIII or FIX). These results suggest that the assay of 
an individual factor may not reflect the full clinical situation in that patient. 
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To conclude: assays triggered by physiological levels of TF using either fibrin 
polymerisation or thrombin generation end-point can be used to screen for hyper- and 
hypocoagulability. The assays provide additional information to that obtained from 
assays of individual haemostatic proteins. Further studies have been initiated to assess 
the clinical implications of these results. 
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APPENDIX I 
Mean min_1 rates for a matrix of TF/TM reagents in a patient population. A matrix of 
42 TF / TM concentrations was assessed in the range I pM TF with no TM to 15pM TF 
and 7nM TM. These combinations are shown in the left-hand column the data table 
below. The selection of donors is shown in the top row of the table. 
x1ii 
Hype Coag lable Control Hyp Coa ul bl Do N - g a e nor o. 2 3 9 5 6 10 4 
Final reaci nt. conc. 
j 
7 8 
TF(pM) TM(nM) 
- 
1 
1 0 0 9 - - . 1 0 .0 0 
70.0 6 0 51.0 48.0 48.0 
- 
61.0 1 54.0 4.0 
. .5 68.0 62.0 79. 42.0 47.0 40.0 51.0 42 0 3 0 1 0 . . . 
2 0 
1.0 54.0 39.0 66. 36.0 26.0 30.0 40.0 28.0 -3.0 
. 
2 0 
0.0 94.0 75.0 116.0 67.0 1 63.0 69.0 105.0 88.0 24.0 
. 
2.0 
0.5 
1.0 
86.0 
64.0 
64.0 
5ý 0 
96.0 
89.0 
54.0 
4-7.0 
51.0 
38.0 
58.0 
47.0 
87.0 
58.0-- 
70.0 
-47.0 
10.0 
6.0 
2.0 2.0 56.0 3 3.0 43.0 25.0 18.0 1 26.0 36.0 28.0 3.0 3.0 0.0 110.0 78.0 125.0 66.0 71.0 75.0 120.0 98.0 28.0 
3.0 0.5 105.0 77.0 121.0 68.0 62.0 70.0 110.0 83.0 26.0 
3.0 1.0 96.0 69.0 109.0 59.0 49.0 61.0 89.0 75.0 9.0 
3.0 2.0 79.0 46.0 72.0 36.0 25.0 1 40.0 57.0 43.0 6.0 
3.0 3.0 63.0 31.0 43.0 22.0 12.0 27.0 34.0 29.0 4.0 
4.0 0.0 129.0 98.0 152.0 87.0 78.0 89.0 149.0 117.0 1 36.0 
4.0 0.5 116.0 92.0 138.0 75.0 65.0 83.0 121.0 111.0 1 27.0 
4.0 1.0 101.0 76.0 120.0 68.0 57.0 74.0 109.0 95.0 26.0 
4.0 2.0 90.0 
1 
58.0 94.0 48.0 35.0 50.0 68.0 69.0 11.0 
4.0 3.0 81.0 37.0 65.0 30.0 19.0 40.0 58.0 45.0 8.0 
4.0 4.0 55.0 24.0 39.0 16.0 11.0 20.0 27.0 25.0 1 5.0 
6.0 0.0 158.0 122.0 180.0 103.0 103.0 115.0 166.0 142.0 50.0 
6.0 0.5 160.0 118.0 179.0 99.0 93.0 106.0 159.0 131.0 41.0 
6.0 1.0 145.0 102.0 154.0 
1 
88.0 85.0 101.0 145.0 126.0 41.0 
6.0 2.0 133.0 90.0 0 148. 77.0 66.0 85.0 124.01 100.0 29.0 
6.0 3.0 131.0 74.0 132.0 65.0 49.0 78.0 99.0 95.0 23.0 
6.0 4.0 119.0 56.0 109.0 55.0 34.0 58.0 93.0 67.0 _ 19.0 
6.0 5.0 103.0 48.0 74.0 41.0 20.0 44.0 63.0 60.0 12.0 
6.0 7.0 88.0 28.0 44.0 19.0 11.0 28.0 34.0 32.0 7.0 
8.0 0.0 165.0 136.0 201.0 111.0 112.0 122.0 183.0 150.0 55.0_ 
8.0 0.5 183.0 127.0 203.0 113.0 115.0 126.0 189.0 158.0 60.0 
8.0 1.0 171.0 126.0 185.0 111.0 103.0 121.0 175.0 152.0 55.0 
8.0 2.0 160.0 111.0 167.0 94.0 85.0 108.0 154.0 138.01 46.0 
8.0 3.0 _ 149.0 87.0 156.0 83.0 69.0 102.0 140.0 113.0 39.0 
8.0 4.0 142.0 66.0 104.0 61.0 36.0 70.0 97.0 97.0 25.0 
8.0 5.0 124.0 52.0 95.0 43.0 30.0 69.0 78.0 66.0 22.0 
8.0 7.0 117.0 38.0 74.0 32.0 21.0 54.0 59.0 51.0 19.0 
15.0 0.0 230.0 184.0 276.0 154.0 161.0 163.0 255.0 231-01 91.0 
15.0 0.5 232.0 184.0 273.0 156.0 159.0 171.0 252.0 226.01 90.0 
15.0 1.0 217.0 138.0 227.0 130.0 125.0 148.0 218.0 190.01 78.0 
15.0 2.0 218.0 146.0 240.0 132.0 126.0 160.0 223.0 203.0 87.0 
15.0 3.0 224.0 146.0 233.0 133.0 109.0 156.0 222.0 200.0 82.0 
15.0 4.0 213.0 127.0 222.0 109.0 99-0 142.0 213.01 172.0 79.0 
15.0 5.0 
1 
225.0 120.0 210.0 118.0 102.0 149.0 191.0 1 172.01 88.0 
15.0 7.0 218.0 99.0 191.0 97.0 65.0 126.0 167,0 150-01 82.0 
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APPENDIX 11 
Mean clot times (seconds) for a matrix of TF/TM reagents in a patient population. A 
matrix of 42 TF / TM concentrations was assessed in the range I pM TF with no TM to 
15pM TF and 7nM TM. These combinations are shown in the left-hand column the data 
table below. The selection of donors is shown in the top row of the table. 
xliv 
II I- --- --ý.. -m FIYP F e Contro l Hypo Coa lable D N g onor o. 2 3 9 5 6 10 4 Final reag ent. conc. 
7 8 
TF(pM) TM(nM) 
1 0 - . 0.0 110 - 
140.7 132.4 113.2 137.6 121.1 112.1 114.1 240 1 .0 0.5 126.7 195.7 163.7 141.2 108.5 151.9 155.4 158.2 240 1 .0 1.0 168 208 157.6 186.1 200.2 179.8 172.3 157.3 >240 2.0 0.0 78.3 109.2 99.4 87.9 100 86.3 78.9 87.2 210.8 
2.0 0.5 89.5 118.1 113.7 105.6 119.8 90.8 87.6 -96 240 
2.0 1.0 99.9 135.4 127.6 11-7.4 139.3 108.7 95.7 110.4 >240 2.0 2.0 13.9 182.8 124 149.6 >240 131.7 141.8 171 >240 
3.0 0.0 70.1 96.8 82.1 76 83.9 74.5 69.3 72.3 163.9 
3.0 0.5 74 99 90.2 81.5 97.8 81.9 71.4 75.8 240 
3.0 1.0 77.6 111.4 101.8 86.5 106.4 82.7 76.3 90.8 >240 
3.0 2.0 101.1 136.5 121.9 107.1 135.6 100.4 95.4 104.4 >240 
3.0 3.0 108.7 157.9 131.7 147.8 >240 128.2 117.9 134.9 >240 
4.0 0.0 61.7 81.6 74 66.1 75.5 66.9 
1 
59.3 62 145.8 
4.0 0.5 65.5 86.1 79.4 70.4 82.3 70.9 65.2 67.2 175.1 
4.0 1.0 71 98.7 86.9 75.8 92.2 70.7 68.3 72.8 >240 
4.0 2.0 75.9 116.5 96.5 95.8 96.3 84.7 69.6 92.9 >240 
4.0 3.0 82.3 108.3 117.5 96 133.1 87.8 91.8 88.4 >240 
4.0 4.0 105.8 182.4 >240 >240 >240 125.5 125 >240 >240 
6.0 0.0 51.4 65.2 62.5 56.9 63 54.6 51.1 53.1 108.5 
6.0 0.5 54.9 69.8 64.2 59 66.6 56.6 53.2 55.5 117.7 
6.0 1.0 58.8 75.6 67.2 63.6 72.5 59.3 54.8 59.8 117 
6.0 2.0 61.2 86 73.2 70.8 81.4 64.6 60.3 64.9 152.9 
6.0 3.0 63.9 83.8 79.9 73.5 74.3 64.8 58.5 67.3 143 
6.0 4.0 66.5 89.2 81.5 79.5 79.9 64.1 67.2 65.5 >240 
6.0 5.0 74.1 97.4 85.6 76.5 >240 74.3 71.3 76.3 >240 
6.0 7.0 82.4 129.7 113.5 >240 >240 100.2 82.3 89.3 >240 
8.0 0.0 48.6 58.1 54.6 51.2 56.6 51.3 48.1 48.3 98.2 
8.0 0.5 47.2 60.6 56 52.4 56.7 50.4 47.3 50.3 95.8 
8.0 1.0 49.2 65 58.3 54.7 59.7 51.5 49.7 52.9 101.3 
8.0 2.0 52.7 67.8 64.4 59.4 64.8 55 52.3 56.7 111.7 
8.0 3.0 55.9 74.4 67.1 65.1 72.2 59 57.2 59.5 125.3 
8.0 4.0 63.5 82.5 78.7 72.3 70.4 62.8 60.2 67.6 126.6 
8.0 5.0 65.4 93.1 81.3 67.2 96.1 67.8 59.1 73.4 142 
8.0 7.0 69.3 89.9 96.6 73.2 120.2_ 73 65.3 69.7 122 
15.0 0.0 37.2 44.1 41.4 39.2 42.5 38.6 36.2 38.3 69.7 
15.0 0.5 37.3 45.9 43.3 38.9 42.7 38.1 36.2 38.4 69.3 
15.0 1.0 41.1 52.7 49.6 44.8 52.6 42.4 39.3 42.4 80.6 
15.0 2.0 40.7 53.6 48.1 45.6 51 41.7 39.4 41.5 79.8 
15.0 3.0 41.7 54.8 49.8 45.6 53.3 43 40.4 42.7 76.9 
15.0 4.0 44.4 57.6 51.5 49 56.5 45.8 
A 
41.6 45.3 80 
15.0 5.0 43 58.2 53.3 48.7 56 _44.7 
42.7 46.2 827 
15.0 7.0 46.1 64.8 58.9 56.5 57.9 48 48 45.6 50.4 
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APPENDIX III 
Mean lagtime (minutes) to start of thrombin generation for a matrix of TF/TM reagents 
in a patient population. A matrix of 42 TF / TM concentrations was assessed in the 
range I pM TF with no TM to 15pM TF and 7nM TM. These combinations are shown in 
the left-hand column the data table below. The selection of donors is shown in the top 
row of the table. NB: * denotes no thrombin generation occurred. 
x1vi 
Donor No. 
Final rea nt. Conc. 
TF(pM) TM(nM) 
1.0 0.5 
1.0 1.0 
2.0 0.0 
2.0 
2.0 
2.0 2.0 
3.0 0.0 
3.0 0.5 
3.0 1.0 
3.0 2.0 
3.0 3.0 
4.0 0.0 
4.0 0.5 
4.0 1.0 
4.0 2.0 
4.0 3.0 
4.0 4.0 
6.0 0.0 
6.0 0.5 
6.0 1.0 
6.0 2.0 
6.0 3.0 
6.0 4.0 
6.0 5.0 
6.0 7.0 
8.0 0.0 
8.0 0.5 
8.0 1.0 
8.0 2.0 
8.0 3.0 
8.0 4.0 
8.0 5.0 
8.0 7.0 
15.0 0.0 
15.0 0.5 
15.0 1.0 
15.0 2.0 
15.0 3.0 
15.0 4.0 
15.0 5.0 
15.0 7.0 
Hype Coagu lable Control Hyp Coagu lable 
2 3 9 
1 
5 6 10 
1 
4 7 8 
32 
__31 23 30 
12.4 20.8 13.2 11.8 15 22 22 
11.6 19.8 17.4 13 25 14.7 17.5 
15.9 25.3 21 13.2 28.5 
26 25 28 19 
8.4 12.9 8.6 14.2 13.8 13 7.7 17.5 10.9 
7.5 11.4 9 7.6 9 9 11 15 
10 17 13 10 15 10 11 
11 17 12 10 12 12 
10 14 17 9 17.5 8 
6.1 9.1 7.8 6.4 8.9 5.8 6.6 9.4 9.7 
7 9 8 7 11 7 7 9 11 
6 9 7 6 9 9 6 8 9 
7 14 9 6 12.5 7 6 11 
9 16 12 9 13 10 9 10 
12 15 12 9 7 12 8 * 
4.9 6.6 5.8 5 6.6 5.4 5.2 7.6 7.6 
6 7 6 5 8 5 6 8 9 
7 9 7 6 10 6 7 10 10 
4 9 7 6 10 6 5 9 9 
6 9 7 _ 6 9 5 5 8 8 
6 9 8 8 10 5 5 8 9 
6 8 6 5 9 5 3 6 7 
5 7 6 4 5 4 2 3 
3.7 5.2 4.8 3.9 5.3 4 4.1 5.2 5.5 
4 5 5 4 5 4 4 6 6 
3 5 4 3 3 4 3 4 4 
4 6 5 4 5 4 4 5 6 
4 6 6 5 6 4 4 6 6 
4 8 6 5 8 4 4 5 6 
5 9 6 5 7 5 3 6 
5 8 6 5 5 7 7 
3 4 4 4 4 3 3 4 4 
6 7 5 5 - 6 4 5 6 6 
4 7 5 5 4 6 4 4 5 5 
3 5 4 3 6 4 4 5 5 
3 5 4 3 5 4 
d 
4 5 5 
3 5 41 4 5 4 3 4 4 
3 4 4 4 3 4 3 3 3 4 4 
3 5 4 4 4 5 3 3 3 4 5 1 
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APPENDIX IV 
Mean peak thrombin generation (nmol) for a matrix of TF/TM reagents in a patient 
population. A matrix of 42 TF / TM concentrations was assessed in the range 1pM TF 
with no TM to 15pM TF and 7nM TM. These combinations are shown in the left-hand 
column the data table below. The selection of donors is shown in the top row of the 
table. NB: * denotes no thrombin generation occurred. 
x1viii 
Hype Coagulable Con I Hyp LP H yp Coag OC oC lable Donor No. 2 3 9 5 0 4 - 
Final rea nt. Conc. 
7 8 
TF(pM) TM(nM) 
F 
t 
1 0 . 
1 0 
0.5 
1 
25 0 0 14 14 0 0 0 0 0 
. 2 0 .0 
24 0 0A 3 0 0 0 0 0 
. 2 0 
1 0.0 91 48 123 72 0 35 5 5 0 
. 0.5 89 28 81 57 24 28 2 0 0 2 0 - - - . 1.0 69 25 58 1 59 1 0 0 0 0 2.0 2.0 19 1 17 2 0 0 0 0 0 
3.0 0.0 135 71 176 93 70 74 13 14 10 
3.0 0.5 156 48 210 122 0 62 9 8 4 
3.0 1.0 124 55 156 68 29 36 2 0 0 
3.0 2.0 98 36 101 -43 1 11 0 0 0 
3.0 3.0 55 8 33 7 - 1 1 0 0 0 
4.0 0.0 186 
1 
122 282 137 
1 
134 127 19 18 12 
4.0 0.5 136 97 291 132 91 100 14 19 9 
4.0 1.0 154 91 237 113 66 72 9 9 6 
4.0 2.0 160 69 194 84 32 54 
1 
' 4 0 2 4.0 3.0 119 32 ill 34 1 11 1 1 0 
4.0 4.0 96 34 
- 
98 24 1 2 1 0 0 
6.0 0.0 268 200 404 215 20 7 185 5 43 40 26 
6.0 0.5 306 240 438 275 1 226 222 53 51 _ 29 
6.0 1.0 270 215 344 . 233 177 252 36 34 23 
6.0 2.0 277 157 319 160 97 122 13 11 10 
6.0 3.0 254 147 342 155 69 79 10 7 6 
6.0 4.0 243 129 257 53 26 77 7 3 2 
6.0 5.0 164 82 199 55 8 48 6 2 2 
6.0 7.0 129 45 164 31 5 25 6 2 0 
8.0 0.0 324 284 447 285 310 282 85 89 48 
8.0 0.5 313 318 471 244 248 268 80 85 62 
8.0 1.0 306 252 439 251 267 237 71 73 43 
8.0 2.0 287 208 449 237 200 187 38 39 1 28 
8.0 3.0 307 210 432 228 247 161 37 23 20 
8.0 4.0 265 139 341 127 35 104 19 9 8 
8.0 5.0 242 71 252 70 14 74 9 7 3 
8.0 7.0 226 98 235 88 12 60 7 7 8 
15.0 0.0 487 485 494 289 483 478 216 204 142 
15.0 0.5 347 541 531 342 388 375 190 164 118 
15.0 1.0 370 313 496 334 375 314 142 144 98 
15.0 2.0 367 448 499 344 263 330 143 145 93 
15.0 3.0 371 432 519 _ 361 351 374 140 119 86 
15.0 4.0 415 342 639 318 282 483 98 1 107 8 
15.0 5.0 487 487 638 458 439 416 155 J _92 
95 
15.0 7.0 508 436 602 356 249 328 107 1 52 49 
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APPENDIX V 
Mean ETP (nmol. min) for a matrix of TF/TM reagents in a patient population. A matrix 
of 42 TF / TM concentrations was assessed in the range IpM TF with no TM to 15pM 
TF and 7rLM TM. These combinations are shown in the left-hand column the data table 
below. The selection of donors is shown in the top row of the table. 
Donor No. 
Final r- Conc. 
F(pM) TM(nM 
1.0 0.5 
1.0 1.0 
_2.0 
0.0 
2.0 0.5 
2.0 1.0 
_2.0 
2.0 
3.0 0.0 
3.0 0.5 
3.0 1.0 
3.0 2.0 
3.0 3.0 
4.0 0.0 
4.0 0.5 
4.0 1.0 
4.0 2.0 
4.0 3.0 
4.0 4.0 
6.0 0.0 
6.0 
6.0 1.0 
6.0 2.0 
6.0 3.0 
6.0 4.0 
6.0 
6.0 7.0 
8.0 0.0 
8.0 0.5 
8.0 1.0 
8.0 2.0 
8.0 3.0 
8.0 4.0 
8.0 5.0 
-8.0 
7.0 
15.0 0.0 
15.0 0.5 
15.0 1.0 
15.0 2.0 
15.0 3.0 
15.0 4.0 
15.0 5.0 
15.0 7.0 
Hype Coagu lable Contro Hyp Coagu lable 
2 3 9 5 6 10 4 7 8 
220 0 0 1 11 0 0 0 0 0 
191 0 0 29 0 0 0 0 0 
1502 470 1131 782 0 372 101 97 0 
806 237 672 409 156 193 33 0 0 
514 179 337 314 14 0 0 0 0 
137 6 136 16 0 0 0 0 0 
1524 734 1573 993 687 777 324 253 56 
1340 357 1442 926 0 434 106 87 49 
966 410 1016 421 167 204 32 0 0 
621 216 532 231 6 69 0 0 0 
321 58 174 42 4 12 0 0 0 
1552 1183 2131 1291 1191 1169 428 455 225 
1097 690 1900 946 530 683 145 192 90 
1192 582 1456 733 366 447 90 81 57 
1080 371 1065 477 166 272 44 0 11 
731 185 533 172 8 63 8 4 0 
560 187 485 131 14 18 
1 
7 0 0 
1877 1659 2929 1587 1586 1379 846 693 471 
1722 1538 2681 1761 1322 1426 518 456 269 
1721 1345 1899 1426 936 1444 313 261 171 
1667 874 1707 891 450 630 108 87 68 
1458 775 1769 825 323 366 82 54 41 
1422 654 1255 218 130 367 58 24 17 
914 410 949 275 44 229 43 18 11 
669 221 710 148 31 110 38 14 0 
2025 2006 2702 1887 2008 1631 1396 1241 683 
1952 2046 2712 1462 
1 
2059 1497 841 810 598 
1839 1548 2331 1557 1567 1322 618 589 342 
1690 1154 2338 1332 1087 950 282 279 178 
1756 1153 2259 1211 1275 795 260 164 132 
1546 664 1769 1 622 161 489 136 1 60 47 
1338 322 1163 323 74 327 61 52 17 
1225 473 1108 441 66 267 52 48 46 
2721 2693' 1- 2873 1658 2665 2467 
2494 2214 1655 
1983 2987 2938 1833 
1 
1986 2883 1884 1434 935 
2111 _ 1709 _ 2495 1745 1813 1510 1084 989 659 
2093 2132- 2611 1650 1270 1563 1034 1006 611 
1995 2181 - 2670 1731 1746 1662 977 759 529 
2151 1633 3188 1 1556 1318 2319 658 685 520 
2792 2568 3251 2494 . 2216 
2034 1059 586 578 
- 
2594 2167 2976 
11704 
1 1181 1503 700 320 1 292 
ii 
APPENDIX VI 
Ethical approval for sample collection from, haemophilia, thrombophilia and 
control donors 
Ethical approval was gained blood sample collection for the clinical studies of this 
thesis. Copies of the awards are included in the following pages. 
Iii 
CAMBRIDGE LOCAL RESEARCH ETHICS COMMITTEE 
Box Chairman: Dr GE Berms 
Addenbrooke's NIHS Trust Administrator: Elaina, I Friend 
Hills Road Tclephonc: 0 12'223 217983 Internal: (151) 3983-3 
Fax: 01 ý '23 216520 Dnibri'duc CB-1 Eniall. ýIai I 
Dr Trcv-or P Baglin 
Box No 2134 
Dept. of Haematologr 
Addenbrooke's NHS Trust 
ffills Road 
Cambridge 
CB2 2QQ 
Dear Dr Baglin 
Quality control in haemostasis laboratory 
Ethics Reference: LREC 03/056 
Documents Reviewed: 
Patient Information Sheet -not dated 
Questionnaire -assessment, not dated 
Consent Form -not dated 
21 Februaxý, 20033 
The Cambridge Local Research Ethics Committee received the above project at its meeting on Friday 21st 
February 2003.1 am pleased to inform you that the Committee approved this project for three years from the 
date of this letter. 
The Committee operates in accordance with ICH Good Clinical Practice Guidelines and has studied and 
approved, where applicable, the completed Cambridge Local Research Ethics Committee application form and 
have reviewed the above listed documents. 
Furthermore, whilst I am sure that every effbi-t is already made to preserve the confidentiality of any patient 
ifformation used in this study, could you please ensure that the team of investigators are aware that everyone 
who has access to patient information appreciates the importance of maintaining that confidentiality, 
particularly in respect of the use of computers and the statutory regulations laid down in the Data Protection 
Act 1998. 
Yours sincerely 
Mrs RL Cannon 
Deputy Chairman 
Local Research Ethics Corr=ttee 
CAMBRIDGE 1.., O('A. I.,. RESEXRCH ETHICS COMMITTEE 
B 
Addeilbnookc's Ni-'I'S 
t-lills Road 
Cant, ridge CB2 -QQ 
Dr Trevor P Beglinn, 
Box No 234 
Dept. of Haernatologv 
Addenbrooke's NHS) Trust 
Hills Road 
Cambridge 
CB2 200 
Dear Dt-Rs-d- 
-Ttn, 
REC Ref: 03/041 
13 Aua ussf 2 16" 0 2'; 
Improving diagnostic accuracy in patients with symptomatic bleeding 
disorders by use of global tests of blood clotting 
Thank you for your letter dated 26th June 2003 clarifying the points raised, by the Local, Research Ethics Committee. 
Ns agreed by the Committee at its meeting on Friday 21 st February 2001,73., 1 am taking Chairman's Action tc approve this pMjecl. This approval is -for three years from 'L, ý, e date of this letter. 
A list of the documents that have been reviewed and approved by the Committee is attached.. 
Conc Mons of approval - 
-i hal the Patient Information Shee'. and Consent. form be labeled as follows: Version 2 dated 2t, -h June 2003 
- Toe protocol agreed must be followed ana any Mang 3 ýIki 'e, ýe phoir LREC approvai. 2 q, tj, ý 
- Any serious or unexpected adverse everiff-s must; be reported to the LRE--C study sponsor and other 
local, invesiagators. 
-A progress report shouid be completed one year from the date of this letter and every 12 months. 
thereafter w1hilst the study is ongoing. A 19nal report must also be sent' to the LREC within 3 months of the research being completed. ' 
-I he LR EEC has g iven approval for th e study on alrou nds on ly, iherefore it is still nece ssary for T 
you to obtain approvýal firorn the R&D Direc. "or or Fe., eývant managerneni of the host organ is a-tion in 
whi& the work will be done. 
Furthermore, whilst I am sure that eVery effort is already rn: ade to preserve the confidenflialitY Of any I 
-, esfigatorss and patie-nt information used in this stuPY, could' you; please ensure that the team of im, 
evenjone who has access to patient information appreciates the importance Of ma: 'nt2'rinctJhaI,, 
confidentiality, parficularty In respect of the use of comPuters and the s-tatutory regulations laid down in 
the Data Protection Azft 1998, 
The Camýýge L. %ý ýi witti ICH Good Clinj , o-cal Research Ethics Committee operates in accordance- 'cal 
Practica, Sutdre-fines, 
YourX, sincerely 
Dr C. -fý-JEW, rr-tos MA (Oxon) MD FRCPs,,; d-,, FBPsS FMeC! SCý 
Pairdan 
Aocal Research Ethics Committee / 
CAMBRIDGE LOCAL RESEARCH ETHICS COMMITTEE 
Box 148 Addenbrooke's NHS Trust Hills Road Cambridge CB2 2QQ 
Dr Trevor P Baglin 
Box No 22334 
Dept. of Haernatology 
Addenbrooke's NHS Trust 
CB2 2QQ 
Dear Dr Baglin 
I 
* Cambridge venous thromboembolism study (CVTE). 
Ethics Reference: LREC 00/332 
Documeuts Reviewed: 
Protocol 
Patient Information Sheet 
Consent Form 
05 January 2001 
Thank you for your letter of 4 January 200 1, claritýirtg the points raised by the Local Research Ethics Conunittee 
and for enclosino, an amended protocol and infonnation sheet. 
As agreed by the Local Research Ethics Committee at its meeting on 15 December 2000,1 am taking Chairman's 
Action to approve this project. This approval is for three years from the date of this letter. 
The Committee operates in accordance with ICH Good Clinical Practice Guidelines and have studied and 
approved, where applicable, the completed Cambridge Local Research Committee application form and have 
reviewed the above listed documents. 
Furthermore, whilst I am sure that every effort is already made to preserve the confidentiality of any patient 
information used in this study, could you please ensure that the team of investigators are aware that everyone who 
has access to patient information appreciates the importance of maintaining that confidentiality, particularly in 
respect of the use of computers and statutory regulations laid down in the Data Protection Act 1998. 
-ý, r 
,. ourO Sincerely 
DrAE Berrios MA (Oxon) MD FRCPsych FBPsS FMedSci 
Research Ethics Con-unittee 
Chairman: Dr GE Berrios Administrator: MrNMay 
Internal: (84) 36969 Internal: (151) 339833 
Telephone: 01223 336965 Telephone: 01223 217983 
Fax: 01223 216520 
